<?xml version="1.0" ?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.3 20210610//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">elife</journal-id>
<journal-id journal-id-type="publisher-id">eLife</journal-id>
<journal-title-group>
<journal-title>eLife</journal-title>
</journal-title-group>
<issn publication-format="electronic" pub-type="epub">2050-084X</issn>
<publisher>
<publisher-name>eLife Sciences Publications, Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">106397</article-id>
<article-id pub-id-type="doi">10.7554/eLife.106397</article-id>
<article-id pub-id-type="doi" specific-use="version">10.7554/eLife.106397.2</article-id>
<article-version-alternatives>
<article-version article-version-type="publication-state">reviewed preprint</article-version>
<article-version article-version-type="preprint-version">1.6</article-version>
</article-version-alternatives>
<article-categories><subj-group subj-group-type="heading">
<subject>Biochemistry and Chemical Biology</subject>
</subj-group>
</article-categories><title-group>
<article-title>Deep Learning Reveals Endogenous Sterols as Allosteric Modulators of the GPCR-Gα Interface</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1375-2223</contrib-id>
<name>
<surname>Mohanty</surname>
<given-names>Sanjay Kumar</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="author-notes" rid="n1">†</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1973-8553</contrib-id>
<name>
<surname>Mittal</surname>
<given-names>Aayushi</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="author-notes" rid="n1">†</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Namra</surname>
</name>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="aff" rid="a4">4</xref>
<xref ref-type="author-notes" rid="n1">†</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gaur</surname>
<given-names>Aakash</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Duari</surname>
<given-names>Subhadeep</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Solanki</surname>
<given-names>Saveena</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sharma</surname>
<given-names>Anmol Kumar</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Arora</surname>
<given-names>Sakshi</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kumar</surname>
<given-names>Suvendu</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gautam</surname>
<given-names>Vishakha</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dixit</surname>
<given-names>Nilesh Kumar</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Subramanian</surname>
<given-names>Karthika</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ghosh</surname>
<given-names>Tarini Shankar</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6353-5411</contrib-id>
<name>
<surname>Sengupta</surname>
<given-names>Debarka</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gupta</surname>
<given-names>Shashi Kumar</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Murugan</surname>
<given-names>Natarajan Arul</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Sharma</surname>
<given-names>Deepak</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="aff" rid="a4">4</xref>
<email>deepaks@imtech.res.in</email>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2837-9361</contrib-id>
<name>
<surname>Ahuja</surname>
<given-names>Gaurav</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a5">5</xref>
<email>gaurav.ahuja@iiitd.ac.in</email>
</contrib>
<aff id="a1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03vfp4g33</institution-id><institution>Department of Computational Biology, Indraprastha Institute of Information Technology-Delhi (IIIT-Delhi)</institution></institution-wrap>, <city>Delhi</city>, <country country="IN">India</country></aff>
<aff id="a2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04t8qjg16</institution-id><institution>Pharmacology Division, CSIR-Central Drug Research Institute</institution></institution-wrap>, <city>Lucknow</city>, <country country="IN">India</country></aff>
<aff id="a3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053rcsq61</institution-id><institution>Academy of Scientific and Innovative Research (AcSIR)</institution></institution-wrap>, <city>Ghaziabad</city>, <country country="IN">India</country></aff>
<aff id="a4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/055rjs771</institution-id><institution>CSIR-Institute of Microbial Technology</institution></institution-wrap>, <city>Chandigarh</city>, <country country="IN">India</country></aff>
<aff id="a5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03vfp4g33</institution-id><institution>Infosys Centre for AI, Indraprastha Institute of Information Technology-Delhi (IIIT-Delhi)</institution></institution-wrap>, <city>Delhi</city>, <country country="IN">India</country></aff>
</contrib-group>
<contrib-group content-type="section">
<contrib contrib-type="editor">
<name>
<surname>Elgeti</surname>
<given-names>Matthias</given-names>
</name>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-0550-4852</contrib-id><role>Reviewing Editor</role>
<aff>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/03s7gtk40</institution-id><institution>Leipzig University</institution>
</institution-wrap>
<city>Leipzig</city>
<country country="DE">Germany</country>
</aff>
</contrib>
<contrib contrib-type="senior_editor">
<name>
<surname>Cui</surname>
<given-names>Qiang</given-names>
</name>
<role>Senior Editor</role>
<aff>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/05qwgg493</institution-id><institution>Boston University</institution>
</institution-wrap>
<city>Boston</city>
<country country="US">United States</country>
</aff>
</contrib>
</contrib-group>
<author-notes><fn id="n1" fn-type="equal"><label>†</label><p>Equal contributions</p></fn>
<fn id="n2" fn-type="con"><p>Author contributions: The study was conceived by G.A. Computational analysis workflows were designed by G.A. Statistical guidance was provided by D.S. Docking, and Molecular Simulations were supervised by N.A.M and conducted by N.A.M, and S.K.M. Data analyses was performed by S.K.M., A.M., S.S., S.K., S.D., A.K.S., S.A., V.G., T.S.G., N.K.D and K.S.. S.K.M built the Gcoupler Python package. G.A. and A.M. designed yeast experimental workflows and performed by A.M. Site-directed yeast mutants were created by N. and D.S. Human cell culture-based experiments were performed and analyzed by A.G., and S.K.G. Illustrations were drafted by A.M., S.K.M., and G.A. G.A. wrote the paper. All authors have read and approved the manuscript.</p></fn>
<fn fn-type="coi-statement"><p>Competing interests: No competing interests declared</p></fn>
</author-notes>
<pub-date date-type="original-publication" iso-8601-date="2025-05-30">
<day>30</day>
<month>05</month>
<year>2025</year>
</pub-date>
<pub-date date-type="update" iso-8601-date="2025-10-30">
<day>30</day>
<month>10</month>
<year>2025</year>
</pub-date>
<volume>14</volume>
<elocation-id>RP106397</elocation-id>
<history>
<date date-type="sent-for-review" iso-8601-date="2025-02-18">
<day>18</day>
<month>02</month>
<year>2025</year>
</date>
</history>
<pub-history>
<event>
<event-desc>Preprint posted</event-desc>
<date date-type="preprint" iso-8601-date="2024-03-07">
<day>07</day>
<month>03</month>
<year>2024</year>
</date>
<self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.02.14.528587"/>
</event>
<event>
<event-desc>Reviewed preprint v1</event-desc>
<date date-type="reviewed-preprint" iso-8601-date="2025-05-30">
<day>30</day>
<month>05</month>
<year>2025</year>
</date>
<self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.106397.1"/>
<self-uri content-type="editor-report" xlink:href="https://doi.org/10.7554/eLife.106397.1.sa3">eLife Assessment</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.106397.1.sa2">Reviewer #1 (Public review):</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.106397.1.sa1">Reviewer #2 (Public review):</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.106397.1.sa0">Reviewer #3 (Public review):</self-uri>
</event>
</pub-history>
<permissions>
<copyright-statement>© 2025, Mohanty et al</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Mohanty et al</copyright-holder>
<ali:free_to_read/>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="elife-preprint-106397-v2.pdf"/>
<abstract>
<p>Endogenous intracellular allosteric modulators of GPCRs remain largely unexplored, with limited binding and phenotype data available. This gap arises from the lack of robust computational methods for unbiased cavity identification, cavity-specific ligand design, synthesis, and validation across GPCR topology. Here, we developed Gcoupler, an AI-driven generalized computational toolkit that leverages an integrative approach combining <italic>de novo</italic> ligand design, statistical methods, Graph Neural Networks, and Bioactivity-based ligand prioritization for rationally predicting high-affinity ligands. Using Gcoupler, we interrogated intracellular metabolites that target and regulate the GPCR-Gα interface (Ste2p-Gpa1p), affecting pheromone-induced programmed cell death in yeast. Our computational analysis, complemented by experimental validations, including genetic screening, multi-omics, site-directed mutagenesis, biochemical assays, and physiological readouts, identified endogenous hydrophobic metabolites, notably sterols, as direct intracellular allosteric modulators of Ste2p. Molecular simulations coupled with biochemical signaling assessment in site-directed Ste2p mutants further confirmed that metabolites binding to GPCR-Gα obstruct downstream signaling, possibly via a cohesive effect. Finally, by utilizing isoproterenol-induced, GPCR-mediated human and neonatal rat cardiac hypertrophy models, we observed that elevated metabolite levels attenuate hypertrophic response, reinforcing the evolutionary relevance of this mechanism.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords</title>
<kwd>Programmed Cell Death</kwd>
<kwd>Deep Learning</kwd>
<kwd>GPCR</kwd>
<kwd>Hypertrophy</kwd>
<kwd>Mating</kwd>
<kwd>Yeast</kwd>
</kwd-group>
<funding-group>
<award-group id="funding-1">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/03tjsyq23</institution-id>
<institution>Department of Biotechnology</institution>
</institution-wrap>
</funding-source>
<award-id>BT/HRD/35/02/2006</award-id>
</award-group>
<award-group id="funding-1a">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/03tjsyq23</institution-id>
<institution>Department of Biotechnology</institution>
</institution-wrap>
</funding-source>
<award-id>BT/RLF/re-entry/14/2019</award-id>
</award-group>
<award-group id="funding-2">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/03ffdsr55</institution-id>
<institution>Science and Engineering Research Board</institution>
</institution-wrap>
</funding-source>
<award-id>SRG/2020/000232</award-id>
</award-group>
<award-group id="funding-3">
<funding-source>
<institution-wrap>
<institution>IHUB Anubhuti</institution>
</institution-wrap>
</funding-source>
<award-id>Project Grant/23</award-id>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta specific-use="meta-only">
<meta-name>publishing-route</meta-name>
<meta-value>prc</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<fn-group content-type="summary-of-updates">
<title>Summary of Updates:</title>
<fn fn-type="update"><p>Revisions were made to enhance the clarity and accuracy of the methods and results. The results section now provides a more detailed discussion of the key findings and their significance.</p></fn>
</fn-group>
</notes>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
    <p>G protein-coupled receptors (GPCRs) are critical regulators of cellular processes and thus represent prime drug targets (<xref ref-type="bibr" rid="c3">Alhosaini et al., 2021</xref>; <xref ref-type="bibr" rid="c12">Calebiro et al., 2021</xref>; <xref ref-type="bibr" rid="c70">Yang et al., 2021</xref>). While traditional GPCR-targeted therapies focus on orthosteric sites, recent advances have revealed allosteric sites offering novel therapeutic avenues (<xref ref-type="bibr" rid="c11">Bourque et al., 2022</xref>; <xref ref-type="bibr" rid="c66">Wold and Zhou, 2018</xref>)(<xref ref-type="bibr" rid="c11">Bourque et al., 2022</xref>; <xref ref-type="bibr" rid="c35">Leach et al., 2007</xref>; <xref ref-type="bibr" rid="c48">Rees et al., 2002</xref>). Although exogenous synthetic allosteric modulators are known, endogenous counterparts remain poorly characterized (<xref ref-type="bibr" rid="c17">Doller, 2017</xref>; <xref ref-type="bibr" rid="c44">O’Callaghan et al., 2012</xref>; <xref ref-type="bibr" rid="c49">Reyes-Alcaraz et al., 2020</xref>; <xref ref-type="bibr" rid="c58">Stornaiuolo et al., 2015</xref>; <xref ref-type="bibr" rid="c63">van der Westhuizen et al., 2015</xref>; <xref ref-type="bibr" rid="c75">Zhang et al., 2015</xref>). Developing high-affinity endogenous modulators requires integrating structure-based design, artificial intelligence (AI), and assays, yet traditional approaches like SAR analysis are hampered by limited GPCR allosteric modulator data (<xref ref-type="bibr" rid="c7">Basith et al., 2018</xref>; <xref ref-type="bibr" rid="c23">Gupta et al., 2021</xref>). While experimental techniques like FRET and BRET can validate allosteric compounds, their use in high-throughput screening for novel intracellular modulators is challenging (<xref ref-type="bibr" rid="c26">Hoffmann and Bünemann, 2010</xref>; <xref ref-type="bibr" rid="c29">Jaeger et al., 2010</xref>; <xref ref-type="bibr" rid="c76">Zhou et al., 2021</xref>). Identifying endogenous GPCR allosteric modulators is further complicated by factors like incomplete GPCR topology data (<xref ref-type="bibr" rid="c16">Congreve et al., 2020</xref>) and vast chemical space (<xref ref-type="bibr" rid="c60">Topiol, 2018a</xref>; <xref ref-type="bibr" rid="c70">Yang et al., 2021</xref>). This necessitates a hybrid computational approach combining allosteric site prediction, <italic>de novo</italic> ligand synthesis, and efficient screening, potentially enhanced by AI. Existing <italic>de novo</italic> drug design tools often lack practical applicability for this purpose due to computational limitations and high technical demands (<xref ref-type="bibr" rid="c10">Böhm, 1992</xref>; <xref ref-type="bibr" rid="c37">Li et al., 2021</xref>; <xref ref-type="bibr" rid="c43">Nishibata and Itai, 1991</xref>; <xref ref-type="bibr" rid="c46">Pearlman and Murcko, 1993</xref>; <xref ref-type="bibr" rid="c53">Sicho et al., 2021</xref>; <xref ref-type="bibr" rid="c57">Spiegel and Durrant, 2020</xref>; <xref ref-type="bibr" rid="c72">Yuan et al., 2011</xref>).</p>
<p>To overcome these challenges, we developed Gcoupler, a software suite (available as a Python package and Docker image) that integrates structural biology, statistical methods, and deep learning to identify GPCR allosteric modulators. We demonstrated the usability and applicability of Gcoupler in identifying novel endogenous modulators of GPCRs by exploiting the α-pheromone (α-factor)-induced mating or programmed cell death (PCD) pathway of <italic>S. cerevisiae</italic>. Notably, it is well documented that the highly elevated, non-physiological levels of α-factor trigger PCD in less than half of the MATa population (<xref ref-type="bibr" rid="c74">Zhang et al., 2006</xref>). Moreover, an equivalent concentration of α-factor triggers distinct PCD kinetics across distinct laboratory strains; for example, BY4741 is more resistant than the W303 strain (<xref ref-type="bibr" rid="c55">Sokolov et al., 2020</xref>). We, therefore, hypothesized that a subset of pheromone-resistant cells might regulate the Ste2p-mediated PCD signaling via the endogenous intracellular metabolites by operating at the Ste2-Gα binding interface. Using Gcoupler, we identified a subset of intracellular metabolites that could potentially bind to Ste2p (GPCR) at the Gpa1 (Gα) binding interface and obstruct the downstream signaling. Our computational results further suggest that hydrophobic ligands such as sterols strengthen the Ste2p-Gpa1p binding and might trigger a cohesive response that potentially obstructs downstream signaling. Experimental evidence further supported these findings that the elevated intracellular levels of these metabolites rescue the pheromone-induced PCD. To evaluate the evolutionary conservation and possible clinically relevant translation of this mechanism, we tested these metabolites on human and rat isoproterenol-induced, GPCR-mediated cardiac hypertrophy model systems and observed attenuated response in the cardiomyocytes pretreated with GPCR-Gα-protein interface modulating metabolites.</p>
</sec>
<sec id="s2">
<title>Results</title>
<sec id="s2a">
<title>Development and validation of Gcoupler</title>
<p>Designing novel target molecules by integrating the topological, chemical, and physical attributes of protein cavities necessitates advanced neural networks. While existing approaches like Bicyclic Generative Adversarial Networks (BicycleGANs) (<xref ref-type="bibr" rid="c54">Skalic et al., 2019</xref>) and Recurrent Neural Networks (RNNs) (<xref ref-type="bibr" rid="c69">Xu et al., 2021</xref>) have demonstrated potential, end-to-end standalone tools for GPCR-specific ligand design remain scarce. To address this, we developed the Gcoupler and provided it to the community as a Python Package and a Docker image. Gcoupler adopts an integrative approach utilizing structure-based, cavity-dependent <italic>de novo</italic> ligand design, robust statistical methods, and highly powerful Graph Neural Networks. Gcoupler consists of four interconnected modules, i.e., Synthesizer, Authenticator, Generator, and BioRanker, that collectively impart a smoother, user-friendly, and minimalistic experience for the end-to-end <italic>de novo</italic> ligand design.</p>
<p>Synthesizer, the first module of Gcoupler, takes a protein structure as input in Protein Data Bank (PDB) format and identifies putative cavities across the protein surface, providing users with the flexibility to select cavities based on druggability scores or user-supplied critical residues. Since cavity-dependent molecule generation mainly depends on the chemical composition and geometric constraints of the cavity, it is, therefore, indispensable to select the cavity for the downstream steps considering its chemical nature (hydrophobicity/hydrophilicity) and functional relevance (proximity to the active site or residue composition), among others. Accounting for these, Gcoupler offers flexibility to the users to select either of its predicted cavities based on the user-supplied critical residue or by user-supplied cavity information (amino acids) using third-party software (e.g., Pocketome) (<xref ref-type="bibr" rid="c24">Hedderich et al., 2022</xref>). To enhance user experience, Gcoupler computes and outputs all identified cavities along with their druggability scores using LigBuilder’s V3 (<xref ref-type="bibr" rid="c71">Yuan et al., 2020</xref>) cavity module. Briefly, these druggability scores consider solvent accessibility, cavity exposure or burial, and detected pharmacophores and cavities, which are further prioritized based on this score. Post cavity selection, the Synthesizer module generates cavity-specific ligands influenced by topology and pharmacophores, outputting SMILES, cavity coordinates, and other requisite files to downstream modules for further steps (<xref rid="fig1" ref-type="fig">Figure 1a</xref>). The chemical composition of the <italic>in silico</italic> synthesized ligands by the Synthesizer module is influenced by the cavity topology (3D) and its composition (pharmacophores). Noteworthy, the Synthesizer module of Gcoupler employs LigBuilder V3 (<xref ref-type="bibr" rid="c71">Yuan et al., 2020</xref>), which utilizes the genetic algorithm for the <italic>in silico</italic> ligand synthesis. Notably, the fragment library of LigBuilder, comprising 177 distinct molecular fragments in Mol2 format, allows the selection of multiple seed structures and extensions that best complement the cavity pharmacophores throughout multiple iterative runs. For each run, once a seed structure is confirmed, Gcoupler employs a hybrid approach of the Growing and Linking modes of the LigBuilder build module, enabling the stepwise addition of small fragments to the seed structure within the binding pocket of the target GPCR to build synthetic ligands. Gcoupler generates 500 unique molecules by default, though it can also be user-defined. The Synthesizer module of Gcoupler enhances LigBuilder V3 practical applicability through automation, dynamic adaptability, and abstraction. This allows for more efficient and targeted ligand generation, even in challenging design scenarios for GPCR ligand design. However, it lacks user-defined library screening, proposes synthetically challenging molecules, and often requires post-processing to isolate high-affinity binders from a broad affinity range of synthetically designed compounds.</p>
<fig id="fig1" position="float" orientation="portrait" fig-type="figure">
<label>Figure 1:</label>
<caption><title>Development, Benchmarking and Validation of Gcoupler Computational Framework.</title>
<p><bold>(a)</bold> Schematic workflow depicting different modules of the Gcoupler package. Of note, Gcoupler possesses four major modules, i.e., Synthesizer, Authenticator, Generator and BioRanker. <bold>(b)</bold> AUC-ROC curves of the finally selected model for each of the indicated GPCRs. Note: Experimentally validated active ligands and decoys were used in the testing dataset. <bold>(c)</bold> Bar graphs depicting the sensitivities and specificities of the indicated GPCRs with experimentally validated active ligands and reported decoys. <bold>(d)</bold> The AUC-ROC curve indicates the model’s performance in the indicated conditions. <bold>(e)</bold> Bar graphs indicating the prediction probabilities for each experimentally validated ligand. <bold>(f)</bold> Schematic workflow illustrates the steps in measuring and comparing the structural conservation of the GPCR-Gα-protein interfaces across human GPCRs. <bold>(g)</bold> Snakeplot depicting the standard human GPCR two-dimensional sequence level information. Conserved motifs of the GPCR-Gα-protein interfaces are depicted as WebLogo. Asterisks represent residues of conserved motifs present in the GPCRs-Gα-protein interfaces. Of note, the location of the motifs indicated in the exemplary GPCR snake plot is approximated. <bold>(h)</bold> Schematic workflow illustrates the steps in measuring and comparing the structural conservation of the GPCR-Gα-protein interfaces across human GPCRs. <bold>(i)</bold> Representative structures of the proteins depicting highly conserved (low RMSD) and highly divergent (high RMSD) GPCR-Gα-protein interfaces. PDB accession numbers are indicated at the bottom. <bold>(j)</bold> Heatmap depicting the RMSD values obtained by comparing all the GPCR-Gα-protein interfaces of the available human GPCRs from the protein databank. Of note, the RMSD of the Gα-protein cavity was normalized with the RMSDs of the respective whole proteins across all pairwise comparisons. <bold>(k)</bold> Heatmap depicting the pairwise cosine similarities between the <italic>in silico</italic> synthesized ligands of the GPCR-Gα-protein interfaces of the available human GPCRs using Gcoupler. <bold>(l)</bold> Schematic diagram depicting the hypothesis that the intracellular metabolites could allosterically modulate the GPCR-Gα interaction.</p></caption>
<graphic xlink:href="528587v6_fig1.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>To address this limitation, we developed the second module of Gcoupler, termed Authenticator. This module processes output files from the Synthesizer module, conducting downstream validation steps and preparing results for constructing Deep Learning-based classification models (third module). The Authenticator requires input protein 3D structure in PDB format, cavity coordinates, and all silico-generated molecules from the synthesizer module. Authenticator utilizes this information to further segregate the synthesized compounds into high-affinity binders (HAB) and low-affinity binders (LAB) by leveraging a structure-based virtual screening approach (AutoDock Vina) (<xref ref-type="bibr" rid="c62">Trott and Olson, 2010</xref>) and statistically-backed hypothesis testing for distribution comparisons (<xref rid="fig1" ref-type="fig">Figure 1a</xref>). The Authenticator module outputs the free binding energies of all the generated compounds, which further segregates the compounds into HABs and LABs by the statistical submodule while ensuring the optimal binding energy threshold and class balance. Of note, the Authenticator is also capable of leveraging the Empirical Cumulative Distribution Function (ECDF) for binding energy distribution comparisons of HABs and LABs and performs the Kolmogorov–Smirnov test (<xref ref-type="bibr" rid="c8">Berger and Zhou, 2014</xref>), Epps-Singleton test (<xref ref-type="bibr" rid="c22">Goerg and Kaiser, 2009</xref>), and Anderson-Darling Test (<xref ref-type="bibr" rid="c18">Engmann and Cousineau, 2011</xref>) for hypothesis testing. This expanded array of statistical tests allows users to employ methodologies that best suit their data distribution characteristics, ensuring robust and comprehensive analyses. Moreover, the Authenticator module incorporates a unique feature for decoy synthesis using high-affinity binders. This functionality enables the generation of a negative dataset in scenarios where the Synthesizer module fails to produce an optimal number of LABs. By synthesizing decoys from high-affinity binders, users can effectively balance their datasets, enhancing the reliability of downstream analyses. Lastly, the Authenticator module also accommodates user-supplied negative datasets as an alternative to LABs (<xref ref-type="bibr" rid="c41">Mysinger et al., 2012</xref>). This feature provides users with the flexibility to incorporate external data sources, enabling robust prediction model building by the subsequent Generator module.</p>
<p>The Generator, the third module, employs state-of-the-art GNN models such as Graph Convolution Model (GCM), Graph Convolution Network (GCN), Attentive FP (AFP), and Graph Attention Network (GAT) to construct predictive classifiers using Authenticator-informed classes. These GNN algorithms are tailored to extract features from the graph structure of the compounds generated by the Synthesizer and apply them to the classification task by leveraging Authenticator-informed class information. For instance, the Graph Convolution Model assimilates features by analyzing neighboring nodes, while the Graph Convolution Network extracts features through a convolutional process. The Attentive FP model focuses attention on specific graph segments, and the Graph Attention Network employs attention mechanisms to learn node representations. By default, Generator tests all four models using standard hyperparameters provided by the DeepChem framework (<ext-link ext-link-type="uri" xlink:href="https://deepchem.io/">https://deepchem.io/</ext-link>), offering a baseline performance comparison across architectures. This includes pre-defined choices for node features, edge attributes, message-passing layers, pooling strategies, activation functions, and dropout values, ensuring reproducibility and consistency. All models are trained with binary cross-entropy loss and support default settings for early stopping, learning rate, and batch standardization where applicable. Gcoupler provides off-the-shelf hyperparameter tuning to ensure adequate training, which is essential for optimizing model performance. After selecting the best parameters and classification algorithm, Gcoupler further ensures the mitigation of overfitting and provides a more precise estimate of model performance through k-fold cross-validation. Notably, by default, Gcoupler employs three-fold cross-validation, but users can adjust this parameter.</p>
<p>Finally, BioRanker, the last module, prioritizes ligands through statistical and bioactivity-based tools. The first level ranking offered by BioRanker is composed of a statistical tool that encompasses two distinct algorithms, namely G-means and Youden’s J statistics, to assist users in identifying the optimal probability threshold, thereby refining the selection of high-confidence hit compounds (Supplementary Figure 1a). Additionally, bioactivity embeddings computed via Signaturizer (<xref ref-type="bibr" rid="c9">Bertoni et al., 2021</xref>) enable multi-activity-based ranking using a modified PageRank algorithm. Briefly, the bioactivity descriptors of the predicted compounds are projected onto various biological activity spaces, including Chemistry, Targets, Networks, Cells, and Clinics, by performing pairwise cosine similarity comparisons with High-Affinity Binders (HABs). The PageRank algorithm is then applied for activity-specific ranking and supports multi-activity-based ranking for sequential screening based on user-defined biological properties. BioRanker also offers flexibility through customizable probability thresholds, enabling stringent or relaxed selection of compounds. Users can also input SMILES representations for direct screening, bypassing prediction probabilities. Taken together, Gcoupler is a versatile platform supporting user-defined inputs, third-party tools for cavity selection, and customizable statistical analyses, enhancing its adaptability for diverse ligand design and screening tasks. This integrated framework streamlines cavity-specific ligand design, screening, and ranking, providing a comprehensive solution for GPCR-targeted drug discovery.</p>
<p>To evaluate Gcoupler’s performance, we tested its modules across five GPCRs (AA2AR, ADRB1, ADRB2, CXCR4, and DRD3) using experimentally validated ligands and matched decoys from the DUD-E dataset (<xref ref-type="bibr" rid="c41">Mysinger et al., 2012</xref>). The DUD-E datasets contain five GPCRs alongside information about their cavity coordinates, positive ligands, and decoys (<ext-link ext-link-type="uri" xlink:href="https://dude.docking.org/subsets/gpcr">https://dude.docking.org/subsets/gpcr</ext-link>). We used these five GPCRs as independent samples to evaluate different modules and sub-modules of Gcoupler. We first checked whether the cavity search algorithm of Synthesizer could accurately detect a given orthosteric ligand-binding site for a GPCR. Gcoupler accurately identified orthosteric ligand-binding sites and additional allosteric cavities across all targets, validating its <italic>de novo</italic> cavity detection algorithm (Supplementary Figure 1b). We next asked whether Gcoupler could also synthesize molecules similar to the reported ligands for respective orthosteric sites based on the cavity’s physical, chemical, and geometric properties. For orthosteric sites, the Synthesizer module generated ∼500 compounds per GPCR. Subsequently, as per the Gcoupler default workflow, the Authenticator module conducted a virtual screening of these newly synthesized compounds, segregating them into high-affinity binders (HAB) and low-affinity binders (LAB). Although the Authenticator module provides flexibility in selecting an optimal threshold to distinguish HAB and LAB, we chose the default cut-off of −7 kcal/mol for AA2AR, CXCR4, and DRD3. For ADRB1 and ADRB2, we selected a threshold of −8 kcal/mol to minimize overlap in distributions and thus avoid class imbalance, a critical parameter that could influence the downstream model generation using the Generator module (Supplementary Figure 1c). Statistical validation confirmed significant separation between these groups (p &lt; 0.0001), enabling the Generator module to construct graph-based classification models with high values of AUC-ROC (&gt;0.95), sensitivity, and specificity (<xref rid="fig1" ref-type="fig">Figure 1b-c</xref>, Supplementary Figure d-e). These models reliably distinguished ligands from decoys, demonstrating Gcoupler’s accuracy in identifying high-affinity ligands.</p>
<p>In addition to evaluating Gcoupler’s performance for the orthosteric sites of GPCRs, we also validated its capability to identify allosteric sites and their corresponding ligands. In this case, we first gathered information about the experimentally validated GPCR-ligand complexes sourced from the PDB database. We chose three GPCR-ligand complexes (β2AR-Cmpd-15PA, CCR2-CCR2-RA-[R], CCR9-Vercirnon) from the PDB (<xref ref-type="bibr" rid="c52">Shen et al., 2023</xref>). We removed the ligands from the PDB files and executed the standard Gcoupler workflow with default parameters. Gcoupler successfully identified allosteric binding sites and generated classification models for synthetic compounds with consistently high AUC-ROC values (&gt;0.95) (<xref rid="fig1" ref-type="fig">Figure 1d</xref>, Supplementary Figure 2a-c). This high level of accuracy indicates the robustness of Gcoupler’s algorithms in distinguishing between true positives (allosteric ligands) and true negatives (non-binders). Projection of experimentally validated ligands onto these models further confirmed their predictive accuracy (<xref rid="fig1" ref-type="fig">Figure 1e</xref>), underscoring Gcoupler’s robustness and versatility for orthosteric and allosteric ligand discovery.</p>
<p>Next, to evaluate the efficiency of Gcoupler, we compared its run time with the biophysics-based gold standard molecular docking (AutoDock) (<xref ref-type="bibr" rid="c40">Morris et al., 2009</xref>). To address the runtime efficiency, we first utilized the ChEMBL31 database (<xref ref-type="bibr" rid="c19">Gaulton et al., 2012</xref>) to identify GPCRs with the highest number of reported experimentally validated agonists. We selected the alpha-1A adrenergic receptor (ADRA1A) since it qualifies for this criterion and contains 993 agonists (Supplementary Figure 3a-b). Methodologically, we followed the conventional steps of AutoDock Tools for molecular docking while keeping track of execution time for each step throughout the entire process until completion (Supplementary Figure 3a, c). In parallel, we applied the same timestamp procedure for Gcoupler, including its individual module sub-functions (Supplementary Figure 3a-d). Gcoupler was 13.5 times faster, leveraging its deep learning-based Generator module and AutoDock Vina’s efficiency. Both methods provided comparable predictions for active compounds, demonstrating Gcoupler’s speed and accuracy, making it ideal for large-scale ligand design and drug discovery (Supplementary Figure 3e-h).</p>
    <p>Finally, we used Gcoupler to evaluate the ligand space conservation (functional conservation) of the GPCR-Gα interface. Specifically, we aimed to explore the possibility of direct small molecule binding to the GPCR-Gα interface to modulate downstream signaling pathways. We analyzed multiple human GPCR-Gα complexes from the PDB (<xref rid="fig1" ref-type="fig">Figure 1f</xref>, Supplementary Table 1), identified conserved motifs (DRY, CWxL, NPxxY) and binding pockets through sequence and structural analyses (<xref rid="fig1" ref-type="fig">Figure 1g</xref>). To determine the topological similarity of the GPCR-Gα protein interface, we undertook a detailed structural analysis across a wide array of GPCR-Gα protein complexes. This analysis involved identifying and extracting the cavities present within each complex. By focusing on these critical regions, we aimed to assess the degree of structural conservation and quantify it through normalized Root Mean Square Deviation (RMSD) values. Specifically, the normalized RMSD values, which provide a measure of the average distance between atoms of superimposed proteins, indicated a high degree of similarity. The mean RMSD value was found to be 1.47 Å, while the median RMSD value was even lower at 0.86 Å. These values suggest that the overall topology of the GPCR-Gα interface is well conserved across different complexes, highlighting the robustness of this interaction site. (<xref rid="fig1" ref-type="fig">Figure 1h-j</xref>, Supplementary Figure 3i-k, Supplementary Table 2). Finally, to test whether this topological and sequence conservation also impacts the ligand profiles that could potentially bind to this interface, we performed the Gcoupler workflow on all 66 GPCRs and synthesized ∼50 unique ligands per GPCR (<xref rid="fig1" ref-type="fig">Figure 1h</xref>). We next computed and compared the physicochemical properties (calculated using Mordred (<xref ref-type="bibr" rid="c39">Moriwaki et al., 2018</xref>)) of these synthesized ligands and observed high cosine similarity, which further supports the functional conservation of the GPCR-Gα interface (<xref rid="fig1" ref-type="fig">Figure 1h, k</xref>, Supplementary Figure 3l, Supplementary Table 3). In summary, we used Gcoupler to systematically evaluate and analyze the ligand profiles of the GPCR-Gα-protein interface and observed a higher degree of sequence, topological, and functional conservation.</p>
</sec>
<sec id="s2b">
<title>Gcoupler reveals endogenous, intracellular Ste2p allosteric modulators</title>
<p>We next utilized Gcoupler to test the hypothesis that the intracellular metabolites could potentially and directly regulate the GPCR signaling by directly interacting with the GPCR-Gα-protein interaction interface (<xref rid="fig1" ref-type="fig">Figure 1l</xref>). To test this hypothesis, we utilized a well-characterized yeast mating pathway mediated via the Ste2p-Gpa1p interface (Supplementary Figure 4a). We used Gcoupler to screen for such metabolites against the Yeast Metabolome Database (YMDB) (<xref ref-type="bibr" rid="c30">Jewison et al., 2012</xref>). We utilized the recently elucidated cryo-EM structure of the Ste2 protein (<xref ref-type="bibr" rid="c64">Velazhahan et al., 2021</xref>) and performed a small-scale molecular dynamics simulation by using a yeast phospholipid composition-based lipid bilayer environment (<xref ref-type="bibr" rid="c32">Kaneko et al., 1976</xref>), and subjected the simulated stable structure to the Gcoupler workflow (Supplementary Figure 4b-i). This led to the identification of 17 potential surface cavities on Ste2p. Careful interrogation of the structurally supported Ste2p-Gpa1p interface revealed two distinct predicted cavities (annotated as IC4 (Intracellular Cavity 4) and IC5 (Intracellular Cavity 5)), collectively capturing &gt;95% of the interface regions (<xref rid="fig2" ref-type="fig">Figure 2a-b</xref>, Supplementary Figure 4j-n). Conservation analysis of these cavities across 14 yeast species further confirmed their structural significance (Supplementary Figure 4o). We next synthesized ∼500 <italic>in silico</italic> synthetic compounds for both IC4 and IC5, each by leveraging the Synthesizer module of Gcoupler. To test whether the chemical space of these <italic>in silico</italic> synthesized ligands is cavity-specific, we performed a stringent evaluation by comparing the chemical heterogeneity of the 100 randomly selected synthesized ligands, each from the pool of 500 for IC4 and IC5, with 100 <italic>de novo</italic> synthesized ligands for an extracellular cavity (EC1). Of note, EC1 does not harbor any overlapping residue with IC4 or IC5 and possesses distinct pharmacophore properties (Supplementary Figure 5a, d-e). Next, we computed the atom pair fingerprints and visualized the chemical heterogeneity in the low-dimensional space using 2D and 3D PCA (Supplementary Figure 5b-c). These results suggest that the Synthesizer module of Gcoupler generated cavity-specific ligands by leveraging both the cavity topology (3D) and its composition (pharmacophore). We further assessed the reproducibility of the Gcoupler by synthesizing 100 in silico compounds per run across five runs for the Ste2p IC4 cavity. Visualization of the chemical heterogeneity between the compounds generated via different runs in the low-dimensional space using 2D/3D PCA and pairwise Tanimoto Similarity using atom pair fingerprints suggests heterogeneous and overlapping chemical composition among the synthesized ligands across all five runs (Supplementary Figure 5f-h).</p>
<fig id="fig2" position="float" orientation="portrait" fig-type="figure">
<label>Figure 2:</label>
<caption><title>Identification of Endogenous, Intracellular Allosteric Modulators of Ste2p Using Gcoupler</title>
<p><bold>(a)</bold> Schematic diagram depicting the topology of all the cavities identified using the Synthesizer module of the Gcoupler Python package. Of note, the cavity nomenclature includes the cavity location, i.e., EC (extracellular), IC (intracellular), and TM (transmembrane), succeeded by a numerical number. <bold>(b)</bold> Diagram depicting the three-dimensional view of the Ste2 protein, with highlighted Gα-protein binding site (Gpa1) and the Gcoupler intracellular cavities (IC4 and IC5). The Venn diagram at the bottom depicts the percentage overlap at the amino acid levels between the Gα-binding site and predicted IC4 and IC5. <bold>(c)</bold> Schematic representation of the overall workflow used to predict the endogenous intracellular allosteric modulators of Ste2 receptor using Gcoupler and molecular docking technique. Of note, Yeast Metabolome DataBase (YMDB) metabolites were used as query compounds. <bold>(d)</bold> Overlapping density plots depicting and comparing the distributions of synthetic compounds predicted to target the IC4 and IC5 of the Ste2 receptor using the Gcoupler package. Of note, the Authenticator module of Gcoupler segregated the synthesized compound for each cavity (IC4 or IC5) into High-Affinity Binders (HAB) and Low-Affinity Binders (LAB). <bold>(e)</bold> AUC (Area under the curve) plots representing the performance of the indicated models. Notably, the models were trained using the cavity-specific synthetic compounds generated using the Gcoupler package. <bold>(f)</bold> Scatter plots depicting the relationship (correlation) between the binding prediction probabilities using Gcoupler and binding free energies computed using molecular docking (AutoDock). <bold>(g)</bold> Scatterplot depicting the Pathway Over Representation Analysis (ORA) results of the endogenous metabolites that were predicted to bind to the GPCR-Gα-protein (Ste2p-Gpa1p) interface using both Gcoupler and molecular docking. <bold>(h)</bold> Alluvial plot showing five-level sub-activity spaces screening of the selected metabolites for IC4. <bold>(i)</bold> Schematic diagram depicting the workflow opted to narrow down on the single metabolic gene mutants. <bold>(j)</bold> Schematic diagram depicting the experimental design used to screen single metabolic gene mutants for α-factor-induced PCD. Cell viability was assessed using a Propidium iodide-based fluorometric assay. <bold>(k)</bold> Scatter plot depicting the impact of α-factor stimuli on cellular viability, assessed using Propidium iodide-based fluorometric assay. The y-axis represents −log10(p-value) of the one-sample Student’s t-test between the normalized PI fluorescence of untreated and treated conditions. The x-axis represents the percentage inhibition or increase in cellular viability, estimated using a Propidium Iodide-based assay. The mutants reported to be involved in mating, PCD, or both are indicated in orange, green, and blue, respectively. The statistically non-significant mutants are indicated below the dashed line in black. <bold>(l)</bold> Heatmap depicting the relative enrichment/de-enrichment of differentially enriched metabolites in the indicated conditions. Of note, four biological replicates per condition were used in the untargeted metabolomics. <bold>(m)</bold> Venn diagram depicting the overlap between the predicted endogenous intracellular allosteric modulators of Ste2p and differentially enriched metabolites (DEMs) identified using untargeted metabolomics. <bold>(n)</bold> Mean-whisker plot depicting the relative abundance of ubiquinone 6 (CoQ6) and zymosterol (ZST) in the indicated conditions. Student’s t-test was used to compute statistical significance. Asterisks indicate statistical significance, whereas ns represents non-significance.</p></caption>
<graphic xlink:href="528587v6_fig2.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Post these performance/reproducibility checks of Gcoupler, we segregated the 500 <italic>in silico</italic> synthesized ligands for IC4 and IC5, each into high-affinity binders (HABs) and low-affinity binders (LABs) by the Authenticator module of Gcoupler. Notably, the estimated binding energy threshold was set at −7 kcal/mol, a widely accepted cutoff in virtual screening (<xref ref-type="bibr" rid="c2">Alanzi et al., 2024</xref>; <xref ref-type="bibr" rid="c67">Wong et al., 2022</xref>) (<xref rid="fig2" ref-type="fig">Figure 2c-d</xref>). A deep investigation into these classified synthetic compounds showed a comparable similarity between the HABs and LABs of the aforementioned target cavities, respectively (Supplementary Figure 6a-c). The Generator module built classification models by implementing four distinct Graph Neural Network algorithms. Comparing the model performance metrics suggests that Attentive FP outperformed other algorithms for both cavities (<xref rid="fig2" ref-type="fig">Figure 2e</xref>, Supplementary Figure 6d). Next, we screened yeast metabolites, compiled from YMDB, on the best-performing model (hyperparameter-tuned Attentive FP model) and predicted metabolites that could potentially bind to the IC4 and IC5 of the Ste2p-Gpa1p interface with a binding probability cutoff of &gt; 0.5 (<xref rid="fig2" ref-type="fig">Figure 2c</xref>). To further optimize the lead metabolite list, we parallelly performed the standard molecular docking using AutoDock with YMDB metabolites against IC4 and IC5 of Ste2p, respectively, and ultimately selected the consensus metabolites (binding energy ≤ −7 kcal/mol and binding probability &gt; 0.5) for the downstream analysis (<xref rid="fig2" ref-type="fig">Figure 2c</xref>, Supplementary Figure 6e, Supplementary Table 4). Of note, the consensus metabolites list was further segregated into HAM (High-Affinity Metabolites) and LAM (Low-Affinity Metabolites) based on the binding prediction probability (cutoff = 0.5). Comparative analysis of the binding prediction probabilities of Gcoupler and binding energies from Autodock of HAM and LAM revealed a significant negative correlation that further validates the authenticity of our novel approach (<xref rid="fig2" ref-type="fig">Figure 2f</xref>). Of note, as expected, HAMs and LAMs possess distinct atomic fingerprints, as indicated by the Principal Component Analysis (Supplementary Figure 6f). Furthermore, HAMs (High-Affinity Metabolites) and LAMs (Low-Affinity Metabolites) displayed distinct atomic fingerprints, with enriched functional groups, including R2NH, R3N, ROPO3, ROH, and ROR, observed in HAMs (Supplementary Figure 6g-h). To gain the pathway-level information about these putative endogenous intracellular allosteric modulators of Ste2p, we performed pathway-level over-representation analysis (<xref ref-type="bibr" rid="c14">Chong et al., 2018</xref>) and observed the selective enrichment of metabolites involved in the steroid, sesquiterpenoid, and triterpenoid biosynthesis and one-carbon pool by folate pathways (<xref rid="fig2" ref-type="fig">Figure 2g</xref>). BioRanker module further pinpointed sterols, including zymosterol (ZST), ubiquinone 6 (CoQ6), and lanosterol (LST), as top candidates, exhibiting high prediction probabilities (&gt;0.99) and structural similarity to HABs (<xref rid="fig2" ref-type="fig">Figure 2h</xref>, Supplementary Figure 6i-j). To validate Gcoupler-identified allosteric modulators, we performed control analyses of the Authenticator and Generator modules along with blind docking of YMDB metabolites with Ste2p. In the former case, we removed the class information (HAB and LAB labels) from the <italic>in silico</italic> compounds synthesized for the IC4 cavity of the Ste2p, which resulted in a heterogeneous pool of chemical compounds. We next randomly split the training and testing data (5 iterations) and build independent models. Our results suggest that compared to the Authenticator-guided data splitting (HAB and LAB), the random splitting resulted in poor model performances (Supplementary Figure 6k), suggesting the robustness of the Authenticator module. Additionally, we also evaluated the impact of the size of the training data on the Generator model performance. To achieve this, we randomly selected 25%, 50%, 75%, and 100% of the <italic>in silico</italic> synthesized compounds of the Ste2p IC4 cavity and built models using default parameters. Our results revealed a significant increase in the model performance with increased training data size (Supplementary Figure 6l-m). For the latter case, we performed blind docking by AutoDock for Ste2p with the YMDB metabolites and compared these results with the cavity-specific Docking via AutoDock and Gcoupler predictions. As expected, in contrast to the cavity-specific Gcoupler and AutoDock, where we observed significant segregation of the HAM and LAM at −7 kcal/mol Binding Energy (BE) cutoff and 0.5 as the probability cutoff of Gcoupler, we failed to observe any striking differences for the HAM in the case of blind docking (Supplementary Figure 6n). All these rigorous control analyses and blind docking validated the reliability of Gcoupler’s predictions, confirming its robustness in identifying cavity-specific modulators.</p>
<p>To experimentally validate the role of Gcoupler-predicted metabolites in Ste2p signaling, we performed a genetic screen of metabolic mutants. We first mapped the predicted allosteric-modulating metabolites to biochemical pathway databases (KEGG and MetaCyc) and identified the enzymes responsible for processing these metabolites (<xref rid="fig2" ref-type="fig">Figure 2i</xref>, Supplementary Figure 7a, Supplementary Table 5). Among the 53 single metabolic mutants (+ <italic>ste2Δ</italic>) screened, only Ste2 was previously reported in KEGG pathways for altered mating response (Supplementary Figure 7b). Next, we performed large-scale activity screening using α-factor-induced PCD assays with Propidium Iodide (PI), assuming that metabolic gene deletions would lead to intracellular accumulation of target metabolites. Briefly, selected single metabolic mutants (MATa) were grown under optimal conditions to late log phase (16 hours). Growth profile analysis revealed varied responses relative to wild-type, with most mutants exhibiting delayed growth kinetics (Supplementary Figure 7c). Late log phase cells were subsequently treated with α-factor, and PCD induction was quantified using PI-based cell viability assays (<xref rid="fig2" ref-type="fig">Figure 2j</xref>). Notably, wild-type BY4741 strains showed significant PI fluorescence increase, indicating pheromone-induced PCD, and <italic>STE2</italic> knockout mutants (<italic>ste2Δ</italic>) showed no significant death as expected. Interestingly, most metabolic mutants (94.4%) resisted α-factor-induced cell death, with some displaying accelerated growth in the presence of α-factor, indicating crosstalk between central metabolism and Ste2 signaling (<xref rid="fig2" ref-type="fig">Figure 2k</xref>). These results indicate that a significant proportion of Gcoupler predicted metabolites could directly or indirectly influence the Ste2 signaling pathway, establishing a link between metabolism and Ste2 signaling.</p>
<p>To further investigate the metabolic pathways associated with PCD resistance, we performed high-resolution metabolomics on cells surviving α-factor treatment at varying concentrations (Supplementary Figure 7d). Unbiased metabolome analysis revealed differentially enriched metabolites in the surviving population (<xref rid="fig2" ref-type="fig">Figure 2l</xref>, Supplementary Figure 7e-i, Supplementary Table 6). Cross-comparison analysis identified seven metabolites overlapping between Gcoupler predictions and survivor-enriched metabolites, with ubiquinone 6 (CoQ6) and zymosterol (ZST) showing prominent enrichment across all tested concentrations (<xref rid="fig2" ref-type="fig">Figure 2m-n</xref>, Supplementary Figure 7j). Over-Representation Analysis of the differentially-enriched metabolites suggests their involvement in glyoxylate and dicarboxylate metabolism, purine metabolism, and vitamin B6 metabolism, among others. (Supplementary Figure 7k). Taken together, the findings from genetic screening and untargeted metabolomics hint towards the interplay between the central metabolism and Ste2 signaling, with computationally predicted metabolites like ZST and CoQ6 potentially conferring resistance to α-factor-induced PCD.</p>
</sec>
<sec id="s2c">
<title>Elevated Endogenous Metabolic levels selectively inhibit GPCR signaling</title>
<p>To evaluate the stability of the interactions of zymosterol (ZST), lanosterol (LST), and ubiquinone 6 (CoQ6) at the Ste2p-Gpa1p interface, we performed three independent replicates of molecular dynamics (MD) simulations (short run of 100 ns) of the Ste2p-metabolite complex for both cavities (<xref rid="fig3" ref-type="fig">Figure 3a-c</xref>, Supplementary Figure 8a). MD simulation results suggest that the interactions between the metabolites and Ste2p at the Ste2p-Gpa1p interface are thermodynamically stable in almost all cases across both the cavities (IC4 and IC5), except for the ubiquinone 6 (CoQ6), which harbored a fluctuating Root Mean Square Deviation (RMSD) over the simulation timeframe (<xref rid="fig3" ref-type="fig">Figure 3c</xref>). Notably, fluctuating RMSD is observed only in the case of IC5, while it is within the permissive range for IC4 (<xref rid="fig3" ref-type="fig">Figure 3c</xref>, Supplementary Figure 8b). We further evaluated IC4 by performing a longer simulation run for 550 ns with these three Ste2p-metabolite complexes and observed stable complexes in the case of zymosterol (ZST) and lanosterol (LST) while observing fluctuations in the ligand RMSD for ubiquinone 6 (CoQ6) post 100 ns (Supplementary Figure 8c), which may be a result of its greater conformational flexibility. To gain further insight into the contributing residues from the MD simulations, we performed a residue-wise decomposition analysis that provides information about the energy contributions from the different residues to total binding free energies (Supplementary Figure 9a). These results suggest that IC4 and IC5 specific residues predominantly contribute to the total binding free energies. Notably, the binding free energies are obtained as an average of over 500 configurations corresponding to the last 50 ns of the MD simulations.</p>
<fig id="fig3" position="float" orientation="portrait" fig-type="figure">
<label>Figure 3:</label>
<caption><title>Elevated Endogenous Metabolite Levels Stabilize Ste2p-Gpa1p Interactions and Selectively Inhibit GPCR Signaling</title>
<p><bold>(a)</bold> Scheme representing the key steps opted for preparing Ste2p structure for downstream computational analysis. <bold>(b)</bold> Barplots depicting the binding energies obtained by the docking of Ste2p and indicated metabolites across IC4 and IC5. <bold>(c)</bold> Line plots depicting the Root Mean Square Deviation (RMSD) changes over simulation timeframes from the three independent replicates of the indicated conditions in the indicated conditions. The spread of the data is indicated as Standard Deviation (SD). Notably, RMSD is provided in Angstroms (Å), whereas the simulation time is in nanoseconds (ns). <bold>(d)</bold> Workflow depicting the steps involved in Ste2p-miniG-protein docking using HADDOCK and PRODIGY web servers. <bold>(e)</bold> Barplots depicting the fold change of the dissociation constant (Kd) in the indicated conditions. Notably, fold change was computed with respect to the wild-type condition (Ste2p-miniG-protein). Inlets represent molecular representations of Ste2p-miniG-protein and the highlighted interface residues. <bold>(f)</bold> The schematic diagram depicts the experimental workflow used to quantify α-factor-induced PCD using a propidium iodide-based cell viability fluorometric assay. Box plot on the right depicting the rescue from the α-factor-induced PCD in the indicated conditions as inferred using propidium iodide-based cell viability fluorometric assay (n=9 or 10 biological replicates; Heat-killed = 2). The y-axis represents the fold change of the propidium iodide fluorescence values with respect to their respective controls. Mann Mann-Whitney U test was used to calculate statistical significance. Asterisks indicate statistical significance, whereas ns represents non-significance. <bold>(g)</bold> Schematic representation (left) of the experimental approach used to measure cell vitality and viability using microscopy-based FUN<sup>TM</sup>1 staining. Representative micrographs (right) depicting the FUN<sup>TM</sup>1 staining results in the indicated conditions, Scale 10 µm. Mean-whisker plot depicting the relative proportion of the vital and viable yeast cells observed using FUN<sup>TM</sup>1 staining in the indicated conditions (n = 3 biological replicates). A Student’s t-test was used to compute statistical significance. Asterisks indicate statistical significance, whereas ns represents non-significance. Error bars represent the standard error of the mean (SEM). <bold>(h)</bold> Schematic representation (left) of the experimental design for the mating assay (n = 3 biological replicates, each with three technical replicates). MATa yeast cells were preloaded with the metabolites and then mated with MATα cells to evaluate the mating efficiency. Representative micrographs in the middle qualitatively depict the mating efficiency in the indicated conditions. The bar plots on the right depict the mating efficiency (mean ± SEM) in the indicated conditions. Student’s t-test was used to compute statistical significance. Asterisks indicate statistical significance, whereas ns represents non-significance. <bold>(i)</bold> Schematic representation depicting the experimental design of phospho-MAPK activity-based Western blot. Barplots depicting the p-Fus3 levels (mean ± SEM) in the indicated conditions. Error bars represent the standard error of the mean (SEM). A Student’s t-test was used to compute statistical significance. Asterisks indicate statistical significance, whereas ns represents non-significance. <bold>(j)</bold> Schematic representation (left) of the experimental approach used to measure the fluorescence in P<italic><sub>FUS1</sub></italic>-eGFP-CYC1 yeast cells. Representative micrographs (right) depicting the eGFP expression in the yeast cells in the indicated conditions. Scale 20 µm. Barplot depicting the Corrected Total Cell Fluorescence (CTCF) value (mean ± SEM) in the indicated conditions. A Student’s t-test was used to compute statistical significance. Asterisks indicate statistical significance, whereas ns represents non-significance.</p></caption>
<graphic xlink:href="528587v6_fig3.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>To gain deeper insight into the mode of action of these metabolites in inhibiting Ste2p signaling, we first analyzed their impact at the orthosteric site, i.e., α-factor binding. We performed protein-peptide docking of Ste2p and α-factor and observed that metabolite-binding at the Ste2p-Gpa1p interface favors the α-factor interaction, as inferred from the binding free energies ΔG (kcal/mol) (Supplementary Figure 9b-c). We also analyzed protein-protein interaction between the Ste2p (GPCR) and miniGpa1p (55) by selecting GPCR configurations with and without metabolite-induced altered cavity topologies (IC4 and IC5), respectively (frames output from the aforementioned Ste2p-metabolite complex simulations), and computed the dissociation constant (Kd), binding affinity (ΔG), and the structural changes in the overall Ste2p topology (<xref rid="fig3" ref-type="fig">Figure 3d-e</xref>, Supplementary Figure 9b-d). These computational analyses revealed that, in contrast to the metabolite-free Ste2p-Gpa1p interaction, referred to as the wild-type (WT) condition, the Kd value is many-fold lower in the presence of metabolites, indicating a cohesive response induced by these metabolites. A multi-fold lower Kd value further indicates and potentially explains that the metabolite binding favors the Ste2p (GPCR) and miniGpa1-protein interaction and enables the establishment of a stable complex that might influence the shielding of the effector-regulating domains of the Gpa1p or influence its binding with the Ste4p (Gβ)-Ste18p (Gγ) complex.</p>
<p>We next asked whether the observed resistance toward α-factor-induced PCD in single metabolic mutants might be the direct consequence of the identified metabolites or a pleiotropic response due to an altered genome. To test this, we exogenously supplemented wild-type yeast with zymosterol (ZST), ubiquinone 6 (CoQ6), and lanosterol (LST). Yeast cells were pre-loaded with metabolites for 24 hours at concentrations (0.1 μM, 1 μM, and 10 μM) that did not significantly alter growth profiles, except for 10 μM lanosterol, which showed mild perturbation (Supplementary Figure 10a), thereby ensuring the physiological relevance of our experimental conditions. Following pre-treatment, cells exhibited marked rescue from α-factor-induced PCD across multiple assays, including growth kinetics, PI-based viability, and FUN<sup>TM</sup>1 measurements (<xref rid="fig3" ref-type="fig">Figure 3f-g</xref>, Supplementary Figure 10b-c). This protective effect was specific to α-factor-induced PCD, as metabolite-treated cells remained sensitive to acetic acid-induced death, suggesting that it is likely due to modulation of the Ste2p-Gpa1p interface and not a consequence of an altered response (<xref rid="fig3" ref-type="fig">Figure 3g</xref>). Next, we probed whether the observed modulation of Ste2 signaling also applies to the natural yeast mating behavior. We investigated this by performing a mating assay, which also revealed a decline in Ste2 signaling in metabolite-preloaded cells, suggesting the interlink between these metabolites and Ste2p signaling. Notably, in the case of CoQ6, we failed to observe any significant decline in the mating response, consistent with its instability observed in molecular dynamics simulations (<xref rid="fig3" ref-type="fig">Figure 3h</xref>, Supplementary Figure 10d).</p>
<p>Further, we evaluated the deactivation of the pathway at the MAPK signaling level by monitoring the Fus3 phosphorylation, where the α-factor-induced p-Fus3 levels were significantly suppressed by ZST and LST (<xref rid="fig3" ref-type="fig">Figure 3i</xref>) but not CoQ6 (data not shown). For final validation, we employed a P<italic><sub>FUS1</sub></italic>-eGFP-CYC1 transcriptional reporter system. Metabolite pretreatment significantly reduced eGFP-positive cells following α-factor stimulation compared to controls (<xref rid="fig3" ref-type="fig">Figure 3j</xref>), further demonstrating that the tested metabolites can inhibit α-factor-induced Ste2p signaling. These findings suggest endogenous metabolites as modulators of Ste2p signaling by stabilizing Ste2p-Gpa1p interactions.</p>
</sec>
<sec id="s2d">
<title>Site-Directed <italic>Ste2</italic> Mutants Abrogate Metabolite-Mediated Rescue Phenotype</title>
<p>To gain a deeper understanding, we investigated the role of metabolite binding in modulating Ste2p-Gpa1p interaction dynamics and employed both computational and experimental approaches. First, we conducted <italic>in silico</italic> screening by generating site-directed mutants of Ste2p designed to alter metabolite binding, followed by docking with Gpa1p to assess the impact of these mutations. We selected mutation sites by analyzing non-covalent interactions in Ste2p-metabolite complexes (IC4 and IC5). We prioritized stronger hydrogen bonds over weaker hydrophobic interactions and pinpointed specific interaction sites for CoQ6 (S75, R233), ZST (L289), and LST (T155, V152, I153). We finally applied a 2.7 Å to 3.3 Å ideal distance range for hydrogen bonds and selected mutants S75A for CoQ6, L289K for ZST, and T155D for LST. This filtering step eliminated unstable or distorted hydrogen bonds. These mutations significantly increased the dissociation constant (Kd) of the Ste2p-Gpa1p complex, indicating weakened interactions compared to wild-type Ste2p (<xref rid="fig4" ref-type="fig">Figure 4a-b</xref>, Supplementary Figure 11a). This computational evidence supports the hypothesis that metabolite binding stabilizes the Ste2p-Gpa1p complex, facilitating the rescue response to α-factor-induced programmed cell death (PCD).</p>
<fig id="fig4" position="float" orientation="portrait" fig-type="figure">
<label>Figure 4:</label>
<caption><title>Site-Directed Ste2p Mutants Disrupt Metabolite-Mediated Rescue</title>
<p><bold>(a)</bold> Workflow depicting the steps involved in Ste2p-miniG-protein docking of the wild-type and site-directed Ste2p mutants. Notably, docking was performed using HADDOCK and PRODIGY web servers. <bold>(b)</bold> Barplots depicting the dissociation constant (K<sub>d</sub>) fold change in Ste2p site-directed mutants and wild-type. Notably, fold change was computed with respect to the metabolite-influenced wild-type condition (Ste2p-miniG-protein). <bold>(c)</bold> The schematic diagram depicts the experimental workflow used to quantify α-factor-induced programmed cell death in generated site-directed missense mutants (T155D, L289K, S75A), alongside reconstituted wild-type <italic>STE2</italic> (rtWT), using a propidium iodide-based cell viability fluorometric assay. The box plot (left) depicts the increase in the relative proportion of dead cells upon α-factor exposure. Box plot (right) depicting the loss of rescue phenotype from the α-factor-induced programmed cell death in the indicated conditions when pre-loaded with metabolites as inferred using propidium iodide-based cell viability fluorometric assay. The y-axis represents the fold change of the propidium iodide fluorescence values with respect to their respective controls. The Mann-Whitney U test was used to calculate statistical significance. Asterisks indicate statistical significance, whereas ns represents non-significance. <bold>(d)</bold> Schematic representation (top) of the experimental approach used to measure cell vitality and viability using microscopy-based FUN<sup>TM</sup>1 staining. Representative micrographs (below) depicting the FUN<sup>TM</sup>1 staining results in the indicated conditions, Scale 10 µm. Mean-whisker plot depicting the relative proportion of the vital and viable yeast cells observed using FUN<sup>TM</sup>1 staining in the indicated conditions (n = 4 biological replicates). A Student’s t-test was used to compute statistical significance. Asterisks indicate statistical significance, whereas ns represents non-significance. Error bars represent the standard error of the mean (SEM). <bold>(e)</bold> Schematic representation (up) depicting the experimental design of phospho-MAPK activity-based Western blot. Barplots (down) depicting the p-Fus3 levels (mean ± SEM) in the indicated conditions. The y-axis represents the p-Fus3/Fus3 ratio for the stimulated condition normalized by its corresponding unstimulated sample. A Student’s t-test was used to compute statistical significance. Asterisks indicate statistical significance, whereas ns represents non-significance. <bold>(f)</bold> Schematic representation depicting the experimental design of RNA sequencing, featuring treatment duration and the sequencing parameters. <bold>(g)</bold> Heatmap depicting the expression of differentially expressed genes obtained from RNA sequencing in the indicated conditions. Notably, Control and LST represent yeast cells unloaded and pre-loaded with lanosterol, respectively. α-factor is represented as α, where plus and minus signs represent its presence and absence, respectively. <bold>(h)</bold> Schematic representation of the experimental workflow followed to deduce the impact of indicated metabolites treatment on isoproterenol (ISO)-induced, GPCR-mediated hypertrophy response in human (AC16) and neonatal rat cardiomyocytes. Notably, in the case of AC16 cells, Wheat germ agglutinin (WGA) was used to stain the cardiomyocytes, whereas, for neonatal cardiomyocytes, alpha-sarcomeric actinin staining was used. <bold>(i)</bold> Micrographs depicting the human (above; green colored) and neonatal rat (below; red colored) cardiomyocytes in the indicated conditions. Scale 50 µm. <bold>(j)</bold> Box plots depicting the surface area of human (AC16) and neonatal rat cardiomyocytes in the indicated conditions. Statistical significance of indicated metabolites with untreated control and isoproterenol-treated conditions is indicated in green and grey text, respectively. Mann-Whitney U test with Bonferroni-corrected p-values was used to compute statistical significance.</p></caption>
<graphic xlink:href="528587v6_fig4.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Next, we performed experimental validation by generating site-directed missense mutants targeting key binding residues at the Ste2p-Gpa1p interface and confirmed these computational predictions (Supplementary Figure 11b, Supplementary Information). These mutants were expressed in a <italic>ste2Δ</italic> background, with the reconstituted wild-type <italic>STE2</italic> (rtWT) serving as a control. Using fluorometry-based cell death assays, we first assessed whether mutants retained the metabolite-mediated rescue response observed in wild-type cells. While rtWT exhibited significant cell death upon α-factor exposure that could be rescued by metabolite pretreatment, the T155D and L289K mutants showed no rescue response despite pretreatment with their respective metabolites (<xref rid="fig4" ref-type="fig">Figure 4c</xref>). This loss of rescue suggests direct metabolite regulation of Ste2p signaling at the intracellular Ste2p-Gpa1p interface. Notably, S75A mutants showed minimal α-factor responsiveness overall, likely due to significant structural disruptions affecting both pheromone sensitivity and metabolite binding. FUN<sup>TM</sup>1 staining assay and p-Fus3 signaling analysis by mapping MAPK pathway activation further supported these findings (<xref rid="fig4" ref-type="fig">Figure 4d-e</xref>). The lack of rescue highlights the direct role of metabolite binding at the Ste2p-Gpa1p interface in regulating downstream signaling. Interestingly, S75A mutants showed no α-factor-induced effects, likely due to significant structural disruptions. Shmoo formation assays further corroborated these findings, with no rescue effects observed in the mutants despite metabolite pre-loading (Supplementary Figure 11c-e).</p>
<p>To gain an unbiased view of the mode of action of these metabolites in attenuating Ste2p (GPCR)-mediated pheromone-induced cell death in yeast, we performed RNA sequencing on LST-preloaded and untreated (control) cells with and without α-factor exposure (<xref rid="fig4" ref-type="fig">Figure 4f</xref>). Transcriptomic analysis of control cells (without metabolite treatment) revealed significant expression changes in genes related to critical cellular processes upon α-factor exposure (<xref rid="fig4" ref-type="fig">Figure 4g</xref>, top panel; Supplementary Figure 12c). A more detailed and careful examination revealed differential expression of genes implicated in PCD and mating responses, including <italic>GSY1</italic>, whose downregulation was linked to α-factor resistance (<xref rid="fig4" ref-type="fig">Figure 4f-g</xref>, Supplementary Figure 12a-c, Supplementary Tables 7-10). LST treatment alone (without α-factor) also induced significant differential gene expression associated with cellular processing, validating its bioactivity (<xref rid="fig4" ref-type="fig">Figure 4g</xref>, middle panel). However, comparison of LST-preloaded versus control cells following α-factor treatment revealed no prominent mating or PCD-related genes among the differentially expressed genes (<xref rid="fig4" ref-type="fig">Figure 4g</xref>, lower panel); however, one cannot rule out the contribution of these genes in providing innate resistance to the α-factor. We tested the contribution of these genes in facilitating metabolite-mediated rescue phenotypes using the α-factor-induced cell-death assay on the knockouts of these differentially upregulated transcripts. Our results showed a significant loss of metabolite-mediated rescue phenotype in six out of ten knockouts, with <italic>YCR095W-A</italic> displaying the most pronounced phenotype loss (Supplementary Figure 12d-f). These results collectively suggest that metabolite binding at the Ste2p-Gpa1p interface directly drives rescue responses, with secondary contributions from differentially expressed genes in attenuating α-factor-induced cell death.</p>
<p>Since our intensive computational interrogation of all the available human GPCR-Gα complexes revealed a higher degree of functional conservation (<xref rid="fig1" ref-type="fig">Figure 1k</xref>), we next explored whether intracellular allosteric modulators such as ubiquinone 6 (CoQ6), zymosterol (ZST), lanosterol (LST), fucosterol (FST), and ubiquinone 10 (CoQ10) modulate GPCR signaling in higher vertebrates such as human and rat beta 1/2-adrenergic receptors signaling. Briefly, by using Gcoupler, we identified the putative GPCR-Gα interface and performed molecular docking with the aforementioned metabolites. Docking results revealed a high binding affinity of these selected metabolites at the GPCR-Gα interface of adrenergic receptors, reminiscent of Ste2p-metabolite interactions (Supplementary Figure 13a-b). Sequence conservation analysis of the GPCR-Gα interface across yeast Ste2p and adrenergic receptors in humans and rats further confirmed a high degree of evolutionary conservation at the metabolite-binding residues (Supplementary Figure 13c). Finally, to test this functional relevance, we evaluated the effect of these metabolites on isoproterenol-induced adrenergic receptor-mediated cardiac hypertrophy in human AC16 cardiomyocytes and neonatal rat cardiomyocytes. Preloading cells with these metabolites significantly attenuated hypertrophic responses, as evidenced by reduced single-cell surface area in quantitative assessments (<xref rid="fig4" ref-type="fig">Figure 4h-j</xref>). Notably, to further evaluate the evolutionary conservation of this phenomenon, we also analyzed 75 unique GPCR-Gα complex structures from six species, selected from the PDB database. Dynamic docking was performed using five metabolites (CoQ6, ZST, LST, FST, and CoQ10) identified by Gcoupler as potential allosteric modulators and five negative controls predicted as poor binders. Results revealed significantly lower docking scores (&lt;-7 kcal/mol) for Gcoupler-recommended metabolites compared to negative controls, irrespective of GPCR type or species (Supplementary Figure 13d-h). These findings demonstrate that intracellular metabolite modulation of GPCR activity is a conserved mechanism extending beyond yeast to higher vertebrates.</p>
</sec>
</sec>
<sec id="s3">
<title>Discussion</title>
<p>Over the last few decades, extensive research has focused on identifying allosteric modulators of GPCRs due to their relevance in drug discovery (<xref ref-type="bibr" rid="c35">Leach et al., 2007</xref>; <xref ref-type="bibr" rid="c60">Topiol, 2018a</xref>). Most known modulators are exogenous and target extracellular sites, while intracellular allosteric sites, identified recently through structural biology, offer novel avenues for regulation (<xref ref-type="bibr" rid="c12">Calebiro et al., 2021</xref>; <xref ref-type="bibr" rid="c35">Leach et al., 2007</xref>; <xref ref-type="bibr" rid="c48">Rees et al., 2002</xref>; <xref ref-type="bibr" rid="c60">Topiol, 2018a</xref>; <xref ref-type="bibr" rid="c63">van der Westhuizen et al., 2015</xref>; <xref ref-type="bibr" rid="c66">Wold and Zhou, 2018</xref>). These sites, overlapping with G-protein and β-arrestin coupling regions, highlight the potential for intracellular allosteric modulation (<xref ref-type="bibr" rid="c11">Bourque et al., 2022</xref>; <xref ref-type="bibr" rid="c63">van der Westhuizen et al., 2015</xref>; <xref ref-type="bibr" rid="c70">Yang et al., 2021</xref>). Intracellular modulators, including chemically diverse agents like auto-antibodies and sodium ions, remain poorly understood, emphasizing the need for systematic exploration of these sites (<xref ref-type="bibr" rid="c11">Bourque et al., 2022</xref>; <xref ref-type="bibr" rid="c42">Nachtergaele et al., 2012</xref>; <xref ref-type="bibr" rid="c44">O’Callaghan et al., 2012</xref>; <xref ref-type="bibr" rid="c48">Rees et al., 2002</xref>; <xref ref-type="bibr" rid="c49">Reyes-Alcaraz et al., 2020</xref>; <xref ref-type="bibr" rid="c58">Stornaiuolo et al., 2015</xref>; <xref ref-type="bibr" rid="c63">van der Westhuizen et al., 2015</xref>; <xref ref-type="bibr" rid="c66">Wold and Zhou, 2018</xref>; <xref ref-type="bibr" rid="c75">Zhang et al., 2015</xref>). However, the lack of data on intracellular modulators limits the feasibility of conventional computational approaches (<xref ref-type="bibr" rid="c7">Basith et al., 2018</xref>; <xref ref-type="bibr" rid="c16">Congreve et al., 2020</xref>; <xref ref-type="bibr" rid="c24">Hedderich et al., 2022</xref>)(<xref ref-type="bibr" rid="c6">Bartuzi et al., 2018</xref>; <xref ref-type="bibr" rid="c13">Chatzigoulas and Cournia, 2021</xref>; <xref ref-type="bibr" rid="c27">Hou et al., 2021</xref>; <xref ref-type="bibr" rid="c61">Topiol, 2018b</xref>).</p>
<p>To address this gap, we developed Gcoupler, a computational framework integrating <italic>de novo</italic> cavity identification, ligand synthesis, statistical analysis, graph neural networks, and Bioactivity-based ligand prioritization. Unlike existing tools, Gcoupler does not require cavity-specific experimentally validated compounds for model training. Gcoupler’s precision in cavity mapping, flexibility for user-defined queries, and ability to screen large chemical libraries make it a versatile and efficient tool. Additionally, Gcoupler’s generic design allows application beyond GPCRs, contrasting with existing platforms that often have limitations in modularity, precision, or open-source availability. Noteworthy, in contrast to other known allosteric sites identification tools for GPCRs, such as Allosite (<xref ref-type="bibr" rid="c28">Huang et al., 2013</xref>), AllositePro (<xref ref-type="bibr" rid="c56">Song et al., 2017</xref>), AlloReverse (<xref ref-type="bibr" rid="c73">Zha et al., 2023</xref>), that largely leverage the ML-based models or require orthosteric ligand-bound structure as input, the cavity detection feature of Gcoupler (LigBuilderV3), a critical step for the entire workflow, is not limited to only the allosteric sites; instead, it identifies all possible cavity-like regions on the protein surface, which then gets classified into druggable, undruggable, or amphibious based on their individual scoring and ligandability, thus making it unbiased and more specific towards query protein. Notably, the rationale for opting for LigBuilder V3 for cavity identification over similar tools such as Fpocket (<xref ref-type="bibr" rid="c36">Le Guilloux et al., 2009</xref>) is that the former uses a hydrogen atom probe, moving along the protein surface grid of 0.5 Å for cavity detection, being much more precise in detecting cavity boundaries, in both breadth and depth mapping; in contrast, the latter considers clusters of alpha spheres (Supplementary Table 11).</p>
<p>To date, only a few methods leverage generative AI models for cavity/pocket-based drug design. Gcoupler is an open-source, end-to-end platform integrating Ligand-Based Drug Design (LBDD) and Structure-Based Drug Design (SBDD) for drug design and large-scale screening. Unlike Pocket Crafter (<xref ref-type="bibr" rid="c51">Shen et al., 2024</xref>), which requires proprietary tools (e.g., MOE QuickPrep) and lacks predictive model-building modules, Gcoupler offers comprehensive functionality. Similarly, DeepLigBuilder (<xref ref-type="bibr" rid="c37">Li et al., 2021</xref>) and Schrodinger’s AutoDesigner are either closed source or limited in features compared to Gcoupler. Comparative analysis highlights Gcoupler’s unique advantages in precision, flexibility, and functionality (Supplementary Table 11).</p>
<p>Using Gcoupler, we investigated the molecular basis of innate resistance to α-factor-induced programmed cell death (PCD) in yeast. Unlike humans, yeast possess only two GPCR systems, making their pheromone-sensing pathway ideal for focused study. Previous research predominantly identified downstream regulatory mechanisms (<xref ref-type="bibr" rid="c4">Alvaro and Thorner, 2016</xref>; <xref ref-type="bibr" rid="c55">Sokolov et al., 2020</xref>; <xref ref-type="bibr" rid="c64">Velazhahan et al., 2021</xref>); however, our findings suggest an upstream, receptor-level regulation via endogenous intracellular metabolites. Computational and experimental evidence pinpointed specific metabolites binding to the Ste2p-miniGpa1 interface, modulating signaling. Site-directed mutagenesis confirmed the functional relevance of these metabolite-interacting residues. Of note, previous mutagenesis experiments also revealed multiple critical amino acid residues that overlap with IC4 and IC5, suggesting their functional relevance in Ste2p downstream signaling (Supplementary Table 12). Despite these advances, certain limitations remain, including the potential pleiotropic effects in metabolic gene knockouts and challenges in replicating natural metabolite concentrations. Mechanistic insights into sterol biosynthesis mutants (<italic>ergΔ</italic>) revealed impaired mating responses due to heterogeneous defects, such as reduced sterol accumulation and shmoo formation, impaired membrane fusion, and decreased <italic>FUS1</italic> expression (<xref ref-type="bibr" rid="c1">Aguilar et al., 2010</xref>; <xref ref-type="bibr" rid="c5">Bagnat and Simons, 2002</xref>; <xref ref-type="bibr" rid="c25">Heese-Peck et al., 2002</xref>; <xref ref-type="bibr" rid="c31">Jin et al., 2008</xref>; <xref ref-type="bibr" rid="c59">Tiedje et al., 2007</xref>). This highlights a novel role for sterols in GPCR regulation and their broader implications for yeast microbial factories and stress tolerance (<xref ref-type="bibr" rid="c45">Ostrov et al., 2017</xref>; <xref ref-type="bibr" rid="c50">Shaw et al., 2019</xref>). Sterols and other endogenous metabolites were shown to modulate GPCR activity by targeting conserved Gα-binding sites, reinforcing the evolutionary conservation of this mechanism across species, as demonstrated in human and rat hypertrophy models in this study.</p>
<p>In summary, our work uncovers a novel regulatory mechanism for GPCRs mediated by intracellular metabolites and presents a computational framework, Gcoupler, to explore unexplored allosteric sites. The proposed model suggests that selective metabolites binding to GPCR-Gα interfaces induce local conformational changes, stabilizing GPCR-G-protein complexes and potentially obstructing downstream signaling. Alternative mechanisms, such as orthosteric site modulation, kinase/arrestin interaction interference, or alterations in membrane dynamics, remain to be explored, warranting further investigation. A critical limitation of our study is the absence of direct binding assays to validate the interaction between the metabolites and Ste2p. While our results from genetic interventions, molecular dynamics simulations, and docking studies strongly suggest that the metabolites interact with the Ste2p-Gpa1 interface, these findings remain indirect. Direct binding confirmation through techniques such as surface plasmon resonance, isothermal titration calorimetry, or co-crystallization would provide definitive evidence of this interaction. Addressing this limitation in future work would significantly strengthen our conclusions and provide deeper insights into the precise molecular mechanisms underlying the observed phenotypic effects. Another critical limitation of our findings is its reliance on tools like AutoDock and PRODIGY for preliminary binding affinity estimates, which lack the thermodynamic precision of advanced methods. Although calibrating docking scores with experimental data or using alchemical free energy calculations can improve accuracy, these methods are computationally expensive and require high-quality data, which is often unavailable. Gcoupler prioritizes speed, scalability, and accessibility, especially for data-sparse scenarios. By focusing on efficient, data-driven classification methods, it balances performance with practicality for large-scale screening. In this study, to address this limitation, we employed MD simulations with MM/GBSA, incorporating factors like protein flexibility and solvation effects for more accurate ΔG calculations. While computationally intensive approaches were beyond this study’s scope, we ensured reported ΔG values reflected system conformational flexibility by basing them on pre-simulated docked structures from molecular dynamics simulations. Further, our results suggest that the metabolite binds to the Ste2p-Gpa1 interface and modulates receptor activity upon pheromone stimulation, as supported by various assays. However, the precise sequence of interactions between Ste2p, the metabolite, and Gpa1 remains unexplored, as it requires sequential experiments beyond this study’s scope. Taken together, addressing these limitations in future work would significantly strengthen our conclusions and provide deeper insights into the precise molecular mechanisms underlying the observed phenotypic effects.</p>
</sec>
<sec id="s4">
<title>Material and methods</title>
<sec id="s4a">
<title>Backend code for the Gcoupler</title>
<p>The back-end code for Gcoupler is implemented entirely in Python (3.8) and comprises four modules: Synthesizer, Authenticator, Generator, and BioRanker. Synthesizer employs LigBuilder V3.0 (<xref ref-type="bibr" rid="c71">Yuan et al., 2020</xref>) for <italic>de novo in silico</italic> ligand synthesis, identifying protein cavities likely to be active or allosteric sites using a hybrid GROW-LINK approach with a Genetic Algorithm. The module autonomously selects one cavity for ligand synthesis based on user-defined residue positions. Using the CAVITY function of LigBuilder (<xref ref-type="bibr" rid="c72">Yuan et al., 2011</xref>), it classifies 3D grid points around the protein into occupied, vacant, and surface points and integrates geometric and physicochemical properties to identify binding sites (<xref ref-type="bibr" rid="c15">Clark et al., 1989</xref>). Synthesizer outputs ligand structures in SMILES and PDBQT formats, alongside cavity grid coordinates for downstream modules. Authenticator validates the synthesized ligands using AutoDock Vina (1.2.3) for virtual screening (<xref ref-type="bibr" rid="c62">Trott and Olson, 2010</xref>). Binding energy calculations classify ligands into High-Affinity Binders (HABs) and Low-Affinity Binders (LABs), preserving balance for subsequent deep learning analysis. The default energy threshold is set to −7 kcal/mol, but users can explore alternative cutoffs, visualize distributions, and perform statistical comparisons within the workflow. These steps ensure precise identification and prioritization of ligand candidates for further analysis. The Authenticator uses the Kolmogorov-Smirnov test (<xref ref-type="bibr" rid="c8">Berger and Zhou, 2014</xref>), Anderson-Darling test (<xref ref-type="bibr" rid="c18">Engmann and Cousineau, 2011</xref>), and Epps-Singleton test (<xref ref-type="bibr" rid="c22">Goerg and Kaiser, 2009</xref>) for hypothesis testing for the comparison of the distributions. The Authenticator module visualizes ligand distributions using overlapping density plots and Empirical Cumulative Distribution Function (ECDF) curves. If the default threshold fails to produce statistically meaningful separation, users can supply alternative negative datasets, such as decoys generated via Gcoupler’s inbuilt RDKit Chem module or custom datasets (Landrum, n.d.). The Generator module builds deep learning-based classification models using the DeepChem (2.6.1) library (<xref ref-type="bibr" rid="c47">Ramsundar et al., 2019</xref>). It accepts High-Affinity Binders (HABs) and Low-Affinity Binders (LABs)/decoys from the Authenticator module to train four graph-based models: Graph Convolution Model (GCM), Graph Convolution Network (GCN) (<xref ref-type="bibr" rid="c33">Kipf and Welling, 2016</xref>), Attentive FP (AFP) (<xref ref-type="bibr" rid="c68">Xiong et al., 2020</xref>), and Graph Attention Network (GAT) (<xref ref-type="bibr" rid="c65">Veličković et al., 2018</xref>). Class imbalance is addressed through upsampling techniques. Generator tests all models using default hyperparameters, returning performance metrics for user selection. Hyperparameters can be tuned via manual settings or using default values followed by k-fold cross-validation. The final optimized model, trained on the complete synthetic dataset (HAB + LAB/decoys), enables large-scale screening of user-supplied compounds based on their SMILES representations. The BioRanker module performs post-prediction analysis for functional activity-based compound screening. Positively predicted compounds are selected using a stringent probability threshold or adaptive methods such as G-means and Youden’s J statistic, which optimize sensitivity and specificity. The selected compounds are projected into biological activity spaces (Chemistry, Targets, Networks, Cells, Clinics) by comparing their biological activity descriptor vectors with those of HABs using cosine similarity (<xref ref-type="bibr" rid="c9">Bertoni et al., 2021</xref>). A modified PageRank algorithm ranks compounds based on activity-specific scores, with support for multi-activity ranking to refine results based on user-defined biological properties, ensuring precise and context-relevant compound prioritization.</p>
<p>Additional information about the backend code for Gcoupler, along with methodology for Runtime analysis, Sequence-structural-functional level analysis, Molecular Dynamics Simulation, Molecular docking (AutoDock), Functional enrichment analysis, and Protein-protein docking, can be accessed in the Supplementary Information.</p>
</sec>
<sec id="s4b">
<title>Gcoupler Benchmarking</title>
<p>To assess batch effects across Gcoupler runs for a specific cavity, we utilized the standard Gcoupler Docker image. Intracellular cavity 4 (IC4) of the Ste2 protein of yeast was used for benchmarking. A total of 100 molecules were <italic>in silico</italic> synthesized by the Synthesizer module of Gcoupler iteratively. Post-generation, atom pair fingerprints (ChemmineR; R package) were calculated for the synthesized molecules from each run, and the data was visualized using Principal Component Analysis and pairwise comparison using Tanimoto Similarity (ChemmineR, R package).</p>
<p>For model benchmarking, Gcoupler was validated on GPCRs from the DUD-E dataset, alongside the information about the active ligands and their randomly selected number-matched decoys (<xref ref-type="bibr" rid="c41">Mysinger et al., 2012</xref>). Additionally, Gcoupler’s performance in identifying experimentally elucidated allosteric sites and modulators was tested using PDB complexes obtained from the RCSB PDB database.</p>
</sec>
<sec id="s4c">
<title>Metabolomics</title>
<p>Wildtype (BY4741) and <italic>ste2Δ</italic> yeast strains were grown in YPD medium at 30°C, 150 rpm, through primary and secondary cultures (16 hours each). Equal cell numbers (1.5 mL) were aliquoted into a 96-well deep well plate. α-factor (Sigma-Aldrich) was added at final concentrations of 10, 20, 30, 40, and 50 μM (eight replicates each). DMSO served as the solvent control, while untreated WT and <italic>ste2Δ</italic> conditions received no treatment. Plates were incubated (30°C, 150 rpm, 4 hours) under a breathable membrane. A 50 μL aliquot was taken for Propidium Iodide (PI; 11195, SRL) assay as described in Supplementary Information. Following the PI assay, four pooled replicates were pelleted (6000 rpm, 5 min, RT), treated with zymolyase (40 U/mL, 1X PBS, 30°C, 1 hour), washed with PBS, and metabolomics analysis was performed. Data analysis included peak normalization, omission of metabolites with constant or &gt;50% missing values, and kNN-based imputation (MetaboAnalyst). Data were IQR-filtered, and differentially enriched metabolites (DEMs) were identified by calculating log2 fold change (|log2FC| ≥ 1, p &lt; 0.05 via Student’s t-test). Pathway Over-Representation Analysis (ORA) was performed using MetaboAnalyst with hypergeometric or Fisher’s exact tests to assess pathway enrichment against background metabolite distributions. Further details about the methodology are available in Supplementary Information.</p>
</sec>
<sec id="s4d">
<title>Genetic Screening</title>
<p>Fifty-three knockout strains from the Yeast Deletion Collection, along with WT and <italic>ste2Δ</italic>, were treated with α-factor (30 μM), while DMSO served as the solvent control. Plates were incubated for 4 hours. A 50 μL aliquot was used to measure the Propidium iodide-based cell viability assessment assay as described in the Supplementary Information. Fluorescence data were normalized to blank-adjusted OD600, followed by two additional rounds of normalization with unstained and HK controls. The percentage fold change for the treated group was calculated relative to the untreated group, and statistical significance was determined using a one-sample Student’s t-test. Further details about the methodology used is available in Supplementary Information.</p>
</sec>
<sec id="s4e">
<title>Pre-loading of Yeast cells with a metabolite</title>
<p>Yeast cells were cultured in YPD medium at 30°C, 200 rpm for 16 hours in primary and secondary cultures. Equal cell densities (5 μL) from secondary cultures were inoculated into 96-well plates containing 145 μL YPD with metabolites Coenzyme Q6 (CoQ6, 900150O, Avanti<sup>®</sup> Polar Lipids), Zymosterol (ZST, 700068P, Avanti<sup>®</sup> Polar Lipids), and Lanosterol (LST, L5768, Sigma-Aldrich) at 0.1 μM, 1 μM, and 10 μM concentrations. Plates were incubated for 24 hours at 30°C, 200 rpm, with multiple biological replicates. Ethanol-treated wells served as solvent controls. For site-directed <italic>STE2</italic> mutants, the mutants were grown in YPD for primary and secondary cultures, but the metabolite pre-loading was performed in YPGR instead of YPD to induce Ste2 expression.</p>
<p>After pre-loading, the following assays were performed: growth kinetics, propidium iodide-based assay, FUN<sup>TM</sup>1 staining, Mating assay, phospho-MAPK activity-based western blot, and transgenic reporter assay. The detailed protocol for each of these assays is available in Supplementary Information.</p>
</sec>
<sec id="s4f">
<title>RNA-Sequencing</title>
<p>Yeast cells (BY4741) were cultured in YPD medium at 30 °C, 200 rpm, with or without lanosterol (LST, 1 μM) in biological duplicates. Cells were subsequently treated or untreated with α-factor (30 μM) for 2 hours. RNA was isolated following Mittal et al. (<xref ref-type="bibr" rid="c38">Mittal et al., 2022</xref>). Sequencing quality was assessed using MultiFastQ, and paired-end reads were trimmed and aligned to the S. cerevisiae reference genome (ENSEMBL R64-1-1; GCA_000146045.2) using the Rsubread package (v2.6.4). Gene expression counts were generated via featureCounts and normalized using TMM (Supplementary Table 7). Differential expression analysis was performed with NOISeq (v2.38.0) (Supplementary Tables 8–10). Functional enrichment was assessed using the Gene Ontology Term Finder (v0.86) from the Saccharomyces Genome Database. Raw FASTQ files and normalized expression data are available on Zenodo. Additional details are available in the Supplementary Information.</p>
</sec>
<sec id="s4g">
<title>Site-Directed Mutagenesis</title>
<p>The gene encoding wild-type <italic>STE2</italic> was PCR amplified from the genome of <italic>Saccharomyces cerevisiae</italic> and further cloned into plasmid pRS304 under galactose-inducible <italic>GAL1</italic> promoter to generate plasmid pRS304-P<italic><sub>GAL1</sub></italic>-STE2-CYC1 using Gibson assembly (<xref ref-type="bibr" rid="c20">Gibson et al., 2010</xref>, <xref ref-type="bibr" rid="c21">2009</xref>). The mutants were generated by PCR amplifying the gene with primers consisting of respective mutations and cloned into plasmid pRS304 under <italic>GAL1</italic> promoter to generate pRS304-P<italic><sub>GAL1</sub></italic>-STE2 S75A-CYC1, pRS304-P<italic><sub>GAL1</sub></italic>-STE2 T155D-CYC1, and pRS304-P<italic><sub>GAL1</sub></italic>-STE2 L289K-CYC1. Wild-type (rtWT) and mutant <italic>STE2</italic> were integrated by digesting the pRS304 vector with restriction enzyme BstXI to generate a linearized plasmid and transformed into the <italic>Saccharomyces cerevisiae</italic> BY4741 <italic>ste2Δ</italic> strain. Additional details about the methodology are available in the Supplementary Information</p>
</sec>
<sec id="s4h">
<title>Cardiomyocytes Hypertrophy Models</title>
<p>Human AC16 cardiomyocytes were cultured in DMEM-F12 (Thermo Scientific) with 12.5% fetal bovine serum (FBS) at 37°C and 5% CO2. Cells were seeded in a 24-well plate for size measurements, treated after 24 hours with metabolites (CoQ6, ZST, LST, FST, CoQ10) at 2.5 μM, and incubated overnight with 1% FBS. The medium was refreshed with fresh metabolites and isoproterenol (25 μM) for 48 hours. Cells were washed with PBS, fixed with 4% paraformaldehyde, and stained with wheat germ agglutinin (Thermo Scientific) and DAPI. Images were captured using a Leica DMI 6000 B microscope at 20X magnification, and cell area was measured using ImageJ. Neonatal rat cardiomyocytes were isolated from 1-3-day-old SD rat pups using Collagenase Type II. After heart explantation and digestion, the cells were centrifuged and pre-plated for 90 minutes to remove fibroblasts. The cardiomyocytes were seeded in a gelatin-coated 24-well plate, incubated overnight with 2.5 μM metabolites and 1% FBS, and then treated with metabolites (2.5 μM) and isoproterenol (10 μM) for 72 hours. Cells were fixed, stained with alpha-sarcomeric actinin and DAPI, and images were captured using a Leica DMI 6000 B at 20X magnification. Cell area was quantified using ImageJ. Additional details about the methodology are available in Supplementary Information.</p>
</sec>
<sec id="s4i">
<title>Statistical Analysis</title>
<p>Statistical analyses were performed using Past4 software or R Programming. The Mann-Whitney U test was applied to compare medians between two distributions (non-parametric), while Student’s t-test was used for pairwise comparisons of means. P-value correction was performed using the Bonferroni method when necessary. A significance threshold of 0.05 was set, with *, **, ***, and **** indicating p-values &lt;0.05, &lt;0.01, &lt;0.001, and &lt;0.0001, respectively.</p>
</sec>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="das18">
<title>Data Availability</title>
<p>The processed untargeted metabolomics data is provided as Supplementary Information. The raw RNA sequencing files are available at ArrayExpress under accession <italic>E-MTAB-12992</italic>.</p>
</sec>
<ack>
<title>Acknowledgements</title>
<p>The authors thank the IT-HelpDesk team of IIIT-Delhi for assisting with the computational resources. We thank all the members of the Ahuja lab for their intellectual contributions at various stages of this project. We thank Prof. G.P.S Raghava for providing critical comments on our manuscript. We thank Dr. Arjun Ray for providing intellectual support. We also thank Dr. Martin Graef and Dr. Kaushik Chakraborty for sharing yeast strains and the NIPER Guwahati central facility for helping us with high-resolution metabolomics. The Ahuja lab is supported by the Ramalingaswami Re-entry Fellowship (BT/HRD/35/02/2006), a re-entry scheme of the Department of Biotechnology, Ministry of Science &amp; Technology, Government of India, Start-Up Research Grant (SRG/2020/000232) from the Science and Engineering Research Board, and a research grant from IHUB Anubhuti (Project Grant/23) and an intramural Start-up grant from Indraprastha Institute of Information Technology-Delhi. The INSPIRE faculty grant from the Department of Science &amp; Technology, India, funds the Sengupta lab. Gupta Lab is funded by the Ramalingaswami Re-entry Fellowship (BT/RLF/re-entry/14/2019) from the Department of Biotechnology, Government of India.</p>
</ack>
<sec id="additional-info" sec-type="additional-information">
<title>Additional information</title>
<sec id="s4k">
<title>Code Availability</title>
<p>A Python package for Gcoupler is provided via pip <ext-link ext-link-type="uri" xlink:href="https://test.pypi.org/project/Gcoupler/">https://test.pypi.org/project/Gcoupler/</ext-link>. A docker container pre-compiled with Gcoupler and all of its dependencies can be found at <ext-link ext-link-type="uri" xlink:href="https://hub.docker.com/r/sanjayk741/gcoupler">https://hub.docker.com/r/sanjayk741/gcoupler</ext-link>. The source code of Gcoupler is available on the project GitHub page: <ext-link ext-link-type="uri" xlink:href="https://github.com/the-ahuja-lab/Gcoupler">https://github.com/the-ahuja-lab/Gcoupler</ext-link> and also at Zenodo with DOI: 10.5281/zenodo.7835335, whereas the raw sequencing files can be accessed using DOI: 10.5281/zenodo.7834294.</p>
</sec>
<sec id="s4l" sec-type="ethics-statement">
<title>Ethical statement</title>
<p>The local IAEC (Institutional Animal Ethics Committee) committee at CSIR-Central Drug Research Institute approved all the animal experiments (IAEC/2020/38) following the guidelines of the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), New Delhi, Government of India.</p>
</sec>
</sec>
    <sec id="additional-files" sec-type="supplementary-material">
        <title>Additional files</title>
        <supplementary-material id="supp1">
            <label>Supplementary Figure 1</label>
            <caption><title>Gcoupler Benchmarking using experimentally validated orthosteric ligands of GPCRs.</title>
            <p><bold>(a)</bold> AUC-ROC curves depicting the optimal probability cutoff recommended by G-means and Youden J index algorithms, respectively. Notably, the optimal threshold is indicated by the black dot on the ROC curve. <bold>(b)</bold> Molecular representation depicting the indicated experimentally validated orthosteric sites of the AA2AR, ADRB1, ADRB2, CXCR4, and DRD3 receptors, with the zoom-in inlet on the right highlighting the ligand and the cavity topologies. <bold>(c)</bold> Overlapping density plots comparing the distributions of synthetic compounds predicted to target the indicated receptors into High-Affinity Binders (HAB) and Low-Affinity Binders (LAB) using the Authenticator module of the Gcoupler package. <bold>(d)</bold> Bar graphs indicating the performance of the indicated models made for the experimentally elucidated orthosteric sites of the indicated GPCRs, generated using the Gcoupler workflow. <bold>(e)</bold> Confusion matrices indicating the relative proportions of experimentally determined ligands and their respective decoys (randomly selected to match # of ligands for each receptor). Note that the number of active ligands and decoys is mentioned at the bottom.</p></caption>   
            <media xlink:href="528587v6_file01.pdf"/>
        </supplementary-material>
        <supplementary-material id="supp2">
            <label>Supplementary Figure 2</label>
            <caption><title>Gcoupler Benchmarking using experimentally validated allosteric ligands of GPCRs.</title>
                <p><bold>(a)</bold> Molecular representation of the β2AR, CCR2, and CCR9 receptors with highlighted experimentally validated intracellular allosteric cavity and ligand. <bold>(b)</bold> Overlapping density plots comparing the distributions of synthetic High-Affinity Binders (HAB) and Low-Affinity Binders (LAB) predicted to target the allosteric cavities of the indicated GPCRs using the Gcoupler package. <bold>(c)</bold> Bar graphs depicting the performance metrics of the indicated classification model generated using Gcoupler for the highlighted allosteric cavities of the indicated proteins.</p></caption>
            <media xlink:href="528587v6_file02.pdf"/>
        </supplementary-material>
        <supplementary-material id="supp3">
            <label>Supplementary Figure 3</label>
            <caption><title>Run Time comparison of Gcoupler and AutoDock.</title>
                <p><bold>(a)</bold> Flowchart depicting the entire workflow used to compute and compare the runtime using AutoDock and Gcoupler. Of note, the Synthesizer, Authenticator, and Generator module of Gcoupler are indicated alongside their key processes. <bold>(b)</bold> Ribbon diagram depicting the ADRA1A predicted structure using Alphafold (ID: AF-P35348). <bold>(c)</bold> A waterfall chart depicts the timestamp information about the key steps involved in AutoDock. Time consumed at the indicated steps is mentioned in seconds and hours along the y-axis and above bars, respectively. <bold>(d)</bold> Waterfall chart depicting the timestamp information about the key steps involved in Gcoupler. Time consumed at the indicated steps is mentioned in seconds and hours along the y-axis and above bars, respectively. <bold>(e)</bold> Bar plot depicting the comparison between the total time consumed by the AutoDock and Gcoupler to predict the binding of experimentally validated ligands for ADRA1A (AF-P35348). <bold>(f)</bold> Boxplot depicting the performance metrics of the 10-fold cross-validation of the training data obtained using Gcoupler. <bold>(g)</bold> Boxplot depicting the performance metrics of the 10-fold cross-validation of the testing data obtained using Gcoupler. <bold>(h)</bold> Scatterplot depicting the relationship between AutoDock computed binding energies and Gcoupler computed prediction probabilities of the experimentally validated ligands of ADRA1A protein. <bold>(i)</bold> Density plot depicting the distribution of RMSD between GPCR-Gα cavity across selected GPCRs-G-protein pairs. Of note, the RMSD of the Gα-protein cavity was normalized with the RMSDs of the respective whole proteins across all pairwise comparisons. <bold>(j)</bold> Heatmap depicting the RMSD values obtained by comparing all the GPCR-Gα-protein interfaces of the available human GPCRs from the protein data bank. <bold>(k)</bold> Heatmap depicting the RMSD values obtained by comparing the selected human GPCRs available in the protein data bank. <bold>(l)</bold> Density plot depicting the distribution of cosine similarities among the <italic>in silico</italic> synthesized ligands of the GPCR-Gα-protein interfaces of the available human GPCRs using Gcoupler.</p></caption>
            <media xlink:href="528587v6_file03.pdf"/>
        </supplementary-material>
        <supplementary-material id="supp4">
            <label>Supplementary Figure 4</label>
            <caption><title>Ste2 protein cavities prediction using Gcoupler.</title>
                <p><bold>(a)</bold> Schematic diagram depicting the hypothesis that the intracellular yeast metabolites could allosterically modulate the GPCR-Gα-protein (Ste2p-Gpa1p) interface and, therefore, the Ste2p signaling pathway in yeast. <bold>(b)</bold> Overlapping Ste2p (GPCR) ribbon diagram depicting the structural similarity between the experimentally elucidated Ste2p structure before and after molecular dynamics simulation using GROMACS software. RMSD value is depicted at the bottom. <bold>(c)</bold> Flowchart depicting the key steps used for the molecular dynamics simulation of Ste2p using CHARMM-GUI and GROMACS software. <bold>(d)</bold> Line plot depicting the changes in the density (kg/m³) along the z-axis of the three-dimensional Ste2p structure. <bold>(e)</bold> Line plot depicting the decline in the potential (kJ/mol) over molecular dynamics simulation time in picoseconds (ps). <bold>(f)</bold> Line plot depicting the changes in the density (kg/m³) of the overall system over molecular dynamics simulation time in picoseconds (ps). <bold>(g)</bold> Line plots depicting the changes in the pressure (in bars) and temperature (in Kelvin) of the overall system during molecular dynamics simulation of Ste2 protein. <bold>(h)</bold> Line plot depicting the Root Mean Square Deviation (RMSD) changes of the Ste2 protein during molecular dynamics simulation. Note that the RMSD values are indicated in nanometers (nm). <bold>(i)</bold> Ramachandran plot depicting the location of simulated Ste2 protein residues in the favorable and unfavorable regions. <bold>(j)</bold> Barplot depicting the predicted cavity volumes (Å). <bold>(k)</bold> Scatterplot depicting the relationship between the cavity volume and surface area in the indicated cavities of the Ste2 protein. <bold>(l)</bold> Heatmap depicting the percentage of amino acids of the indicated cavities residing in the EC (extracellular), IC (intracellular), and TM (transmembrane) region of the Ste2 protein. <bold>(m)</bold> Scatterplot depicting the predicted drug score of the indicated cavities of the Ste2 protein. <bold>(n)</bold> Snake plot depicting the key amino acids of the Ste2 protein alongside their location within the indicated functional cavities. <bold>(o)</bold> Snake plot depicting the conservation of Ste2 protein at the amino acid level. Of note, Ste2 proteins from 15 related yeast species were used for computing the conservation score.</p></caption>
            <media xlink:href="528587v6_file04.pdf"/>
        </supplementary-material>
        <supplementary-material id="supp5">
            <label>Supplementary Figure 5</label>
            <caption><title>Comparison of the chemical composition of cavity-specific ligands of Ste2 protein.</title>
                <p><bold>(a)</bold> Venn diagram depicting the number of overlapping amino acids constituting the Extracellular Cavity 1 (EC1), Intracellular Cavity 4 (IC4), and Intracellular Cavity 5 (IC5) of the Ste2p. <bold>(b)</bold> Two-dimensional and <bold>(c)</bold> three-dimensional Principal Component Analysis plots depicting the segregation of <italic>in silico</italic> synthesized ligands for the indicated cavities via Gcoupler. Of note, atom pair fingerprints were used as features for this analysis. <bold>(d)</bold> Scatter plot depicting the relationship between the depth of the pharmacophore features and the neighboring grids. <bold>(e)</bold> Donut charts illustrating the properties of amino acids constituting the pharmacophore for each of the indicated cavities. <bold>(f)</bold> Two-dimensional and <bold>(g)</bold> three-dimensional Principal Component Analysis plots depicting the chemical properties of <italic>in silico</italic> synthesized ligands from five independent runs on the IC4 of the Ste2p using the Gcoupler Synthesizer module. Of note, atom pair fingerprints were used as features for this analysis. <bold>(h)</bold> Heatmap depicting the Tanimoto Similarities scores between the synthesized ligands for IC4 of Ste2p across five independent runs using Gcoupler.</p></caption>
        <media xlink:href="528587v6_file05.pdf"/>
        </supplementary-material>
        <supplementary-material id="supp6">
            <label>Supplementary Figure 6</label>
            <caption><title>Sanity Check of Gcoupler Predictions.</title>
                <p><bold>(a)</bold> Principal Component Analysis depicting chemical heterogeneity of synthetic compounds synthesized using Gcoupler across intracellular cavities (IC4 and IC5). Notably, the compounds were segregated into High-Affinity Binders (HAB) and Low-Affinity Binders (LAB) by the Authenticator module of the Gcoupler. <bold>(b)</bold> Heatmap depicting the chemical similarity of the <italic>de novo</italic> synthesized HAB (dark green) and LAB (light green) across intracellular cavities (IC4 and IC5) of the Ste2 protein. Tanimoto similarities were computed using Atomic fingerprints. <bold>(c)</bold> Heatmaps illustrating the relative enrichment of the indicated functional groups (RNH2: primary amine, R2NH: secondary amine, R3N: tertiary amine, ROPO3: monophosphate, ROH: alcohol, RCHO: aldehyde, RCOR: ketone, RCOOH: carboxylic acid, RCOOR: ester, ROR: ether, RCCH: terminal alkyne, RCN: nitrile) among the Gcoupler-based <italic>de novo</italic> synthesized binders of Ste2p receptor across IC4 and IC5. <bold>(d)</bold> Box plots depicting the model’s performances across the 10-fold cross-validation. The upper and lower box plots depict the performance metrics of models trained using the <italic>de novo</italic> ligands for intracellular cavities (IC4 and IC5), respectively, of the Ste2 protein. <bold>(e)</bold> Venn diagrams depicting the number of yeast metabolites from YMDB predicted to bind to the Ste2p-Gpa1p interface, predicted using Gcoupler and AutoDock. Of note, IC4 and IC5 represent intracellular cavities 4 and 5 of the Ste2 protein, respectively. <bold>(f)</bold> Principal Component Analysis depicting chemical heterogeneity of endogenous yeast metabolites predicted to bind to the intracellular cavities (IC4 and IC5) of the Ste2 protein. Notably, the compounds were segregated into High-Affinity Metabolites (HAM) and Low-Affinity Metabolites (LAM) by the Generator module of the Gcoupler. <bold>(g)</bold> Heatmap illustrating the relative enrichment of the indicated functional groups among the endogenous intracellular allosteric modulators (metabolites) of Ste2 receptor across IC4 and IC5. <bold>(h)</bold> Percentage stacked barplot depicting the relative enrichment of the indicated functional groups of the High-Affinity Metabolites (HAM) and Low-Affinity Metabolites (LAM) across intracellular cavities (IC4 and IC5) of the Ste2 protein. <bold>(i)</bold> Heatmap depicting PageRank score of the selected metabolites for IC4 and <bold>(j)</bold> IC5 with respect to different biological properties. <bold>(k)</bold> Box plots depicting the performance parameters of the indicated models generated using Gcoupler against the IC4 cavity of Ste2p. Note that the training and testing datasets were generated randomly (5 iterations) from the <italic>in silico</italic> synthesized ligands from Gcoupler. <bold>(l)</bold> Scatter plots depicting the segregation of High/Low-Affinity Metabolites (HAM/LAM) (indicated in green and red) identified using the Gcoupler workflow with 100% training data. Of note, models trained on lesser training data size (25%, 50%, and 75% of HAB/LAB) severely failed to segregate High-Affinity Metabolites (HAM) and Low-Affinity Metabolites (LAM) (along the Y-axis). The X-axis represents the binding affinity calculated using IC4-specific docking using AutoDock. <bold>(m)</bold> Bar plots depicting the correlation values obtained between the Gcoupler prediction probabilities and AutoDock computed binding energies in the indicated training data size. <bold>(n)</bold> Box plots depicting the distributions for binding energies of the High-Affinity Metabolites and Low-Affinity Metabolites computed using cavity-specific docking and full docking via Autodock for IC4 and IC5 of the Ste2p.</p></caption>
            <media xlink:href="528587v6_file06.pdf"/>
        </supplementary-material>
        <supplementary-material id="supp7">
            <label>Supplementary Figure 7</label>
            <caption><title>Untargeted metabolomics and genetic screening suggest an interlink between metabolites and Ste2p-mediated Programmed Cell Death.</title>
                <p><bold>(a)</bold> Screenshot of the central yeast metabolism from the Kyoto Encyclopedia of Genes and Genomes (KEGG) indicating the key metabolic pathways (highlighted in red) harboring metabolic intermediates predicted as high-affinity binders of GPCR-Gα-protein (Ste2p-Gpa1p) interface by Gcoupler. <bold>(b)</bold> Venn diagram depicting the percentage overlaps of the mating-related genes reported in the literature and those used in the screening. The <italic>STE2</italic> was the only common gene. <bold>(c)</bold> Heatmap depicting the growth curve profiles of the wild-type, single metabolic mutants, and <italic>ste2Δ</italic> under optimal growth conditions. <bold>(d)</bold> Schematic diagram depicting the experimental workflow of the untargeted metabolomics experiment. Notably, the experiment involves the usage of increasing doses of α-factor to induce PCD and to enrich the surviving cells selectively. <bold>(e)</bold> Boxplot depicting the increase in the propidium iodide fluorescence upon the increasing concentration of α-factor treatment. Heat-killed (HK), untreated, and vehicle (DMSO-treated) were used as controls, whereas the increasing concentration of α-factor surviving wild-type cells was used as test conditions. The Mann-Whitney U test was used to calculate statistical significance. Asterisks indicate statistical significance, whereas ns represents non-significance. <bold>(f)</bold> Heatmap depicting the relative (de)enrichment of differentially enriched metabolites in the indicated conditions. Of note, four biological replicates per condition were used in the untargeted metabolomics. <bold>(g)</bold> Principal Component Analysis depicting the segregation of indicated samples based on their metabolomics profiles along the PC1, PC2, and PC3. <bold>(h)</bold> Correlation plot depicting Pearson’s correlation of the metabolome of the indicated samples. <bold>(i)</bold> Heatmap depicting the relative enrichment of all the detected metabolites in the indicated condition. Heat-killed (HK), untreated, and vehicle (DMSO-treated) were used as controls, whereas the increasing concentration of α-factor surviving wild-type cells was used as test conditions. <bold>(j)</bold> Venn diagram indicating that 38 predicted intracellular allosteric modulators of Ste2p were identified in the untargeted metabolomics profiling. <bold>(k)</bold> Scatterplot depicting the Pathway Over Representation Analysis (ORA) results of the differentially enriched metabolites (treated vs. vehicle control) identified using untargeted metabolomics.</p></caption>
            <media xlink:href="528587v6_file07.pdf"/>
        </supplementary-material>
        <supplementary-material id="supp8">
            <label>Supplementary Figure 8</label>
            <caption><title>Docking and Molecular Dynamics simulations suggest the stability of the Ste2-metabolite complex.</title>
                <p><bold>(a)</bold> Ligplots depicting the interacting amino acid residues and atoms of the Ste2 protein and indicated metabolites for the intracellular cavities (IC4 and IC5). <bold>(b)</bold> Table indicating the Van der Waals (ΔE<sub>vdw</sub>), electrostatic (ΔE<sub>elec</sub>), polar solvation (ΔE<sub>psolv</sub>), and non-polar solvation (ΔE<sub>npsolv</sub>) energies along with net binding free-energy (ΔG<sub>bind</sub>) in kcal/mol of the three independent replicates of the indicated metabolites across intracellular cavities IC4 and IC5 of the Ste2p. Note the values in the table are provided as mean ± standard errors. <bold>(c)</bold> Line plot depicting the variation in the RMSD of the indicated metabolites bound to the intracellular cavity 4 (IC4) at the GPCR-Gα interface of the Ste2p, obtained using longer MD simulation runs. Notably, RMSD is provided in Angstroms (Å), whereas the simulation time is in nanoseconds (ns).</p>         </caption>
            <media xlink:href="528587v6_file08.pdf"/>
        </supplementary-material>
        <supplementary-material id="supp9">
            <label>Supplementary Figure 9</label>
            <caption><title>Divergent characteristics of site-directed missense mutants of <italic>STE2</italic> gene.</title>
                <p><bold>(a)</bold> Line plots depicting the total energy decomposition of the individual amino acids of the Ste2p (three independent replicates) computed using MD simulations in IC4 (left) and IC5 (right). <bold>(b)</bold> Molecular representation of the Ste2 protein structures (blue) and the miniGpa1-proteins (cyan), with the highlighted interface residues (red and green) in the indicated conditions. <bold>(c)</bold> Scatterplot depicting the net binding free-energy ΔG (kcal/mol) of the Ste2p (with and without indicated metabolites) with miniG-protein (y-axis) and α-factor (x-axis). <bold>(d)</bold> Barplot depicting RMSD values of the Ste2 protein with indicated metabolite across intracellular cavities IC4 and IC5.</p></caption>
            <media xlink:href="528587v6_file09.pdf"/>
        </supplementary-material>
        <supplementary-material id="supp10">
            <label>Supplementary Figure 10</label>
            <caption><title>Exogenous supplementation of selective metabolites rescues α-factor-mediated Programmed Cell Death.</title>
                <p><bold>(a)</bold> Growth curve profiles of the wild-type (control), <italic>ste2Δ,</italic> and wild-type yeast pre-treated with the indicated metabolites. <bold>(b)</bold> Schematic diagram (left) depicting the workflow opted to monitor α-factor-induced programmed cell death (PCD) in the wild-type yeast cells pre-loaded for 24 hours with ubiquinone 6 (CoQ6), zymosterol (ZST), and lanosterol (LST) at three different concentrations. Beanplots on the right depict the changes in the α-factor-mediated PCD in the indicated conditions. Notably, cell viability was assessed by computing the area under the curve (AUC) of the growth kinetics. The Mann-Whitney U test was used to calculate statistical significance. Asterisks indicate statistical significance, whereas ns represents non-significance. <bold>(c)</bold> Beanplot depicting the fold change in the α-factor-mediated programmed cell death, assessed using the propidium iodide-mediated programmed cell death in the indicated conditions. The Mann-Whitney U test was used to calculate statistical significance. Asterisks indicate statistical significance, whereas ns represents non-significance. <bold>(d)</bold> Representative micrographs (left) depicting the growth of the cells (mating response) pretreated with indicated metabolites in the indicated single drop-out medium (SC-Lys and SC-Met). Quantifications of the mating response with respect to the SC-Met control are indicated as a bar graph (mean ± SEM) on the right (n = 3 biological replicates, each with three technical replicates). The Student’s t-test was used to compute the statistical significance. Asterisks indicate statistical significance, whereas ns represents non-significance.</p>            </caption>
            <media xlink:href="528587v6_file10.pdf"/>
        </supplementary-material>
        <supplementary-material id="supp11">
            <label>Supplementary Figure 11</label>
            <caption><title>Effects of Ste2 Mutants on Shmoo Formation in Response to α-Factor.</title>
                <p><bold>(a)</bold> Ligplots depicting the interacting amino acid residues of the mutant Ste2 proteins (mutation site indicated) and atoms of indicated metabolites at the intracellular cavities (IC4 and IC5). <bold>(b)</bold> Growth curve profiles of the reconstituted wild-type (rtWT), and indicated missense site-directed mutants. <bold>(c)</bold> Schematic representation depicting the overall experimental workflow designed for the quantitative assessment of the shmoos formation upon α-factor treatment. <bold>(d)</bold> Micrographs depicting the phase contrast images of the rtWT cells, pretreated with the indicated metabolites, with and without α-factor treatment, Scale 10 µm. Mean-Whisker plot (right) indicating the relative proportions of shmoos forming cells in the indicated conditions. <bold>(e)</bold> Micrographs depicting the phase contrast images of the indicated site-directed missense mutants of the <italic>STE2</italic> gene, pretreated with the indicated metabolites, with and without α-factor treatment, Scale 10 µm. Mean-Whisker plot (right) indicating the relative proportions of shmoos forming cells in the indicated conditions. The Student’s t-test was used to compute the statistical significance of <bold>d</bold> and <bold>e</bold>. Asterisks indicate statistical significance, whereas ns represents non-significance. Error bars represent the standard error of the mean (SEM).</p></caption>
            <media xlink:href="528587v6_file11.pdf"/>
        </supplementary-material>
        <supplementary-material id="supp12">
            <label>Supplementary Figure 12</label>
            <caption><title>RNA-Sequencing unveils genes involved in attenuating α-factor-induced cell death response.</title>
                <p><bold>(a)</bold> A table highlighting the key differentially expressed genes in the indicated conditions reported to be involved in regulating yeast mating response. Arrowheads and their direction represent the direction of differential expression. <bold>(b)</bold> A table highlighting the key differentially expressed genes in the indicated conditions reported to be involved in regulating yeast PCD-like signaling response. Arrowheads and their direction represent the direction of differential expression. <bold>(c)</bold> M-D plots (left) from the NOIseq analysis highlighting the differentially expressed genes (colored) in the indicated conditions. Bar plots (middle) depicting the prominent Gene Ontologies in the indicated conditions. Venn diagram (right) depicting the overlaps between the differentially expressed genes and the genes used in biochemical assays in this study. <bold>(d)</bold> Venn diagram depicting the overlap between the differentially expressed genes obtained from the RNA-Seq analysis and the yeast knockout library. <bold>(e)</bold> Growth curve profiles of the wild-type and indicated knockouts from the yeast knockout library. <bold>(f)</bold> Box plot depicting the relative proportion of dead cells upon α-factor exposure in the indicated knockouts from the yeast knockout library as inferred using propidium iodide-based cell viability fluorometric assay (n=12 biological replicates from 2 experiments). The y-axis represents the fold change of the propidium iodide fluorescence values with respect to their respective controls. The Mann-Whitney U test was used to calculate statistical significance. Asterisks indicate statistical significance, whereas ns represents non-significance.</p></caption>
            <media xlink:href="528587v6_file12.pdf"/>
        </supplementary-material>
        <supplementary-material id="supp13">
            <label>Supplementary Figure 13</label>
            <caption><title>Evolutionary Conservation of GPCR-Gα interface.</title>
                <p><bold>(a)</bold> Molecular representations depicting the topology of human and rat ADRB1 and ADRB2 receptors. GPCR-Gα interface cavities are color-coded at the intracellular sites. Of note, in the case of human ADRB1, the nomenclature of the two cavities detected at the interface includes ‘Cv’ (cavity) succeeded by the numerical number. <bold>(b)</bold> Barplots depicting the binding energies obtained by the docking of Human ADRB1 (7BVQ), Human ADRB2 (5X7D), Rat ADRB1 (P18090), and Rat ADRB2 (P10608) with the indicated metabolites at the GPCR-Gα interfaces. <bold>(c)</bold> Table depicting the conservation of yeast Ste2p-metabolite (ZST, CoQ6, and LST) interacting residues in the adrenergic receptors from humans and rats. <bold>(d)</bold> The schematic workflow illustrates the steps involved in measuring and comparing the sequential and ligand-interaction conservation of GPCRs across six different species. <bold>(e)</bold> Donut charts illustrating the GPCR count across different species. <bold>(f)</bold> Phylogenetic tree representing 75 unique GPCRs from six species. <bold>(g)</bold> Empirical cumulative distribution function (ECDF) plot depicting binding energy distribution of Gcoupler identified potential allosteric modulators along with five negative controls. <bold>(h)</bold> Heatmap depicting the pairwise d-values/p-values from the Kolmogorov-Smirnov statistical test under specified conditions. The lower triangle of the heatmap represents d-values, while the upper triangle shows p-values for the specified pair. The test provides two key outputs: the D-value, which represents the maximum difference between the cumulative distribution functions (CDFs) of the two groups, and the p-value, which indicates the statistical significance of the observed difference. Symbols *, **, ***, and **** refer to p-values &lt;0.05, &lt;0.01, &lt;0.001, and &lt;0.0001, respectively.</p></caption>
            <media xlink:href="528587v6_file13.pdf"/>
        </supplementary-material>
        <supplementary-material id="supp14">
            <label>Supplementary Tables</label>
            <caption>
                <p>Supplementary Table 1: Table contains information about the structure of the human GPCR-Gα-Protein complexes downloaded from the Protein Data Bank (PDB). It also contains information about the PDB IDs, Protein name, species information, whether it is used in this study or not, UniProt IDs, and other information.</p>
                <p>Supplementary Table 2: The table contains information about the normalized Root Mean Square Deviation (RMSD) of the pairwise comparison of the GPCR-Gα-Protein interface (cavities) for the indicated GPCRs.</p>
                <p>Supplementary Table 3: The table contains information about the chemical similarities of the <italic>de novo</italic> synthesized synthetic compounds of the indicated GPCR-Gα-Protein interface (cavities). Of note, the chemical similarity was computed using the Tanimoto coefficient on the Atomic fingerprints.</p>
                <p>Supplementary Table 4: The table contains information about the YMDB metabolites predicted to bind at the intracellular cavities IC4 and IC5 of the Ste2 protein. Of note, predictions were made using molecular docking and Gcoupler. It contains information about the YMDB ID, Metabolite name, SMILES (Simplified Molecular Input Line Entry System), and cavity information. Of note, BE refers to binding energies, whereas probabilities were the outcome of Gcoupler.</p>
                <p>Supplementary Table 5: The table contains information about the list of metabolite-gene pairs from the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway that is used in this study.</p>
                <p>Supplementary Table 6: The table contains the results of the untargeted metabolomics. Of note, the values represent normalized and imputed peak intensities of the indicated metabolites.</p>
                <p>Supplementary Table 7: The table contains the TMM normalized read counts after RNA Sequencing.</p>
                <p>Supplementary Table 8: The table contains the list of Differentially Expressed Genes (DEGs) of the Control groups, alongside the other standard output from the NOISeq analysis, such as M and D values, mean values of the two conditions, probability ranking, and other gene-associated features.</p>
                <p>Supplementary Table 9: The table contains the list of Differentially Expressed Genes (DEGs) of the Control vs LST group, alongside the other standard output from the NOISeq analysis, such as M and D values, mean values of the two conditions, probability ranking, and other gene-associated features.</p>
                <p>Supplementary Table 10: The table contains the list of Differentially Expressed Genes (DEGs) of the LST group, alongside the other standard output from the NOISeq analysis, such as M and D values, mean values of the two conditions, probability ranking, and other gene-associated features.</p>
                <p>Supplementary Table 11: The table contains information about the comparison of <italic>de novo</italic> drug design and cavity detection tools. Please note, SBDD refers to Structure-Based Drug Design, and LBDD refers to Ligand-Based Drug Design.</p>
                <p>Supplementary Table 12: The table contains information about the known mutants from the literature that could modulate Ste2 signaling. Of note, the table also contains information about the site of mutation, the nature of the mutation, its position within the intracellular cavities IC4 and IC5, its impact on the Ste2 signaling pathway, and references.</p>
            </caption>
            <media xlink:href="528587v6_file14.xlsx"/>
        </supplementary-material>
        <supplementary-material id="supp15">
        <label>Supplementary Information</label>
            <caption><p>The Supplementary Information provides details of the nucleotide and amino acid Multiple Sequence Alignments (MSAs) of the wild-type <italic>STE2</italic> and the site-directed missense mutants of <italic>STE2</italic>. Each row starts with the sequence identifier followed by the aligned sequence (in chunks) with the ending position of the aligned sequence provided at the end, separated by tabs. The mutation sites are highlighted in red (S75A), yellow (T155D), and blue (L289K). Supplementary Information also contains detailed materials and methods.</p>
            </caption>
        <media xlink:href="528587v6_file15.pdf"/>
        </supplementary-material>
    </sec>
<ref-list>
<title>References</title>
<ref id="c1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Aguilar</surname> <given-names>PS</given-names></string-name>, <string-name><surname>Heiman</surname> <given-names>MG</given-names></string-name>, <string-name><surname>Walther</surname> <given-names>TC</given-names></string-name>, <string-name><surname>Engel</surname> <given-names>A</given-names></string-name>, <string-name><surname>Schwudke</surname> <given-names>D</given-names></string-name>, <string-name><surname>Gushwa</surname> <given-names>N</given-names></string-name>, <string-name><surname>Kurzchalia</surname> <given-names>T</given-names></string-name>, <string-name><surname>Walter</surname> <given-names>P</given-names></string-name></person-group>. <year>2010</year>. <article-title>Structure of sterol aliphatic chains affects yeast cell shape and cell fusion during mating</article-title>. <source>Proceedings of the National Academy of Sciences</source> <volume>107</volume>:<fpage>4170</fpage>–<lpage>4175</lpage>.</mixed-citation></ref>
<ref id="c2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Alanzi</surname> <given-names>AR</given-names></string-name>, <string-name><surname>Moussa</surname> <given-names>AY</given-names></string-name>, <string-name><surname>Alsalhi</surname> <given-names>MS</given-names></string-name>, <string-name><surname>Nawaz</surname> <given-names>T</given-names></string-name>, <string-name><surname>Ali</surname> <given-names>I</given-names></string-name></person-group>. <year>2024</year>. <article-title>Integration of pharmacophore-based virtual screening, molecular docking, ADMET analysis, and MD simulation for targeting EGFR: A comprehensive drug discovery study using commercial databases</article-title>. <source>PLoS One</source> <volume>19</volume>:<fpage>e0311527</fpage>.</mixed-citation></ref>
<ref id="c3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Alhosaini</surname> <given-names>K</given-names></string-name>, <string-name><surname>Azhar</surname> <given-names>A</given-names></string-name>, <string-name><surname>Alonazi</surname> <given-names>A</given-names></string-name>, <string-name><surname>Al-Zoghaibi</surname> <given-names>F</given-names></string-name></person-group>. <year>2021</year>. <article-title>GPCRs: The most promiscuous druggable receptor of the mankind</article-title>. <source>Saudi Pharmaceutical Journal</source> <volume>29</volume>:<fpage>539</fpage>–<lpage>551</lpage>.</mixed-citation></ref>
<ref id="c4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Alvaro</surname> <given-names>CG</given-names></string-name>, <string-name><surname>Thorner</surname> <given-names>J</given-names></string-name></person-group>. <year>2016</year>. <article-title>Heterotrimeric G Protein-coupled Receptor Signaling in Yeast Mating Pheromone Response</article-title>. <source>J Biol Chem</source> <volume>291</volume>:<fpage>7788</fpage>–<lpage>7795</lpage>.</mixed-citation></ref>
<ref id="c5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bagnat</surname> <given-names>M</given-names></string-name>, <string-name><surname>Simons</surname> <given-names>K</given-names></string-name></person-group>. <year>2002</year>. <article-title>Cell surface polarization during yeast mating</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>99</volume>:<fpage>14183</fpage>–<lpage>14188</lpage>.</mixed-citation></ref>
<ref id="c6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bartuzi</surname> <given-names>D</given-names></string-name>, <string-name><surname>Kaczor</surname> <given-names>AA</given-names></string-name>, <string-name><surname>Matosiuk</surname> <given-names>D</given-names></string-name></person-group>. <year>2018</year>. <article-title>Opportunities and Challenges in the Discovery of Allosteric Modulators of GPCRs</article-title>. <source>Methods Mol Biol</source> <volume>1705</volume>:<fpage>297</fpage>–<lpage>319</lpage>.</mixed-citation></ref>
<ref id="c7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Basith</surname> <given-names>S</given-names></string-name>, <string-name><surname>Cui</surname> <given-names>M</given-names></string-name>, <string-name><surname>Macalino</surname> <given-names>SJY</given-names></string-name>, <string-name><surname>Park</surname> <given-names>J</given-names></string-name>, <string-name><surname>Clavio</surname> <given-names>NAB</given-names></string-name>, <string-name><surname>Kang</surname> <given-names>S</given-names></string-name>, <string-name><surname>Choi</surname> <given-names>S</given-names></string-name></person-group>. <year>2018</year>. <article-title>Exploring G Protein-Coupled Receptors (GPCRs) Ligand Space via Cheminformatics Approaches: Impact on Rational Drug Design</article-title>. <source>Front Pharmacol</source> <volume>9</volume>:<fpage>128</fpage>.</mixed-citation></ref>
<ref id="c8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Berger</surname> <given-names>VW</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>Y</given-names></string-name></person-group>. <year>2014</year>. <article-title>Kolmogorov–Smirnov Test: Overview</article-title>. <source>Wiley StatsRef: Statistics Reference Online</source>. doi:<pub-id pub-id-type="doi">10.1002/9781118445112.stat06558</pub-id></mixed-citation></ref>
<ref id="c9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bertoni</surname> <given-names>M</given-names></string-name>, <string-name><surname>Duran-Frigola</surname> <given-names>M</given-names></string-name>, <string-name><surname>Badia-I-Mompel</surname> <given-names>P</given-names></string-name>, <string-name><surname>Pauls</surname> <given-names>E</given-names></string-name>, <string-name><surname>Orozco-Ruiz</surname> <given-names>M</given-names></string-name>, <string-name><surname>Guitart-Pla</surname> <given-names>O</given-names></string-name>, <string-name><surname>Alcalde</surname> <given-names>V</given-names></string-name>, <string-name><surname>Diaz</surname> <given-names>VM</given-names></string-name>, <string-name><surname>Berenguer-Llergo</surname> <given-names>A</given-names></string-name>, <string-name><surname>Brun-Heath</surname> <given-names>I</given-names></string-name>, <string-name><surname>Villegas</surname> <given-names>N</given-names></string-name>, <string-name><surname>de Herreros</surname> <given-names>AG</given-names></string-name>, <string-name><surname>Aloy</surname> <given-names>P.</given-names></string-name></person-group> <year>2021</year>. <article-title>Bioactivity descriptors for uncharacterized chemical compounds</article-title>. <source>Nat Commun</source> <volume>12</volume>:<fpage>3932</fpage>.</mixed-citation></ref>
<ref id="c10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Böhm</surname> <given-names>HJ</given-names></string-name></person-group>. <year>1992</year>. <article-title>The computer program LUDI: a new method for the de novo design of enzyme inhibitors</article-title>. <source>J Comput Aided Mol Des</source> <volume>6</volume>:<fpage>61</fpage>–<lpage>78</lpage>.</mixed-citation></ref>
<ref id="c11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bourque</surname> <given-names>K</given-names></string-name>, <string-name><surname>Dallagnol</surname> <given-names>JCC</given-names></string-name>, <string-name><surname>Nassour</surname> <given-names>H</given-names></string-name>, <string-name><surname>Chatenet</surname> <given-names>D</given-names></string-name>, <string-name><surname>Allen</surname> <given-names>BG</given-names></string-name>, <string-name><surname>Hébert</surname> <given-names>TE</given-names></string-name></person-group>. <year>2022</year>. <article-title>Exploring the use of intracellular and extracellular allosteric modulators to understand GPCR signaling</article-title>. <source>Allosteric Modulation of G Protein-Coupled Receptors</source>. doi:<pub-id pub-id-type="doi">10.1016/b978-0-12-819771-4.00008-7</pub-id></mixed-citation></ref>
<ref id="c12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Calebiro</surname> <given-names>D</given-names></string-name>, <string-name><surname>Koszegi</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Lanoiselée</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Miljus</surname> <given-names>T</given-names></string-name>, <string-name><surname>O’Brien</surname> <given-names>S</given-names></string-name></person-group>. <year>2021</year>. <article-title>G protein-coupled receptor-G protein interactions: a single-molecule perspective</article-title>. <source>Physiol Rev</source> <volume>101</volume>:<fpage>857</fpage>–<lpage>906</lpage>.</mixed-citation></ref>
<ref id="c13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chatzigoulas</surname> <given-names>A</given-names></string-name>, <string-name><surname>Cournia</surname> <given-names>Z</given-names></string-name></person-group>. <year>2021</year>. <article-title>Rational design of allosteric modulators: Challenges and successes</article-title>. <source>Wiley Interdiscip Rev Comput Mol Sci</source> <volume>11</volume>. doi:<pub-id pub-id-type="doi">10.1002/wcms.1529</pub-id></mixed-citation></ref>
<ref id="c14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chong</surname> <given-names>J</given-names></string-name>, <string-name><surname>Soufan</surname> <given-names>O</given-names></string-name>, <string-name><surname>Li</surname> <given-names>C</given-names></string-name>, <string-name><surname>Caraus</surname> <given-names>I</given-names></string-name>, <string-name><surname>Li</surname> <given-names>S</given-names></string-name>, <string-name><surname>Bourque</surname> <given-names>G</given-names></string-name>, <string-name><surname>Wishart</surname> <given-names>DS</given-names></string-name>, <string-name><surname>Xia</surname> <given-names>J</given-names></string-name></person-group>. <year>2018</year>. <article-title>MetaboAnalyst 4.0: towards more transparent and integrative metabolomics analysis</article-title>. <source>Nucleic Acids Res</source> <volume>46</volume>:<fpage>W486</fpage>–<lpage>W494</lpage>.</mixed-citation></ref>
<ref id="c15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Clark</surname> <given-names>M</given-names></string-name>, <string-name><surname>Cramer</surname> <given-names>RD</given-names></string-name>, <string-name><surname>Van Opdenbosch</surname> <given-names>N.</given-names></string-name></person-group> <year>1989</year>. <article-title>Validation of the general purpose tripos 5.2 force field</article-title>. <source>J Comput Chem</source> <volume>10</volume>:<fpage>982</fpage>–<lpage>1012</lpage>.</mixed-citation></ref>
<ref id="c16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Congreve</surname> <given-names>M</given-names></string-name>, <string-name><surname>de Graaf</surname> <given-names>C</given-names></string-name>, <string-name><surname>Swain</surname> <given-names>NA</given-names></string-name>, <string-name><surname>Tate</surname> <given-names>CG.</given-names></string-name></person-group> <year>2020</year>. <article-title>Impact of GPCR Structures on Drug Discovery</article-title>. <source>Cell</source> <volume>181</volume>:<fpage>81</fpage>–<lpage>91</lpage>.</mixed-citation></ref>
<ref id="c17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Doller</surname> <given-names>D</given-names></string-name></person-group>. <year>2017</year>. <article-title>Endogenous Allosteric Modulators of G Protein-Coupled Receptors: Implications in Drug Design</article-title>. <volume>2017</volume> <source>Medicinal Chemistry Reviews</source>. doi:<pub-id pub-id-type="doi">10.29200/acsmedchemrev-v52.ch18</pub-id></mixed-citation></ref>
<ref id="c18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Engmann</surname> <given-names>S</given-names></string-name>, <string-name><surname>Cousineau</surname> <given-names>D</given-names></string-name></person-group>. <year>2011</year>. <article-title>Comparing distributions: the two-sample Anderson-Darling test as an alternative to the Kolmogorov-Smirnoff test</article-title>. <source>Journal of applied quantitative methods</source> <volume>6</volume>.</mixed-citation></ref>
<ref id="c19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gaulton</surname> <given-names>A</given-names></string-name>, <string-name><surname>Bellis</surname> <given-names>LJ</given-names></string-name>, <string-name><surname>Bento</surname> <given-names>AP</given-names></string-name>, <string-name><surname>Chambers</surname> <given-names>J</given-names></string-name>, <string-name><surname>Davies</surname> <given-names>M</given-names></string-name>, <string-name><surname>Hersey</surname> <given-names>A</given-names></string-name>, <string-name><surname>Light</surname> <given-names>Y</given-names></string-name>, <string-name><surname>McGlinchey</surname> <given-names>S</given-names></string-name>, <string-name><surname>Michalovich</surname> <given-names>D</given-names></string-name>, <string-name><surname>Al-Lazikani</surname> <given-names>B</given-names></string-name>, <string-name><surname>Overington</surname> <given-names>JP</given-names></string-name></person-group>. <year>2012</year>. <article-title>ChEMBL: a large-scale bioactivity database for drug discovery</article-title>. <source>Nucleic Acids Res</source> <volume>40</volume>:<fpage>D1100</fpage>–<lpage>7</lpage>.</mixed-citation></ref>
<ref id="c20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gibson</surname> <given-names>DG</given-names></string-name>, <string-name><surname>Glass</surname> <given-names>JI</given-names></string-name>, <string-name><surname>Lartigue</surname> <given-names>C</given-names></string-name>, <string-name><surname>Noskov</surname> <given-names>VN</given-names></string-name>, <string-name><surname>Chuang</surname> <given-names>R-Y</given-names></string-name>, <string-name><surname>Algire</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Benders</surname> <given-names>GA</given-names></string-name>, <string-name><surname>Montague</surname> <given-names>MG</given-names></string-name>, <string-name><surname>Ma</surname> <given-names>L</given-names></string-name>, <string-name><surname>Moodie</surname> <given-names>MM</given-names></string-name>, <string-name><surname>Merryman</surname> <given-names>C</given-names></string-name>, <string-name><surname>Vashee</surname> <given-names>S</given-names></string-name>, <string-name><surname>Krishnakumar</surname> <given-names>R</given-names></string-name>, <string-name><surname>Assad-Garcia</surname> <given-names>N</given-names></string-name>, <string-name><surname>Andrews-Pfannkoch</surname> <given-names>C</given-names></string-name>, <string-name><surname>Denisova</surname> <given-names>EA</given-names></string-name>, <string-name><surname>Young</surname> <given-names>L</given-names></string-name>, <string-name><surname>Qi</surname> <given-names>Z-Q</given-names></string-name>, <string-name><surname>Segall-Shapiro</surname> <given-names>TH</given-names></string-name>, <string-name><surname>Calvey</surname> <given-names>CH</given-names></string-name>, <string-name><surname>Parmar</surname> <given-names>PP</given-names></string-name>, <string-name><surname>Hutchison</surname> <given-names>CA</given-names> <suffix>3rd</suffix></string-name>, <string-name><surname>Smith</surname> <given-names>HO</given-names></string-name>, <string-name><surname>Venter</surname> <given-names>JC.</given-names></string-name></person-group> <year>2010</year>. <article-title>Creation of a bacterial cell controlled by a chemically synthesized genome</article-title>. <source>Science</source> <volume>329</volume>:<fpage>52</fpage>–<lpage>56</lpage>.</mixed-citation></ref>
<ref id="c21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gibson</surname> <given-names>DG</given-names></string-name>, <string-name><surname>Young</surname> <given-names>L</given-names></string-name>, <string-name><surname>Chuang</surname> <given-names>R-Y</given-names></string-name>, <string-name><surname>Venter</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Hutchison</surname> <given-names>CA</given-names> <suffix>3rd</suffix></string-name>, <string-name><surname>Smith</surname> <given-names>HO.</given-names></string-name></person-group> <year>2009</year>. <article-title>Enzymatic assembly of DNA molecules up to several hundred kilobases</article-title>. <source>Nat Methods</source> <volume>6</volume>:<fpage>343</fpage>–<lpage>345</lpage>.</mixed-citation></ref>
<ref id="c22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Goerg</surname> <given-names>SJ</given-names></string-name>, <string-name><surname>Kaiser</surname> <given-names>J</given-names></string-name></person-group>. <year>2009</year>. <article-title>Nonparametric Testing of Distributions—the Epps–Singleton Two-Sample Test using the Empirical Characteristic Function</article-title>. <source>Stata J</source> <volume>9</volume>:<fpage>454</fpage>–<lpage>465</lpage>.</mixed-citation></ref>
<ref id="c23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gupta</surname> <given-names>A</given-names></string-name>, <string-name><surname>Choudhary</surname> <given-names>M</given-names></string-name>, <string-name><surname>Mohanty</surname> <given-names>SK</given-names></string-name>, <string-name><surname>Mittal</surname> <given-names>A</given-names></string-name>, <string-name><surname>Gupta</surname> <given-names>K</given-names></string-name>, <string-name><surname>Arya</surname> <given-names>A</given-names></string-name>, <string-name><surname>Kumar</surname> <given-names>S</given-names></string-name>, <string-name><surname>Katyayan</surname> <given-names>N</given-names></string-name>, <string-name><surname>Dixit</surname> <given-names>NK</given-names></string-name>, <string-name><surname>Kalra</surname> <given-names>S</given-names></string-name>, <string-name><surname>Goel</surname> <given-names>M</given-names></string-name>, <string-name><surname>Sahni</surname> <given-names>M</given-names></string-name>, <string-name><surname>Singhal</surname> <given-names>V</given-names></string-name>, <string-name><surname>Mishra</surname> <given-names>T</given-names></string-name>, <string-name><surname>Sengupta</surname> <given-names>D</given-names></string-name>, <string-name><surname>Ahuja</surname> <given-names>G.</given-names></string-name></person-group> <year>2021</year>. <article-title>Machine-OlF-Action: A unified framework for developing and interpreting machine-learning models for chemosensory research</article-title>. <source>Bioinformatics</source>. doi:<pub-id pub-id-type="doi">10.1093/bioinformatics/btaa1104</pub-id></mixed-citation></ref>
<ref id="c24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hedderich</surname> <given-names>JB</given-names></string-name>, <string-name><surname>Persechino</surname> <given-names>M</given-names></string-name>, <string-name><surname>Becker</surname> <given-names>K</given-names></string-name>, <string-name><surname>Heydenreich</surname> <given-names>FM</given-names></string-name>, <string-name><surname>Gutermuth</surname> <given-names>T</given-names></string-name>, <string-name><surname>Bouvier</surname> <given-names>M</given-names></string-name>, <string-name><surname>Bünemann</surname> <given-names>M</given-names></string-name>, <string-name><surname>Kolb</surname> <given-names>P</given-names></string-name></person-group>. <year>2022</year>. <article-title>The pocketome of G-protein-coupled receptors reveals previously untargeted allosteric sites</article-title>. <source>Nat Commun</source> <volume>13</volume>:<fpage>2567</fpage>.</mixed-citation></ref>
<ref id="c25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Heese-Peck</surname> <given-names>A</given-names></string-name>, <string-name><surname>Pichler</surname> <given-names>H</given-names></string-name>, <string-name><surname>Zanolari</surname> <given-names>B</given-names></string-name>, <string-name><surname>Watanabe</surname> <given-names>R</given-names></string-name>, <string-name><surname>Daum</surname> <given-names>G</given-names></string-name>, <string-name><surname>Riezman</surname> <given-names>H</given-names></string-name></person-group>. <year>2002</year>. <article-title>Multiple functions of sterols in yeast endocytosis</article-title>. <source>Mol Biol Cell</source> <volume>13</volume>:<fpage>2664</fpage>–<lpage>2680</lpage>.</mixed-citation></ref>
<ref id="c26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hoffmann</surname> <given-names>C</given-names></string-name>, <string-name><surname>Bünemann</surname> <given-names>M</given-names></string-name></person-group>. <year>2010</year>. <article-title>Fluorescence and Resonance Energy Transfer Shine New Light on GPCR Function</article-title>. <source>GPCR Molecular Pharmacology and Drug Targeting</source>. doi:<pub-id pub-id-type="doi">10.1002/9780470627327.ch10</pub-id></mixed-citation></ref>
<ref id="c27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hou</surname> <given-names>T</given-names></string-name>, <string-name><surname>Bian</surname> <given-names>Y</given-names></string-name>, <string-name><surname>McGuire</surname> <given-names>T</given-names></string-name>, <string-name><surname>Xie</surname> <given-names>X-Q</given-names></string-name></person-group>. <year>2021</year>. <article-title>Integrated Multi-Class Classification and Prediction of GPCR Allosteric Modulators by Machine Learning Intelligence</article-title>. <source>Biomolecules</source> <volume>11</volume>. doi:<pub-id pub-id-type="doi">10.3390/biom11060870</pub-id></mixed-citation></ref>
<ref id="c28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname> <given-names>W</given-names></string-name>, <string-name><surname>Lu</surname> <given-names>S</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>X</given-names></string-name>, <string-name><surname>Mou</surname> <given-names>L</given-names></string-name>, <string-name><surname>Luo</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Zhao</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Hou</surname> <given-names>T</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>J</given-names></string-name></person-group>. <year>2013</year>. <article-title>Allosite: a method for predicting allosteric sites</article-title>. <source>Bioinformatics</source> <volume>29</volume>:<fpage>2357</fpage>–<lpage>2359</lpage>.</mixed-citation></ref>
    <ref id="c29"><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Jaeger</surname> <given-names>WC</given-names></string-name>, <string-name><surname>Pfleger</surname> <given-names>KDG</given-names></string-name>, <string-name><surname>Eidne</surname> <given-names>KA.</given-names></string-name></person-group> <chapter-title>Monitoring GPCR-Protein Complexes Using Bioluminescence Resonance Energy Transfer</chapter-title>. <source>G Protein-Coupled Receptors</source>. <person-group person-group-type="editor"><string-name><surname>Poyner</surname> <given-names>DR</given-names></string-name>, <string-name><surname>Wheatley</surname> <given-names>M</given-names></string-name></person-group> doi:<pub-id pub-id-type="doi">10.1002/9780470749210.ch6</pub-id> <year>2010</year></mixed-citation></ref>
<ref id="c30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jewison</surname> <given-names>T</given-names></string-name>, <string-name><surname>Knox</surname> <given-names>C</given-names></string-name>, <string-name><surname>Neveu</surname> <given-names>V</given-names></string-name>, <string-name><surname>Djoumbou</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Guo</surname> <given-names>AC</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>J</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>P</given-names></string-name>, <string-name><surname>Mandal</surname> <given-names>R</given-names></string-name>, <string-name><surname>Krishnamurthy</surname> <given-names>R</given-names></string-name>, <string-name><surname>Sinelnikov</surname> <given-names>I</given-names></string-name>, <string-name><surname>Wilson</surname> <given-names>M</given-names></string-name>, <string-name><surname>Wishart</surname> <given-names>DS</given-names></string-name></person-group>. <year>2012</year>. <article-title>YMDB: the Yeast Metabolome Database</article-title>. <source>Nucleic Acids Res</source> <volume>40</volume>:<fpage>D815</fpage>–<lpage>20</lpage>.</mixed-citation></ref>
<ref id="c31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jin</surname> <given-names>H</given-names></string-name>, <string-name><surname>McCaffery</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Grote</surname> <given-names>E</given-names></string-name></person-group>. <year>2008</year>. <article-title>Ergosterol promotes pheromone signaling and plasma membrane fusion in mating yeast</article-title>. <source>J Cell Biol</source> <volume>180</volume>:<fpage>813</fpage>–<lpage>826</lpage>.</mixed-citation></ref>
<ref id="c32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kaneko</surname> <given-names>H</given-names></string-name>, <string-name><surname>Hosohara</surname> <given-names>M</given-names></string-name>, <string-name><surname>Tanaka</surname> <given-names>M</given-names></string-name>, <string-name><surname>Itoh</surname> <given-names>T</given-names></string-name></person-group>. <year>1976</year>. <article-title>Lipid composition of 30 species of yeast</article-title>. <source>Lipids</source> <volume>11</volume>:<fpage>837</fpage>–<lpage>844</lpage>.</mixed-citation></ref>
<ref id="c33"><mixed-citation publication-type="preprint"><person-group person-group-type="author"><string-name><surname>Kipf</surname> <given-names>TN</given-names></string-name>, <string-name><surname>Welling</surname> <given-names>M.</given-names></string-name></person-group> <year>2016</year>. <article-title>Semi-Supervised Classification with Graph Convolutional Networks</article-title>. <source>arXiv</source>.</mixed-citation></ref>
<ref id="c34"><mixed-citation publication-type="web"><person-group person-group-type="author"><string-name><surname>Landrum</surname> <given-names>G.</given-names></string-name></person-group> <article-title>RDKit: A software suite for cheminformatics, computational chemistry, and predictive modeling</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.rdkit.org/RDKit_Overview.pdf">http://www.rdkit.org/RDKit_Overview.pdf</ext-link> <year>no date</year></mixed-citation></ref>
<ref id="c35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Leach</surname> <given-names>K</given-names></string-name>, <string-name><surname>Sexton</surname> <given-names>PM</given-names></string-name>, <string-name><surname>Christopoulos</surname> <given-names>A</given-names></string-name></person-group>. <year>2007</year>. <article-title>Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology</article-title>. <source>Trends Pharmacol Sci</source> <volume>28</volume>:<fpage>382</fpage>–<lpage>389</lpage>.</mixed-citation></ref>
<ref id="c36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Le Guilloux</surname> <given-names>V</given-names></string-name>, <string-name><surname>Schmidtke</surname> <given-names>P</given-names></string-name>, <string-name><surname>Tuffery</surname> <given-names>P.</given-names></string-name></person-group> <year>2009</year>. <article-title>Fpocket: an open source platform for ligand pocket detection</article-title>. <source>BMC Bioinformatics</source> <volume>10</volume>:<fpage>168</fpage>.</mixed-citation></ref>
<ref id="c37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Pei</surname> <given-names>J</given-names></string-name>, <string-name><surname>Lai</surname> <given-names>L</given-names></string-name></person-group>. <year>2021</year>. <article-title>Structure-based de novo drug design using 3D deep generative models</article-title>. <source>Chem Sci</source> <volume>12</volume>:<fpage>13664</fpage>–<lpage>13675</lpage>.</mixed-citation></ref>
<ref id="c38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mittal</surname> <given-names>A</given-names></string-name>, <string-name><surname>Mohanty</surname> <given-names>SK</given-names></string-name>, <string-name><surname>Gautam</surname> <given-names>V</given-names></string-name>, <string-name><surname>Arora</surname> <given-names>S</given-names></string-name>, <string-name><surname>Saproo</surname> <given-names>S</given-names></string-name>, <string-name><surname>Gupta</surname> <given-names>R</given-names></string-name>, <string-name><surname>Sivakumar</surname> <given-names>R</given-names></string-name>, <string-name><surname>Garg</surname> <given-names>P</given-names></string-name>, <string-name><surname>Aggarwal</surname> <given-names>A</given-names></string-name>, <string-name><surname>Raghavachary</surname> <given-names>P</given-names></string-name>, <string-name><surname>Dixit</surname> <given-names>NK</given-names></string-name>, <string-name><surname>Singh</surname> <given-names>VP</given-names></string-name>, <string-name><surname>Mehta</surname> <given-names>A</given-names></string-name>, <string-name><surname>Tayal</surname> <given-names>J</given-names></string-name>, <string-name><surname>Naidu</surname> <given-names>S</given-names></string-name>, <string-name><surname>Sengupta</surname> <given-names>D</given-names></string-name>, <string-name><surname>Ahuja</surname> <given-names>G</given-names></string-name></person-group>. <year>2022</year>. <article-title>Artificial intelligence uncovers carcinogenic human metabolites</article-title>. <source>Nat Chem Biol</source>. doi:<pub-id pub-id-type="doi">10.1038/s41589-022-01110-7</pub-id></mixed-citation></ref>
<ref id="c39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Moriwaki</surname> <given-names>H</given-names></string-name>, <string-name><surname>Tian</surname> <given-names>Y-S</given-names></string-name>, <string-name><surname>Kawashita</surname> <given-names>N</given-names></string-name>, <string-name><surname>Takagi</surname> <given-names>T</given-names></string-name></person-group>. <year>2018</year>. <article-title>Mordred: a molecular descriptor calculator</article-title>. <source>J Cheminform</source> <volume>10</volume>:<fpage>4</fpage>.</mixed-citation></ref>
<ref id="c40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Morris</surname> <given-names>GM</given-names></string-name>, <string-name><surname>Huey</surname> <given-names>R</given-names></string-name>, <string-name><surname>Lindstrom</surname> <given-names>W</given-names></string-name>, <string-name><surname>Sanner</surname> <given-names>MF</given-names></string-name>, <string-name><surname>Belew</surname> <given-names>RK</given-names></string-name>, <string-name><surname>Goodsell</surname> <given-names>DS</given-names></string-name>, <string-name><surname>Olson</surname> <given-names>AJ</given-names></string-name></person-group>. <year>2009</year>. <article-title>AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility</article-title>. <source>J Comput Chem</source> <volume>30</volume>:<fpage>2785</fpage>–<lpage>2791</lpage>.</mixed-citation></ref>
<ref id="c41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mysinger</surname> <given-names>MM</given-names></string-name>, <string-name><surname>Carchia</surname> <given-names>M</given-names></string-name>, <string-name><surname>Irwin</surname> <given-names>JJ</given-names></string-name>, <string-name><surname>Shoichet</surname> <given-names>BK</given-names></string-name></person-group>. <year>2012</year>. <article-title>Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking</article-title>. <source>J Med Chem</source> <volume>55</volume>:<fpage>6582</fpage>–<lpage>6594</lpage>.</mixed-citation></ref>
<ref id="c42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nachtergaele</surname> <given-names>S</given-names></string-name>, <string-name><surname>Mydock</surname> <given-names>LK</given-names></string-name>, <string-name><surname>Krishnan</surname> <given-names>K</given-names></string-name>, <string-name><surname>Rammohan</surname> <given-names>J</given-names></string-name>, <string-name><surname>Schlesinger</surname> <given-names>PH</given-names></string-name>, <string-name><surname>Covey</surname> <given-names>DF</given-names></string-name>, <string-name><surname>Rohatgi</surname> <given-names>R</given-names></string-name></person-group>. <year>2012</year>. <article-title>Oxysterols are allosteric activators of the oncoprotein Smoothened</article-title>. <source>Nat Chem Biol</source> <volume>8</volume>:<fpage>211</fpage>–<lpage>220</lpage>.</mixed-citation></ref>
<ref id="c43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nishibata</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Itai</surname> <given-names>A</given-names></string-name></person-group>. <year>1991</year>. <article-title>Automatic creation of drug candidate structures based on receptor structure. Starting point for artificial lead generation</article-title>. <source>Tetrahedron</source> <volume>47</volume>:<fpage>8985</fpage>–<lpage>8990</lpage>.</mixed-citation></ref>
<ref id="c44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>O’Callaghan</surname> <given-names>K</given-names></string-name>, <string-name><surname>Kuliopulos</surname> <given-names>A</given-names></string-name>, <string-name><surname>Covic</surname> <given-names>L</given-names></string-name></person-group>. <year>2012</year>. <article-title>Turning receptors on and off with intracellular pepducins: new insights into G-protein-coupled receptor drug development</article-title>. <source>J Biol Chem</source> <volume>287</volume>:<fpage>12787</fpage>–<lpage>12796</lpage>.</mixed-citation></ref>
<ref id="c45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ostrov</surname> <given-names>N</given-names></string-name>, <string-name><surname>Jimenez</surname> <given-names>M</given-names></string-name>, <string-name><surname>Billerbeck</surname> <given-names>S</given-names></string-name>, <string-name><surname>Brisbois</surname> <given-names>J</given-names></string-name>, <string-name><surname>Matragrano</surname> <given-names>J</given-names></string-name>, <string-name><surname>Ager</surname> <given-names>A</given-names></string-name>, <string-name><surname>Cornish</surname> <given-names>VW</given-names></string-name></person-group>. <year>2017</year>. <article-title>A modular yeast biosensor for low-cost point-of-care pathogen detection</article-title>. <source>Sci Adv</source> <volume>3</volume>:<fpage>e1603221</fpage>.</mixed-citation></ref>
<ref id="c46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pearlman</surname> <given-names>DA</given-names></string-name>, <string-name><surname>Murcko</surname> <given-names>MA</given-names></string-name></person-group>. <year>1993</year>. <article-title>CONCEPTS: New dynamic algorithm forde novo drug suggestion</article-title>. <source>J Comput Chem</source> <volume>14</volume>:<fpage>1184</fpage>–<lpage>1193</lpage>.</mixed-citation></ref>
    <ref id="c47"><mixed-citation publication-type="software"><person-group person-group-type="author"><string-name><surname>Ramsundar</surname> <given-names>B</given-names></string-name>, <string-name><surname>Eastman</surname> <given-names>P</given-names></string-name>, <string-name><surname>Feinberg</surname> <given-names>E</given-names></string-name>, <string-name><surname>Gomes</surname> <given-names>J</given-names></string-name>, <string-name><surname>Leswing</surname> <given-names>K</given-names></string-name>, <string-name><surname>Pappu</surname> <given-names>A</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>M</given-names></string-name>, <string-name><surname>Pande</surname> <given-names>V.</given-names></string-name></person-group> <year>2019</year>. <article-title>DeepChem: Democratizing Deep-Learning for Drug Discovery, Quantum Chemistry, Materials Science and Biology</article-title>. <source>GitHub</source> <ext-link ext-link-type="uri" xlink:href="https://github.com/deepchem/deepchem">https://github.com/deepchem/deepchem</ext-link> (<date-in-citation>accessed Aug 8, 2017</date-in-citation>).</mixed-citation></ref>
<ref id="c48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rees</surname> <given-names>S</given-names></string-name>, <string-name><surname>Morrow</surname> <given-names>D</given-names></string-name>, <string-name><surname>Kenakin</surname> <given-names>T</given-names></string-name></person-group>. <year>2002</year>. <article-title>GPCR Drug Discovery Through the Exploitation of Allosteric Drug Binding Sites</article-title>. <source>Receptors and Channels</source>. doi:<pub-id pub-id-type="doi">10.3109/10606820214640</pub-id></mixed-citation></ref>
<ref id="c49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Reyes-Alcaraz</surname> <given-names>A</given-names></string-name>, <string-name><surname>Lucero Garcia-Rojas</surname> <given-names>EY</given-names></string-name>, <string-name><surname>Bond</surname> <given-names>RA</given-names></string-name>, <string-name><surname>McConnell</surname> <given-names>BK</given-names></string-name></person-group>. <year>2020</year>. <article-title>Allosteric Modulators for GPCRs as a Therapeutic Alternative with High Potential in Drug Discovery</article-title>. <source>Molecular Pharmacology</source>. doi:<pub-id pub-id-type="doi">10.5772/intechopen.91838</pub-id></mixed-citation></ref>
<ref id="c50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shaw</surname> <given-names>WM</given-names></string-name>, <string-name><surname>Yamauchi</surname> <given-names>H</given-names></string-name>, <string-name><surname>Mead</surname> <given-names>J</given-names></string-name>, <string-name><surname>Gowers</surname> <given-names>G-OF</given-names></string-name>, <string-name><surname>Bell</surname> <given-names>DJ</given-names></string-name>, <string-name><surname>Öling</surname> <given-names>D</given-names></string-name>, <string-name><surname>Larsson</surname> <given-names>N</given-names></string-name>, <string-name><surname>Wigglesworth</surname> <given-names>M</given-names></string-name>, <string-name><surname>Ladds</surname> <given-names>G</given-names></string-name>, <string-name><surname>Ellis</surname> <given-names>T</given-names></string-name></person-group>. <year>2019</year>. <article-title>Engineering a Model Cell for Rational Tuning of GPCR Signaling</article-title>. <source>Cell</source> <volume>177</volume>:<fpage>782</fpage>–<lpage>796.e27</lpage>.</mixed-citation></ref>
<ref id="c51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shen</surname> <given-names>L</given-names></string-name>, <string-name><surname>Fang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>L</given-names></string-name>, <string-name><surname>Yang</surname> <given-names>F</given-names></string-name>, <string-name><surname>Jenkins</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Kutchukian</surname> <given-names>PS</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>H</given-names></string-name></person-group>. <year>2024</year>. <article-title>Pocket Crafter: a 3D generative modeling based workflow for the rapid generation of hit molecules in drug discovery</article-title>. <source>J Cheminform</source> <volume>16</volume>:<fpage>33</fpage>.</mixed-citation></ref>
<ref id="c52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shen</surname> <given-names>S</given-names></string-name>, <string-name><surname>Zhao</surname> <given-names>C</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>C</given-names></string-name>, <string-name><surname>Sun</surname> <given-names>S</given-names></string-name>, <string-name><surname>Li</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Yan</surname> <given-names>W</given-names></string-name>, <string-name><surname>Shao</surname> <given-names>Z</given-names></string-name></person-group>. <year>2023</year>. <article-title>Allosteric modulation of G protein-coupled receptor signaling</article-title>. <source>Front Endocrinol</source> <volume>14</volume>:<fpage>1137604</fpage>.</mixed-citation></ref>
<ref id="c53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sicho</surname> <given-names>M</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>X</given-names></string-name>, <string-name><surname>Svozil</surname> <given-names>D</given-names></string-name>, <string-name><surname>van Westen</surname> <given-names>GJP.</given-names></string-name></person-group> <year>2021</year>. <article-title>GenUI: interactive and extensible open source software platform for de novo molecular generation and cheminformatics</article-title>. <source>J Cheminform</source> <volume>13</volume>:<fpage>73</fpage>.</mixed-citation></ref>
<ref id="c54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Skalic</surname> <given-names>M</given-names></string-name>, <string-name><surname>Sabbadin</surname> <given-names>D</given-names></string-name>, <string-name><surname>Sattarov</surname> <given-names>B</given-names></string-name>, <string-name><surname>Sciabola</surname> <given-names>S</given-names></string-name>, <string-name><surname>De Fabritiis</surname> <given-names>G.</given-names></string-name></person-group> <year>2019</year>. <article-title>From Target to Drug: Generative Modeling for the Multimodal Structure-Based Ligand Design</article-title>. <source>Mol Pharm</source> <volume>16</volume>:<fpage>4282</fpage>–<lpage>4291</lpage>.</mixed-citation></ref>
<ref id="c55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sokolov</surname> <given-names>SS</given-names></string-name>, <string-name><surname>Galkina</surname> <given-names>KV</given-names></string-name>, <string-name><surname>Litvinova</surname> <given-names>EA</given-names></string-name>, <string-name><surname>Knorre</surname> <given-names>DA</given-names></string-name>, <string-name><surname>Severin</surname> <given-names>FF</given-names></string-name></person-group>. <year>2020</year>. <article-title>The Role of LAM Genes in the Pheromone-Induced Cell Death of S. cerevisiae Yeast</article-title>. <source>Biochemistry</source> <volume>85</volume>:<fpage>300</fpage>–<lpage>309</lpage>.</mixed-citation></ref>
<ref id="c56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Song</surname> <given-names>K</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>X</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>W</given-names></string-name>, <string-name><surname>Lu</surname> <given-names>S</given-names></string-name>, <string-name><surname>Shen</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>L</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>J</given-names></string-name></person-group>. <year>2017</year>. <article-title>Improved Method for the Identification and Validation of Allosteric Sites</article-title>. <source>J Chem Inf Model</source> <volume>57</volume>:<fpage>2358</fpage>–<lpage>2363</lpage>.</mixed-citation></ref>
<ref id="c57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Spiegel</surname> <given-names>JO</given-names></string-name>, <string-name><surname>Durrant</surname> <given-names>JD</given-names></string-name></person-group>. <year>2020</year>. <article-title>AutoGrow4: an open-source genetic algorithm for de novo drug design and lead optimization</article-title>. <source>J Cheminform</source> <volume>12</volume>:<fpage>25</fpage>.</mixed-citation></ref>
<ref id="c58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stornaiuolo</surname> <given-names>M</given-names></string-name>, <string-name><surname>Bruno</surname> <given-names>A</given-names></string-name>, <string-name><surname>Botta</surname> <given-names>L</given-names></string-name>, <string-name><surname>La Regina</surname> <given-names>G</given-names></string-name>, <string-name><surname>Cosconati</surname> <given-names>S</given-names></string-name>, <string-name><surname>Silvestri</surname> <given-names>R</given-names></string-name>, <string-name><surname>Marinelli</surname> <given-names>L</given-names></string-name>, <string-name><surname>Novellino</surname> <given-names>E.</given-names></string-name></person-group> <year>2015</year>. <article-title>Endogenous vs Exogenous Allosteric Modulators in GPCRs: A dispute for shuttling CB1 among different membrane microenvironments</article-title>. <source>Sci Rep</source> <volume>5</volume>:<fpage>15453</fpage>.</mixed-citation></ref>
<ref id="c59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tiedje</surname> <given-names>C</given-names></string-name>, <string-name><surname>Holland</surname> <given-names>DG</given-names></string-name>, <string-name><surname>Just</surname> <given-names>U</given-names></string-name>, <string-name><surname>Höfken</surname> <given-names>T</given-names></string-name></person-group>. <year>2007</year>. <article-title>Proteins involved in sterol synthesis interact with Ste20 and regulate cell polarity</article-title>. <source>J Cell Sci</source> <volume>120</volume>:<fpage>3613</fpage>–<lpage>3624</lpage>.</mixed-citation></ref>
<ref id="c60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Topiol</surname> <given-names>S</given-names></string-name></person-group>. <year>2018a</year>. <article-title>Current and Future Challenges in GPCR Drug Discovery</article-title>. <source>Methods Mol Biol</source> <volume>1705</volume>:<fpage>1</fpage>–<lpage>21</lpage>.</mixed-citation></ref>
<ref id="c61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Topiol</surname> <given-names>S</given-names></string-name></person-group>. <year>2018b</year>. <article-title>New opportunities for GPCR allosteric modulators</article-title>. <source>Future Medicinal Chemistry</source>. doi:<pub-id pub-id-type="doi">10.4155/fmc-2017-0313</pub-id></mixed-citation></ref>
<ref id="c62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Trott</surname> <given-names>O</given-names></string-name>, <string-name><surname>Olson</surname> <given-names>AJ</given-names></string-name></person-group>. <year>2010</year>. <article-title>AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</article-title>. <source>J Comput Chem</source> <volume>31</volume>:<fpage>455</fpage>–<lpage>461</lpage>.</mixed-citation></ref>
<ref id="c63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>van der Westhuizen</surname> <given-names>ET</given-names></string-name>, <string-name><surname>Valant</surname> <given-names>C</given-names></string-name>, <string-name><surname>Sexton</surname> <given-names>PM</given-names></string-name>, <string-name><surname>Christopoulos</surname> <given-names>A.</given-names></string-name></person-group> <year>2015</year>. <article-title>Endogenous Allosteric Modulators of G Protein–Coupled Receptors</article-title>. <source>J Pharmacol Exp Ther</source> <volume>353</volume>:<fpage>246</fpage>–<lpage>260</lpage>.</mixed-citation></ref>
<ref id="c64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Velazhahan</surname> <given-names>V</given-names></string-name>, <string-name><surname>Ma</surname> <given-names>N</given-names></string-name>, <string-name><surname>Pándy-Szekeres</surname> <given-names>G</given-names></string-name>, <string-name><surname>Kooistra</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Gloriam</surname> <given-names>DE</given-names></string-name>, <string-name><surname>Vaidehi</surname> <given-names>N</given-names></string-name>, <string-name><surname>Tate</surname> <given-names>CG</given-names></string-name></person-group>. <year>2021</year>. <article-title>Structure of the class D GPCR Ste2 dimer coupled to two G proteins</article-title>. <source>Nature</source> <volume>589</volume>:<fpage>148</fpage>–<lpage>153</lpage>.</mixed-citation></ref>
    <ref id="c65"><mixed-citation publication-type="preprint"><person-group person-group-type="author"><string-name><surname>Veličković</surname> <given-names>P</given-names></string-name>, <string-name><surname>Cucurull</surname> <given-names>G</given-names></string-name>, <string-name><surname>Casanova</surname> <given-names>A</given-names></string-name>, <string-name><surname>Romero</surname> <given-names>A</given-names></string-name>, <string-name><surname>Liò</surname> <given-names>P</given-names></string-name>, <string-name><surname>Bengio</surname> <given-names>Y.</given-names></string-name></person-group> <year>2018</year>. <article-title>Graph Attention Networks</article-title> <source>arXiv</source>.</mixed-citation></ref>
<ref id="c66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wold</surname> <given-names>EA</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>J</given-names></string-name></person-group>. <year>2018</year>. <article-title>GPCR Allosteric Modulators: Mechanistic Advantages and Therapeutic Applications</article-title>. <source>Curr Top Med Chem</source> <volume>18</volume>:<fpage>2002</fpage>–<lpage>2006</lpage>.</mixed-citation></ref>
<ref id="c67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wong</surname> <given-names>F</given-names></string-name>, <string-name><surname>Krishnan</surname> <given-names>A</given-names></string-name>, <string-name><surname>Zheng</surname> <given-names>EJ</given-names></string-name>, <string-name><surname>Stärk</surname> <given-names>H</given-names></string-name>, <string-name><surname>Manson</surname> <given-names>AL</given-names></string-name>, <string-name><surname>Earl</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Jaakkola</surname> <given-names>T</given-names></string-name>, <string-name><surname>Collins</surname> <given-names>JJ</given-names></string-name></person-group>. <year>2022</year>. <article-title>Benchmarking AlphaFold-enabled molecular docking predictions for antibiotic discovery</article-title>. <source>Mol Syst Biol</source> <volume>18</volume>:<fpage>e11081</fpage>.</mixed-citation></ref>
<ref id="c68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xiong</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>D</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>X</given-names></string-name>, <string-name><surname>Zhong</surname> <given-names>F</given-names></string-name>, <string-name><surname>Wan</surname> <given-names>X</given-names></string-name>, <string-name><surname>Li</surname> <given-names>X</given-names></string-name>, <string-name><surname>Li</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Luo</surname> <given-names>X</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>K</given-names></string-name>, <string-name><surname>Jiang</surname> <given-names>H</given-names></string-name>, <string-name><surname>Zheng</surname> <given-names>M</given-names></string-name></person-group>. <year>2020</year>. <article-title>Pushing the Boundaries of Molecular Representation for Drug Discovery with the Graph Attention Mechanism</article-title>. <source>J Med Chem</source> <volume>63</volume>:<fpage>8749</fpage>–<lpage>8760</lpage>.</mixed-citation></ref>
<ref id="c69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xu</surname> <given-names>M</given-names></string-name>, <string-name><surname>Ran</surname> <given-names>T</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>H</given-names></string-name></person-group>. <year>2021</year>. <article-title>De Novo Molecule Design Through the Molecular Generative Model Conditioned by 3D Information of Protein Binding Sites</article-title>. <source>J Chem Inf Model</source> <volume>61</volume>:<fpage>3240</fpage>–<lpage>3254</lpage>.</mixed-citation></ref>
<ref id="c70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname> <given-names>D</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Labroska</surname> <given-names>V</given-names></string-name>, <string-name><surname>Qin</surname> <given-names>S</given-names></string-name>, <string-name><surname>Darbalaei</surname> <given-names>S</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Yuliantie</surname> <given-names>E</given-names></string-name>, <string-name><surname>Xie</surname> <given-names>L</given-names></string-name>, <string-name><surname>Tao</surname> <given-names>H</given-names></string-name>, <string-name><surname>Cheng</surname> <given-names>J</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Zhao</surname> <given-names>S</given-names></string-name>, <string-name><surname>Shui</surname> <given-names>W</given-names></string-name>, <string-name><surname>Jiang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>M-W</given-names></string-name></person-group>. <year>2021</year>. <article-title>G protein-coupled receptors: structure- and function-based drug discovery</article-title>. <source>Signal Transduction and Targeted Therapy</source> <volume>6</volume>:<fpage>1</fpage>–<lpage>27</lpage>.</mixed-citation></ref>
<ref id="c71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yuan</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Pei</surname> <given-names>J</given-names></string-name>, <string-name><surname>Lai</surname> <given-names>L</given-names></string-name></person-group>. <year>2020</year>. <article-title>LigBuilder V3: A Multi-Target de novo Drug Design Approach</article-title>. <source>Front Chem</source> <volume>8</volume>:<fpage>142</fpage>.</mixed-citation></ref>
<ref id="c72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yuan</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Pei</surname> <given-names>J</given-names></string-name>, <string-name><surname>Lai</surname> <given-names>L</given-names></string-name></person-group>. <year>2011</year>. <article-title>LigBuilder 2: a practical de novo drug design approach</article-title>. <source>J Chem Inf Model</source> <volume>51</volume>:<fpage>1083</fpage>–<lpage>1091</lpage>.</mixed-citation></ref>
<ref id="c73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zha</surname> <given-names>J</given-names></string-name>, <string-name><surname>Li</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>X</given-names></string-name>, <string-name><surname>Lin</surname> <given-names>W</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>T</given-names></string-name>, <string-name><surname>Wei</surname> <given-names>J</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Lu</surname> <given-names>X</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>J</given-names></string-name>, <string-name><surname>Ni</surname> <given-names>D</given-names></string-name>, <string-name><surname>Song</surname> <given-names>K</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>L</given-names></string-name>, <string-name><surname>Lu</surname> <given-names>X</given-names></string-name>, <string-name><surname>Lu</surname> <given-names>S</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>J</given-names></string-name></person-group>. <year>2023</year>. <article-title>AlloReverse: multiscale understanding among hierarchical allosteric regulations</article-title>. <source>Nucleic Acids Res</source> <volume>51</volume>:<fpage>W33</fpage>–<lpage>W38</lpage>.</mixed-citation></ref>
<ref id="c74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname> <given-names>N-N</given-names></string-name>, <string-name><surname>Dudgeon</surname> <given-names>DD</given-names></string-name>, <string-name><surname>Paliwal</surname> <given-names>S</given-names></string-name>, <string-name><surname>Levchenko</surname> <given-names>A</given-names></string-name>, <string-name><surname>Grote</surname> <given-names>E</given-names></string-name>, <string-name><surname>Cunningham</surname> <given-names>KW</given-names></string-name></person-group>. <year>2006</year>. <article-title>Multiple signaling pathways regulate yeast cell death during the response to mating pheromones</article-title>. <source>Mol Biol Cell</source> <volume>17</volume>:<fpage>3409</fpage>–<lpage>3422</lpage>.</mixed-citation></ref>
<ref id="c75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname> <given-names>P</given-names></string-name>, <string-name><surname>Covic</surname> <given-names>L</given-names></string-name>, <string-name><surname>Kuliopulos</surname> <given-names>A</given-names></string-name></person-group>. <year>2015</year>. <article-title>Pepducins and Other Lipidated Peptides as Mechanistic Probes and Therapeutics</article-title>. <source>Methods Mol Biol</source> <volume>1324</volume>:<fpage>191</fpage>–<lpage>203</lpage>.</mixed-citation></ref>
<ref id="c76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhou</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Meng</surname> <given-names>J</given-names></string-name>, <string-name><surname>Xu</surname> <given-names>C</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>J</given-names></string-name></person-group>. <year>2021</year>. <article-title>Multiple GPCR Functional Assays Based on Resonance Energy Transfer Sensors</article-title>. <source>Front Cell Dev Biol</source> <volume>9</volume>:<fpage>611443</fpage>.</mixed-citation></ref>
</ref-list>
</back>
<sub-article id="sa0" article-type="editor-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.106397.2.sa3</article-id>
<title-group>
<article-title>eLife Assessment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Elgeti</surname>
<given-names>Matthias</given-names>
</name>
<role specific-use="editor">Reviewing Editor</role>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-0550-4852</contrib-id>
<aff>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/03s7gtk40</institution-id><institution>Leipzig University</institution>
</institution-wrap>
<city>Leipzig</city>
<country>Germany</country>
</aff>
</contrib>
</contrib-group>
<kwd-group kwd-group-type="evidence-strength">
<kwd>Incomplete</kwd>
</kwd-group>
<kwd-group kwd-group-type="claim-importance">
<kwd>Useful</kwd>
</kwd-group>
</front-stub>
<body>
<p>The authors present a set of wrappers around previously developed software and machine-learning toolkits, and demonstrate their use in identifying endogenous sterols binding to a GPCR. The resulting pipeline is potentially <bold>useful</bold> for molecular pharmacology researchers due to its accessibility and ease of use. However, the evidence supporting the GPCR-related findings remains <bold>incomplete</bold>, as the machine-learning model shows indications of overfitting, and no direct ligand-binding assays are provided for validation.</p>
</body>
</sub-article>
<sub-article id="sa1" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.106397.2.sa1</article-id>
<title-group>
<article-title>Reviewer #1 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>This is a re-review following an author revision. I will go point-by-point in response to my original critiques and the authors' responses. I appreciate the authors taking the time to thoughtfully respond to the reviewer critiques.</p>
<p>Query 1. Based on the authors' description of their contribution to the algorithm design, it sounds like a hyperparameter search wrapped around existing software tools. I think that the use of their own language to describe these modules is confusing to potential users as well as unintentionally hides the contributions of the original LigBuilder developers. The authors should just explain the protocol plainly using language that refers specifically to the established software tools. Whether they use LigBuilder or something else, at the end of the day the description is a protocol for a specific use of an existing software rather than the creation of a new toolkit.</p>
<p>Query 2. I see. Correct me if I am mistaken, but it seems as though the authors are proposing using the Authenticator to identify the best distributions of compounds based on an in silico oracle (in this case, Vina score), and train to discriminate them. This is similar to training QSAR models to predict docking scores, such as in the manuscript I shared during the first round of review. In principle, one could perform this in successive rounds to create molecules that are increasingly composed of features that yield higher docking scores. This is an established idea that the authors demonstrate in a narrow context, but it also raises concern that one is just enriching for compounds with e.g., an abundance of hydrogen bond donors and acceptors. Regarding points (4) and (5), it is unclear to me how the authors perform train/test splits on unlabeled data with supervised machine learning approaches in this setting. This seems akin to a Y-scramble sanity check. Finally, regarding the discussion on the use of experimental data or FEP calculations for the determination of HABs and LABs, I appreciate the authors' point; however, the concern here is that in the absence of any true oracle the models will just learn to identify and/or generate compounds that exploit limitations of docking scores. Again, please correct me if I am mistaken. It is unclear to me how this advances previous literature in CADD outside of the specific context of incorporating some ideas into a GPCR-Gprotein framework.</p>
<p>Query 3. The authors mention that the hyperparameters for the ML models are just the package defaults in the absence of specification by the user. I would be helpful to know specifically what the the hyperparameters were for the benchmarks in this study; however, I think a deeper concern is still that these models are almost certainly far overparameterized given the limited training data used for the models. It is unclear why the authors did not just build a random forest classifier to discriminate their HABs and LABs using ligand- or protein-ligand interaction fingerprints or related ideas.</p>
<p>Query 4. It is good, and expected, that increasing the fraction of the training set size in a random split validation all the way to 100% would allow the model to perfectly discriminate HABs and LABs. This does not demonstrate that the model has significant enrichment in prospective screening, particularly compared to simpler methods. The concern remains that these models are overparameterized and insufficiently validated. The authors did not perform any scaffold splits or other out-of-distribution analysis.</p>
<p>Query 5. The authors contend that Gcoupler uniquely enables training models when data is scarce and ultra-large screening libraries are unavailable. Today, it is rather straightforward to dock a minimum of thousands of compounds. Using tools such as QuickVina2-GPU (<ext-link ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acs.jcim.2c01504">https://pubs.acs.org/doi/10.1021/acs.jcim.2c01504</ext-link>), it is possible to quite readily dock millions in a day with a single GPU and obtain the AutoDock Vina score. GPU-acclerated Vina has been combined with cavity detection tools likely multiple times, including here (<ext-link ext-link-type="uri" xlink:href="https://arxiv.org/abs/2506.20043">https://arxiv.org/abs/2506.20043</ext-link>). There are multiple cavity detection tools, including the ones the authors use in their protocol.</p>
<p>Query 6. The authors contend that the simulations are converged, but they elected not to demonstrate stability in the predicting MM/GBSA binding energies with block averaging across the trajectory. This could have been done through the existing trajectories without additional simulation.</p>
</body>
</sub-article>
<sub-article id="sa2" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.106397.2.sa2</article-id>
<title-group>
<article-title>Reviewer #1 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>This is a re-review following an author revision. I will go point-by-point in response to my original critiques and the authors' responses. I appreciate the authors taking the time to thoughtfully respond to the reviewer critiques.</p>
<p>Query 1. Based on the authors' description of their contribution to the algorithm design, it sounds like a hyperparameter search wrapped around existing software tools. I think that the use of their own language to describe these modules is confusing to potential users as well as unintentionally hides the contributions of the original LigBuilder developers. The authors should just explain the protocol plainly using language that refers specifically to the established software tools. Whether they use LigBuilder or something else, at the end of the day the description is a protocol for a specific use of an existing software rather than the creation of a new toolkit.</p>
<p>Query 2. I see. Correct me if I am mistaken, but it seems as though the authors are proposing using the Authenticator to identify the best distributions of compounds based on an in silico oracle (in this case, Vina score), and train to discriminate them. This is similar to training QSAR models to predict docking scores, such as in the manuscript I shared during the first round of review. In principle, one could perform this in successive rounds to create molecules that are increasingly composed of features that yield higher docking scores. This is an established idea that the authors demonstrate in a narrow context, but it also raises concern that one is just enriching for compounds with e.g., an abundance of hydrogen bond donors and acceptors. Regarding points (4) and (5), it is unclear to me how the authors perform train/test splits on unlabeled data with supervised machine learning approaches in this setting. This seems akin to a Y-scramble sanity check. Finally, regarding the discussion on the use of experimental data or FEP calculations for the determination of HABs and LABs, I appreciate the authors' point; however, the concern here is that in the absence of any true oracle the models will just learn to identify and/or generate compounds that exploit limitations of docking scores. Again, please correct me if I am mistaken. It is unclear to me how this advances previous literature in CADD outside of the specific context of incorporating some ideas into a GPCR-Gprotein framework.</p>
<p>Query 3. The authors mention that the hyperparameters for the ML models are just the package defaults in the absence of specification by the user. I would be helpful to know specifically what the the hyperparameters were for the benchmarks in this study; however, I think a deeper concern is still that these models are almost certainly far overparameterized given the limited training data used for the models. It is unclear why the authors did not just build a random forest classifier to discriminate their HABs and LABs using ligand- or protein-ligand interaction fingerprints or related ideas.</p>
<p>Query 4. It is good, and expected, that increasing the fraction of the training set size in a random split validation all the way to 100% would allow the model to perfectly discriminate HABs and LABs. This does not demonstrate that the model has significant enrichment in prospective screening, particularly compared to simpler methods. The concern remains that these models are overparameterized and insufficiently validated. The authors did not perform any scaffold splits or other out-of-distribution analysis.</p>
<p>Query 5. The authors contend that Gcoupler uniquely enables training models when data is scarce and ultra-large screening libraries are unavailable. Today, it is rather straightforward to dock a minimum of thousands of compounds. Using tools such as QuickVina2-GPU (<ext-link ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acs.jcim.2c01504">https://pubs.acs.org/doi/10.1021/acs.jcim.2c01504</ext-link>), it is possible to quite readily dock millions in a day with a single GPU and obtain the AutoDock Vina score. GPU-acclerated Vina has been combined with cavity detection tools likely multiple times, including here (<ext-link ext-link-type="uri" xlink:href="https://arxiv.org/abs/2506.20043">https://arxiv.org/abs/2506.20043</ext-link>). There are multiple cavity detection tools, including the ones the authors use in their protocol.</p>
<p>Query 6. The authors contend that the simulations are converged, but they elected not to demonstrate stability in the predicting MM/GBSA binding energies with block averaging across the trajectory. This could have been done through the existing trajectories without additional simulation.</p>
</body>
</sub-article>
<sub-article id="sa3" article-type="author-comment">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.106397.2.sa0</article-id>
<title-group>
<article-title>Author response:</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Mohanty</surname>
<given-names>Sanjay Kumar</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1375-2223</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Mittal</surname>
<given-names>Aayushi</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1973-8553</contrib-id></contrib>
<contrib contrib-type="author">
<name>
    <surname>Namra</surname>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gaur</surname>
<given-names>Aakash</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Duari</surname>
<given-names>Subhadeep</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Solanki</surname>
<given-names>Saveena</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sharma</surname>
<given-names>Anmol Kumar</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Arora</surname>
<given-names>Sakshi</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kumar</surname>
<given-names>Suvendu</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gautam</surname>
<given-names>Vishakha</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dixit</surname>
<given-names>Nilesh Kumar</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Subramanian</surname>
<given-names>Karthika</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ghosh</surname>
<given-names>Tarini Shankar</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sengupta</surname>
<given-names>Debarka</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6353-5411</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Gupta</surname>
<given-names>Shashi Kumar</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Murugan</surname>
<given-names>Natarajan Arul</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sharma</surname>
<given-names>Deepak</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ahuja</surname>
<given-names>Gaurav</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2837-9361</contrib-id></contrib>
</contrib-group>
</front-stub>
<body>
<p>The following is the authors’ response to the original reviews</p>
<disp-quote content-type="editor-comment">
<p><bold>Public Reviews:</bold></p>
<p><bold>Reviewer #1 (Public review):</bold></p>
<p>Summary</p>
<p>Query: In this manuscript, the authors introduce Gcoupler, a Python-based computational pipeline designed to identify endogenous intracellular metabolites that function as allosteric modulators at the G protein-coupled receptor (GPCR) - Gα protein interface. Gcoupler is comprised of four modules:</p>
<p>I. Synthesizer - identifies protein cavities and generates synthetic ligands using LigBuilder3</p>
<p>II. Authenticator - classifies ligands into high-affinity binders (HABs) and low-affinity binders (LABs) based on AutoDock Vina binding energies</p>
<p>III. Generator - trains graph neural network (GNN) models (GCM, GCN, AFP, GAT) to predict binding affinity using synthetic ligands</p>
<p>IV. BioRanker - prioritizes ligands based on statistical and bioactivity data</p>
<p>The authors apply Gcoupler to study the Ste2p-Gpa1p interface in yeast, identifying sterols such as zymosterol (ZST) and lanosterol (LST) as modulators of GPCR signaling. Our review will focus on the computational aspects of the work. Overall, we found the Gcoupler approach interesting and potentially valuable, but we have several concerns with the methods and validation that need to be addressed prior to publication/dissemination.</p>
</disp-quote>
<p>We express our gratitude to Reviewer #1 for their concise summary and commendation of our work. We sincerely apologize for the lack of sufficient detail in summarizing the underlying methods employed in Gcoupler, as well as its subsequent experimental validations using yeast, human cell lines, and primary rat cardiomyocyte-based assays.</p>
<p>We wish to state that substantial improvements have been made in the revised manuscript, every section has been elaborated upon to enhance clarity. Please refer to the point-by-point response below and the revised manuscript.</p>
<disp-quote content-type="editor-comment">
<p>Query: (1) The exact algorithmic advancement of the Synthesizer beyond being some type of application wrapper around LigBuilder is unclear. Is the grow-link approach mentioned in the methods already a component of LigBuilder, or is it custom? If it is custom, what does it do? Is the API for custom optimization routines new with the Synthesizer, or is this a component of LigBuilder? Is the genetic algorithm novel or already an existing software implementation? Is the cavity detection tool a component of LigBuilder or novel in some way? Is the fragment library utilized in the Synthesizer the default fragment library in LigBuilder, or has it been customized? Are there rules that dictate how molecule growth can occur? The scientific contribution of the Synthesizer is unclear. If there has not been any new methodological development, then it may be more appropriate to just refer to this part of the algorithm as an application layer for LigBuilder.</p>
</disp-quote>
<p>We appreciate Reviewer #1's constructive suggestion. We wish to emphasize that</p>
<p>(1) The LigBuilder software comprises various modules designed for distinct functions. The Synthesizer in Gcoupler strategically utilizes two of these modules: &quot;CAVITY&quot; for binding site detection and &quot;BUILD&quot; for de novo ligand design.</p>
<p>(2) While both modules are integral to LigBuilder, the Synthesizer plays a crucial role in enabling their targeted, automated, and context-aware application for GPCR drug discovery.</p>
<p>(3) The CAVITY module is a structure-based protein binding site detection program, which the Synthesizer employs for identifying ligand binding sites on the protein surface.</p>
<p>(4) The Synthesizer also leverages the BUILD module for constructing molecules tailored to the target protein, implementing a fragment-based design strategy using its integrated fragment library.</p>
<p>(5) The GROW and LINK methods represent two independent approaches encompassed within the aforementioned BUILD module.</p>
<fig id="sa3fig1">
<label>Author response image 1.</label>
<caption>
<title>Schematic representation of the key strategy used in the Synthesizer module of Gcoupler.</title>
</caption>
<graphic mime-subtype="jpg" xlink:href="elife-106397-sa3-fig1.jpg" mimetype="image"/>
</fig>
<p>Our manuscript details the &quot;grow-link&quot; hybrid approach, which was implemented using a genetic algorithm through the following stages:</p>
<p>(1) Initial population generation based on a seed structure via the GROW method.</p>
<p>(2) Selection of &quot;parent&quot; molecules from the current population for inclusion in the mating pool using the LINK method.</p>
<p>(3) Transfer of &quot;elite&quot; molecules from the current population to the new population.</p>
<p>(4) Population expansion through structural manipulations (mutation, deletion, and crossover) applied to molecules within the mating pool.</p>
<p>Please note, the outcome of this process is not fixed, as it is highly dependent on the target cavity topology and the constraint parameters employed for population evaluation. Synthesizer customizes generational cycles and optimization parameters based on cavity-specific constraints, with the objective of either generating a specified number of compounds or comprehensively exploring chemical diversity against a given cavity topology.</p>
<p>While these components are integral to LigBuilder, Synthesizer's innovation lies</p>
<p>(1) in its programmatic integration and dynamic adjustment of these modules.</p>
<p>(2) Synthesizer distinguishes itself not by reinventing these algorithms, but by their automated coordination, fine-tuning, and integration within a cavity-specific framework.</p>
<p>(3) It dynamically modifies generation parameters according to cavity topology and druggability constraints, a capability not inherently supported by LigBuilder.</p>
<p>(4) This renders Synthesizer particularly valuable in practical scenarios where manual optimization is either inefficient or impractical.</p>
<p>In summary, Synthesizer offers researchers a streamlined interface, abstracting the technical complexities of LigBuilder and thereby enabling more accessible and reproducible ligand generation pipelines, especially for individuals with limited experience in structural or cheminformatics tools.</p>
<disp-quote content-type="editor-comment">
<p>Query: (2) The use of AutoDock Vina binding energy scores to classify ligands into HABs and LABs is problematic. AutoDock Vina's energy function is primarily tuned for pose prediction and displays highly system-dependent affinity ranking capabilities. Moreover, the HAB/LAB thresholds of -7 kcal/mol or -8 kcal/mol lack justification. Were these arbitrarily selected cutoffs, or was benchmarking performed to identify appropriate cutoffs? It seems like these thresholds should be determined by calibrating the docking scores with experimental binding data (e.g., known binders with measured affinities) or through re-scoring molecules with a rigorous alchemical free energy approach.</p>
</disp-quote>
<p>We again express our gratitude to Reviewer #1 for these inquiries. We sincerely apologize for the lack of sufficient detail in the original version of the manuscript. In the revised manuscript, we have ensured the inclusion of a detailed rationale for every threshold utilized to prioritize high-affinity binders. Please refer to the comprehensive explanation below, as well as the revised manuscript, for further details.</p>
<p>We would like to clarify that:</p>
<p>(1) The Authenticator module is not solely reliant on absolute binding energy values for classification. Instead, it calculates binding energies for all generated compounds and applies a statistical decision-making layer to define HAB and LAB classes.</p>
<p>(2) Rather than using fixed thresholds, the module employs distribution-based methods, such as the Empirical Cumulative Distribution Function (ECDF), to assess the overall energy landscape of the compound set. We then applied multiple statistical tests to evaluate the HAB and LAB distributions and determine an optimal, data-specific cutoff that balances class sizes and minimizes overlap.</p>
<p>(3) This adaptive approach avoids rigid thresholds and instead ensures context-sensitive classification, with safeguards in place to maintain adequate representation of both classes for downstream model training, and in this way, the framework prioritizes robust statistical reasoning over arbitrary energy cutoffs and aims to reduce the risks associated with direct reliance on Vina scores alone.</p>
<p>(4) To assess the necessity and effectiveness of the Authenticator module, we conducted a benchmarking analysis where we deliberately omitted the HAB and LAB class labels, treating the compound pool as a heterogeneous, unlabeled dataset. We then performed random train-test splits using the Synthesizer-generated compounds and trained independent models.</p>
<p>(5) The results from this approach demonstrated notably poorer model performance, indicating that arbitrary or unstructured data partitioning does not effectively capture the underlying affinity patterns. These experiments highlight the importance of using the statistical framework within the Authenticator module to establish meaningful, data-driven thresholds for distinguishing High- and Low-Affinity Binders. The cutoff values are thus not arbitrary but emerge from a systematic benchmarking and validation process tailored to each dataset.</p>
<p>Please note: While calibrating docking scores with experimental binding affinities or using rigorous methods like alchemical free energy calculations can improve precision, these approaches are often computationally intensive and reliant on the availability of high-quality experimental data, a major limitation in many real-world screening scenarios.</p>
<p>In summary, the primary goal of Gcoupler is to enable fast, scalable, and broadly accessible screening, particularly for cases where experimental data is sparse or unavailable. Incorporating such resource-heavy methods would not only significantly increase computational overhead but also undermine the framework’s intended usability and efficiency for large-scale applications. Instead, our workflow relies on statistically robust, data-driven classification methods that balance speed, generalizability, and practical feasibility.</p>
<disp-quote content-type="editor-comment">
<p>Query: (3) Neither the Results nor Methods sections provide information on how the GNNs were trained in this study. Details such as node features, edge attributes, standardization, pooling, activation functions, layers, dropout, etc., should all be described in detail. The training protocol should also be described, including loss functions, independent monitoring and early stopping criteria, learning rate adjustments, etc.</p>
</disp-quote>
<p>We again thank Reviewer #1 for this suggestion. We would like to mention that in the revised manuscript, we have added all the requested details. Please refer to the points below for more information.</p>
<p>(1) The Generator module of Gcoupler is designed as a flexible and automated framework that leverages multiple Graph Neural Network architectures, including Graph Convolutional Model (GCM), Graph Convolutional Network (GCN), Attentive FP, and Graph Attention Network (GAT), to build classification models based on the synthetic ligand datasets produced earlier in the pipeline.</p>
<p>(2) By default, Generator tests all four models using standard hyperparameters provided by the DeepChem framework <ext-link ext-link-type="uri" xlink:href="https://deepchem.io/">(</ext-link><ext-link ext-link-type="uri" xlink:href="https://deepchem.io/">https://deepchem.io/</ext-link>), offering a baseline performance comparison across architectures. This includes pre-defined choices for node features, edge attributes, message-passing layers, pooling strategies, activation functions, and dropout values, ensuring reproducibility and consistency. All models are trained with binary cross-entropy loss and support default settings for early stopping, learning rate, and batch standardization where applicable.</p>
<p>(3) In addition, Generator supports model refinement through hyperparameter tuning and k-fold cross-validation (default: 3 folds). Users can either customize the hyperparameter grid or rely on Generator’s recommended parameter ranges to optimize model performance. This allows for robust model selection and stability assessment of tuned parameters.</p>
<p>(4) Finally, the trained models can be used to predict binding probabilities for user-supplied compounds, making it a comprehensive and user-adaptive tool for ligand screening.</p>
<p>Based on the reviewer #1 suggestion, we have now added a detailed description about the Generator module of Gcoupler, and also provided relevant citations regarding the DeepChem workflow.</p>
<disp-quote content-type="editor-comment">
<p>Query: (4) GNN model training seems to occur on at most 500 molecules per training run? This is unclear from the manuscript. That is a very small number of training samples if true. Please clarify. How was upsampling performed? What were the HAB/LAB class distributions? In addition, it seems as though only synthetically generated molecules are used for training, and the task is to discriminate synthetic molecules based on their docking scores. Synthetic ligands generated by LigBuilder may occupy distinct chemical space, making classification trivial, particularly in the setting of a random split k-folds validation approach. In the absence of a leave-class-out validation, it is unclear if the model learns generalizable features or exploits clear chemical differences. Historically, it was inappropriate to evaluate ligand-based QSAR models on synthetic decoys such as the DUD-E sets - synthetic ligands can be much more easily distinguished by heavily parameterized ligand-based machine learning models than by physically constrained single-point docking score functions.</p>
</disp-quote>
<p>We thank reviewer #1 for these detailed technical queries. We would like to clarify that:</p>
<p>(1) The recommended minimum for the training set is 500 molecules, but users can add as many synthesized compounds as needed to thoroughly explore the chemical space related to the target cavity.</p>
<p>(2) Our systematic evaluation demonstrated that expanding the training set size consistently enhanced model performance, especially when compared to AutoDock docking scores. This observation underscores the framework's scalability and its ability to improve predictive accuracy with more training compounds.</p>
<p>(3) The Authenticator module initially categorizes all synthesized molecules into HAB and LAB classes. These labeled molecules are then utilized for training the Generator module. To tackle class imbalance, the class with fewer data points undergoes upsampling. This process aims to achieve an approximate 1:1 ratio between the two classes, thereby ensuring balanced learning during GNN model training.</p>
<p>(4) The Authenticator module's affinity scores are the primary determinant of the HAB/LAB class distribution, with a higher cutoff for HABs ensuring statistically significant class separation. This distribution is also indirectly shaped by the target cavity's topology and druggability, as the Synthesizer tends to produce more potent candidates for cavities with favorable binding characteristics.</p>
<p>(5) While it's true that synthetic ligands may occupy distinct chemical space, our benchmarking exploration for different sites on the same receptor still showed inter-cavity specificity along with intra-cavity diversity of the synthesized molecules.</p>
<p>(6) The utility of random k-fold validation shouldn't be dismissed outright; it provides a reasonable estimate of performance under practical settings where class boundaries are often unknown. Nonetheless, we agree that complementary validation strategies like leave-class-out could further strengthen the robustness assessment.</p>
<p>(7) We agree that using synthetic decoys like those from the DUD-E dataset can introduce bias in ligand-based QSAR model evaluations if not handled carefully. In our workflow, the inclusion of DUD-E compounds is entirely optional and only considered as a fallback, specifically in scenarios where the number of low-affinity binders (LABs) synthesized by the Synthesizer module is insufficient to proceed with model training.</p>
<p>(8) The primary approach relies on classifying generated compounds based on their derived affinity scores via the Authenticator module. However, in rare cases where this results in a heavily imbalanced dataset, DUD-E compounds are introduced not as part of the core benchmarking, but solely to maintain minimal class balance for initial model training. Even then, care is taken to interpret results with this limitation in mind. Ultimately, our framework is designed to prioritize data-driven generation of both HABs and LABs, minimizing reliance on synthetic decoys wherever possible.</p>
<fig id="sa3fig2">
<label>Author response image 2.</label>
<caption>
<title>Scatter plots depicting the segregation of High/Low-Affinity Metabolites (HAM/LAM) (indicated in green and red) identified using Gcoupler workflow with 100% training data.</title>
<p>Notably, models trained on lesser training data size (25%, 50%, and 75% of HAB/LAB) severely failed to segregate HAM and LAM (along Y-axis). X-axis represents the binding affinity calculated using IC4-specific docking using AutoDock.</p>
</caption>
<graphic mime-subtype="jpg" xlink:href="elife-106397-sa3-fig2.jpg" mimetype="image"/>
</fig>
<p>Based on the reviewer #1’s suggestion, we have now added all these technical details in the revised version of the manuscript.</p>
<disp-quote content-type="editor-comment">
<p>Query: (5) Training QSAR models on docking scores to accelerate virtual screening is not in itself novel (see here for a nice recent example: <ext-link ext-link-type="uri" xlink:href="https://www.nature.com/articles/s43588-025-00777-x">https://www.nature.com/articles/s43588-025-00777-x</ext-link>), but can be highly useful to focus structure-based analysis on the most promising areas of ligand chemical space; however, we are perplexed by the motivation here. If only a few hundred or a few thousand molecules are being sampled, why not just use AutoDock Vina? The models are trained to try to discriminate molecules by AutoDock Vina score rather than experimental affinity, so it seems like we would ideally just run Vina? Perhaps we are misunderstanding the scale of the screening that was done here. Please clarify the manuscript methods to help justify the approach.</p>
</disp-quote>
<p>We acknowledge the effectiveness of training QSAR models on docking scores for prioritizing chemical space, as demonstrated by the referenced study <ext-link ext-link-type="uri" xlink:href="https://www.nature.com/articles/s43588-025-00777-x">(</ext-link><ext-link ext-link-type="uri" xlink:href="https://www.nature.com/articles/s43588-025-00777-x">https://www.nature.com/articles/s43588-025-00777-x</ext-link>) on machine-learning-guided docking screen frameworks.</p>
<p>We would like to mention that:</p>
<p>(1) While such protocols often rely on extensive pre-docked datasets across numerous protein targets or utilize a highly skewed input distribution, training on as little as 1-10% of ligand-protein complexes and testing on the remainder in iterative cycles.</p>
<p>(2) While powerful for ultra-large libraries, this approach can introduce bias towards the limited training set and incur significant overhead in data curation, pre-computation, and infrastructure.</p>
<p>(3) In contrast, Gcoupler prioritizes flexibility and accessibility, especially when experimental data is scarce and large pre-docked libraries are unavailable. Instead of depending on fixed docking scores from external pipelines, Gcoupler integrates target-specific cavity detection, de novo compound generation, and model training into a self-contained, end-to-end framework. Its QSAR models are trained directly on contextually relevant compounds synthesized for a given binding site, employing a statistical classification strategy that avoids arbitrary thresholds or precomputed biases.</p>
<p>(4) Furthermore, Gcoupler is open-source, lightweight, and user-friendly, making it easily deployable without the need for extensive infrastructure or prior docking expertise. While not a complete replacement for full-scale docking in all use cases, Gcoupler aims to provide a streamlined and interpretable screening framework that supports both focused chemical design and broader chemical space exploration, without the computational burden associated with deep learning docking workflows.</p>
<p>(5) Practically, even with computational resources, manually running AutoDock Vina on millions of compounds presents challenges such as format conversion, binding site annotation, grid parameter tuning, and execution logistics, all typically requiring advanced structural bioinformatics expertise.</p>
<p>(6) Gcoupler's Authenticator module, however, streamlines this process. Users only need to input a list of SMILES and a receptor PDB structure, and the module automatically handles compound preparation, cavity mapping, parameter optimization, and high-throughput scoring. This automation reduces time and effort while democratizing access to structure-based screening workflows for users without specialized expertise.</p>
<p>Ultimately, Gcoupler's motivation is to make large-scale, structure-informed virtual screening both efficient and accessible. The model serves as a surrogate to filter and prioritize compounds before deeper docking or experimental validation, thereby accelerating targeted drug discovery.</p>
<disp-quote content-type="editor-comment">
<p>Query: (6) The brevity of the MD simulations raises some concerns that the results may be over-interpreted. RMSD plots do not reliably compare the affinity behavior in this context because of the short timescales coupled with the dramatic topological differences between the ligands being compared; CoQ6 is long and highly flexible compared to ZST and LST. Convergence metrics, such as block averaging and time-dependent MM/GBSA energies, should be included over much longer timescales. For CoQ6, the authors may need to run multiple simulations of several microseconds, identify the longest-lived metastable states of CoQ6, and perform MM/GBSA energies for each state weighted by each state's probability.</p>
</disp-quote>
<p>We appreciate Reviewer #1's suggestion regarding simulation length, as it is indeed crucial for interpreting molecular dynamics (MD) outcomes. We would like to mention that:</p>
<p>(1) Our simulation strategy varied based on the analysis objective, ranging from short (~5 ns) runs for preliminary or receptor-only evaluations to intermediate (~100 ns) and extended (~550 ns) runs for receptor-ligand complex validation and stability assessment.</p>
<p>(2) Specifically, we conducted three independent 100 ns MD simulations for each receptor-metabolite complex in distinct cavities of interest. This allowed us to assess the reproducibility and persistence of binding interactions. To further support these observations, a longer 550 ns simulation was performed for the IC4 cavity, which reinforced the 100 ns findings by demonstrating sustained interaction stability over extended timescales.</p>
<p>(3) While we acknowledge that even longer simulations (e.g., in the microsecond range) could provide deeper insights into metastable state transitions, especially for highly flexible molecules like CoQ6, our current design balances computational feasibility with the goal of screening multiple cavities and ligands.</p>
<p>(4) In our current workflow, MM/GBSA binding free energies were calculated by extracting 1000 representative snapshots from the final 10 ns of each MD trajectory. These configurations were used to compute time-averaged binding energies, incorporating contributions from van der Waals, electrostatic, polar, and non-polar solvation terms. This approach offers a more reliable estimate of ligand binding affinity compared to single-point molecular docking, as it accounts for conformational flexibility and dynamic interactions within the binding cavity.</p>
<p>(5) Although we did not explicitly perform state-specific MM/GBSA calculations weighted by metastable state probabilities, our use of ensemble-averaged energy estimates from a thermally equilibrated segment of the trajectory captures many of the same benefits. We acknowledge, however, that a more rigorous decomposition based on metastable state analysis could offer finer resolution of binding behavior, particularly for highly flexible ligands like CoQ6, and we consider this a valuable direction for future refinement of the framework.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #2 (Public review):</bold></p>
<p>Summary:</p>
<p>Query: Mohanty et al. present a new deep learning method to identify intracellular allosteric modulators of GPCRs. This is an interesting field for e.g. the design of novel small molecule inhibitors of GPCR signalling. A key limitation, as mentioned by the authors, is the limited availability of data. The method presented, Gcoupler, aims to overcome these limitations, as shown by experimental validation of sterols in the inhibition of Ste2p, which has been shown to be relevant molecules in human and rat cardiac hypertrophy models. They have made their code available for download and installation, which can easily be followed to set up software on a local machine.</p>
<p>Strengths:</p>
<p>Clear GitHub repository</p>
<p>Extensive data on yeast systems</p>
</disp-quote>
<p>We sincerely thank Reviewer #2 for their thorough review, summary, and appreciation of our work. We highly value their comments and suggestions.</p>
<disp-quote content-type="editor-comment">
<p>Weaknesses:</p>
<p>Query: No assay to directly determine the affinity of the compounds to the protein of interest.</p>
</disp-quote>
<p>We thank Reviewer #2 for raising these insightful questions. During the experimental design phase, we carefully accounted for validating the impact of metabolites in the rescue response by pheromone.</p>
<p>We would like to mention that we performed an array of methods to validate our hypothesis and observed similar rescue effects. These assays include:</p>
<p>a. Cell viability assay (FDA/PI Flourometry-based)</p>
<p>b. Cell growth assay</p>
<p>c. FUN1<sup>TM</sup>-based microscopy assessment</p>
<p>d. Shmoo formation assays</p>
<p>e. Mating assays</p>
<p>f. Site-directed mutagenesis-based loss of function</p>
<p>g. ransgenic reporter-based assay</p>
<p>h. MAPK signaling assessment using Western blot.</p>
<p>i. And via computational techniques.</p>
<p>Concerning the in vitro interaction studies of Ste2p and metabolites, we made significant efforts to purify Ste2p by incorporating a His tag at the N-terminal. Despite dedicated attempts over the past year, we were unsuccessful in purifying the protein, primarily due to our limited expertise in protein purification for this specific system. As a result, we opted for genetic-based interventions (e.g., point mutants), which provide a more physiological and comprehensive approach to demonstrating the interaction between Ste2p and the metabolites.</p>
<fig id="sa3fig3">
<label>Author response image 3.</label>
<caption>
<title>(a) Affinity purification of Ste2p from Saccharomyces cerevisiae.</title>
<p>Western blot analysis using anti-His antibody showing the distribution of Ste2p in various fractions during the affinity purification process. The fractions include pellet, supernatant, wash buffer, and sequential elution fractions (1–4). Wild-type and ste2Δ strains served as positive and negative controls, respectively. (b) Optimization of Ste2p extraction protocol. Ponceau staining (left) and Western blot analysis using anti-His antibody (right) showing Ste2p extraction efficiency. The conditions tested include lysis buffers containing different concentrations of CHAPS detergent (0.5%, 1%) and glycerol (10%, 20%).</p>
</caption>
<graphic mime-subtype="jpg" xlink:href="elife-106397-sa3-fig3.jpg" mimetype="image"/>
</fig>
<p>Furthermore, in addition to the clarification above, we have added the following statement in the discussion section to tone down our claims: “A critical limitation of our study is the absence of direct binding assays to validate the interaction between the metabolites and Ste2p. While our results from genetic interventions, molecular dynamics simulations, and docking studies strongly suggest that the metabolites interact with the Ste2p-Gpa1 interface, these findings remain indirect. Direct binding confirmation through techniques such as surface plasmon resonance, isothermal titration calorimetry, or co-crystallization would provide definitive evidence of this interaction. Addressing this limitation in future work would significantly strengthen our conclusions and provide deeper insights into the precise molecular mechanisms underlying the observed phenotypic effects.”</p>
<p>We request Reviewer #2 to kindly refer to the assays conducted on the point mutants created in this study, as these experiments offer robust evidence supporting our claims.</p>
<disp-quote content-type="editor-comment">
<p>Query: In conclusion, the authors present an interesting new method to identify allosteric inhibitors of GPCRs, which can easily be employed by research labs. Whilst their efforts to characterize the compounds in yeast cells, in order to confirm their findings, it would be beneficial if the authors show their compounds are active in a simple binding assay.</p>
</disp-quote>
<p>We express our gratitude and sincere appreciation for the time and effort dedicated by Reviewer #2 in reviewing our manuscript. We are confident that our clarifications address the reviewer's concerns.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #3 (Public review):</bold></p>
<p>Summary:</p>
<p>Query: In this paper, the authors introduce the Gcoupler software, an open-source deep learning-based platform for structure-guided discovery of ligands targeting GPCR interfaces. Overall, this manuscript represents a field-advancing contribution at the intersection of AI-based ligand discovery and GPCR signaling regulation.</p>
<p>Strengths:</p>
<p>The paper presents a comprehensive and well-structured workflow combining cavity identification, de novo ligand generation, statistical validation, and graph neural network-based classification. Notably, the authors use Gcoupler to identify endogenous intracellular sterols as allosteric modulators of the GPCR-Gα interface in yeast, with experimental validations extending to mammalian systems. The ability to systematically explore intracellular metabolite modulation of GPCR signaling represents a novel and impactful contribution. This study significantly advances the field of GPCR biology and computational ligand discovery.</p>
</disp-quote>
<p>We thank and appreciate Reviewer #3 for vesting time and efforts in reviewing our manuscript and for appreciating our efforts.</p>
<disp-quote content-type="editor-comment">
<p><bold>Recommendations for the authors:</bold></p>
<p><bold>Reviewing Editor Comments:</bold></p>
<p>We encourage the authors to address the points raised during revision to elevate the assessment from &quot;incomplete&quot; to &quot;solid&quot; or ideally &quot;convincing.&quot; In particular, we ask the authors to improve the justification for their methodological choices and to provide greater detail and clarity regarding each computational layer of the pipeline.</p>
</disp-quote>
<p>We are grateful for the editors' suggestions. We have incorporated significant revisions into the manuscript, providing comprehensive technical details to prevent any misunderstandings. Furthermore, we meticulously explained every aspect of the computational workflow.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #2 (Recommendations for the authors):</bold></p>
<p>Query: Would it be possible to make the package itself pip installable?</p>
</disp-quote>
<p>Yes, it already exists under the testpip repository and we have now migrated it to the main pip. Please access the link from here: <ext-link ext-link-type="uri" xlink:href="https://pypi.org/project/gcoupler/">https://pypi.org/project/gcoupler/</ext-link></p>
<disp-quote content-type="editor-comment">
<p>Query: I am confused by the binding free energies reported in Supplementary Figure 8. Is the total DG reported that of the protein-ligand complex? If that is the case, the affinities of the ligands would be extremely high. They are also very far off from the reported -7 kcal/mol active/inactive cut-off.</p>
</disp-quote>
<p>We thank Reviewer #2 for this query. We would like to mention that we have provided a detailed explanation in the point-by-point response to Reviewer #2's original comment. Briefly, to clarify, the -7 kcal/mol active/inactive cutoff mentioned in the manuscript refers specifically to the docking-based binding free energies (ΔG) calculated using AutoDock or AutoDock Vina, which are used for compound classification or validation against the Gcoupler framework.</p>
<p>In contrast, the binding free energies reported in Supplementary Figure 8 are obtained through the MM-GBSA method, which provides a more detailed and physics-based estimate of binding affinity by incorporating solvation and enthalpic contributions. It is well-documented in the literature that MM-GBSA tends to systematically underestimate absolute binding free energies when compared to experimental values (10.2174/1568026616666161117112604; Table 1).</p>
<fig id="sa3fig4">
<label>Author response image 4.</label>
<caption>
<title>Scatter plot comparing the predicted binding affinity calculated by Docking and MM/GBSA methods, against experimental ΔG (10.</title>
<p>1007/s10822-023-00499-0)</p>
</caption>
<graphic mime-subtype="jpg" xlink:href="elife-106397-sa3-fig4.jpg" mimetype="image"/>
</fig>
<p>Our use of MM-GBSA is not to match experimental ΔG directly, but rather to assess relative binding preferences among ligands. Despite its limitations in predicting absolute affinities, MM-GBSA is known to perform better than docking for ranking compounds by their binding potential. In this context, an MM-GBSA energy value still reliably indicates stronger predicted binding, even if the numerical values appear extremely higher than typical experimental or docking-derived cutoffs.</p>
<p>Thus, the two energy values, docking-based and MM-GBSA, serve different purposes in our workflow. Docking scores are used for classification and thresholding, while MM-GBSA energies provide post hoc validation and a higher-resolution comparison of binding strength across compounds.</p>
<disp-quote content-type="editor-comment">
<p>To corroborate their findings, can the authors include direct binding affinity assays for yeast and human Ste2p? This will help in establishing whether the observed phenotypic effects are indeed driven by binding of the metabolites.</p>
</disp-quote>
<p>We thank Reviewer #2 for raising these insightful questions. During the experimental design phase, we carefully accounted for validating the impact of metabolites in the rescue response by pheromone.</p>
<p>We would like to mention that we performed an array of methods to validate our hypothesis and observed similar rescue effects. These assays include:</p>
<p>a. Cell viability assay (FDA/PI Flourometry- based)</p>
<p>b. Cell growth assay</p>
<p>c. FUN1<sup>TM</sup>-based microscopy assessment</p>
<p>d. Shmoo formation assays</p>
<p>e. Mating assays</p>
<p>f. Site-directed mutagenesis-based loss of function</p>
<p>g. Transgenic reporter-based assay</p>
<p>h. MAPK signaling assessment using Western blot.</p>
<p>i. And via computational techniques.</p>
<p>Concerning the in vitro interaction studies of Ste2p and metabolites, we made significant efforts to purify Ste2p by incorporating a His tag at the N-terminal. Despite dedicated attempts over the past year, we were unsuccessful in purifying the protein, primarily due to our limited expertise in protein purification for this specific system. As a result, we opted for genetic-based interventions (e.g., point mutants), which provide a more physiological and comprehensive approach to demonstrating the interaction between Ste2p and the metabolites.</p>
<p>Furthermore, in addition to the clarification above, we have added the following statement in the discussion section to tone down our claims: “A critical limitation of our study is the absence of direct binding assays to validate the interaction between the metabolites and Ste2p. While our results from genetic interventions, molecular dynamics simulations, and docking studies strongly suggest that the metabolites interact with the Ste2p-Gpa1 interface, these findings remain indirect. Direct binding confirmation through techniques such as surface plasmon resonance, isothermal titration calorimetry, or co-crystallization would provide definitive evidence of this interaction. Addressing this limitation in future work would significantly strengthen our conclusions and provide deeper insights into the precise molecular mechanisms underlying the observed phenotypic effects.”</p>
<p>We request Reviewer #2 to kindly refer to the assays conducted on the point mutants created in this study, as these experiments offer robust evidence supporting our claims.</p>
<disp-quote content-type="editor-comment">
<p>Did the authors perform expression assays to make sure the mutant proteins were similarly expressed to wt?</p>
</disp-quote>
<p>We thank reviewer #2 for this comment. We would like to mention that:</p>
<p>(1) In our mutants (S75A, T155D, L289K)-based assays, all mutants were generated using integration at the same chromosomal TRP1 locus under the GAL1 promoter and share the same C-terminal CYC1 terminator sequence used for the reconstituted wild-type (rtWT) construct, thus reducing the likelihood of strain-specific expression differences.</p>
<p>(2) Furthermore, all strains were grown under identical conditions using the same media, temperature, and shaking parameters. Each construct underwent the same GAL1 induction protocol in YPGR medium for identical durations, ensuring uniform transcriptional activation across all strains and minimizing culture-dependent variability in protein expression.</p>
<p>(3) Importantly, both the rtWT and two of the mutants (T155D, L289K) retained α-factor-induced cell death (PI and FUN1-based fluorometry and microscopy; Figure 4c-d) and MAPK activation (western blot; Figure 4e), demonstrating that the mutant proteins are expressed at levels sufficient to support signalling.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #3 (Recommendations for the authors):</bold></p>
<p>My comments that would enhance the impact of this method are:</p>
<p>(1) While the authors have compared the accuracy and efficiency of Gcoupler to AutoDock Vina, one of the main points of Gcoupler is the neural network module. It would be beneficial to have it evaluated against other available deep learning ligand generative modules, such as the following: 10.1186/s13321-024-00829-w, 10.1039/D1SC04444C.</p>
</disp-quote>
<p>Thank you for the observation. To clarify, our benchmarking of Gcoupler’s accuracy and efficiency was performed against AutoDock, not AutoDock Vina. This choice was intentional, as AutoDock is one of the most widely used classical techniques in computer-aided drug design (CADD) for obtaining high-resolution predictions of ligand binding energy, binding poses, and detailed atomic-level interactions with receptor residues. In contrast, AutoDock Vina is primarily optimized for large-scale virtual screening, offering faster results but typically with lower resolution and limited configurational detail.</p>
<p>Since Gcoupler is designed to balance accuracy with computational efficiency in structure-based screening, AutoDock served as a more appropriate reference point for evaluating its predictions.</p>
<p>We agree that benchmarking against other deep learning-based ligand generative tools is important for contextualizing Gcoupler’s capabilities. However, it's worth noting that only a few existing methods focus specifically on cavity- or pocket-driven de novo drug design using generative AI, and among them, most are either partially closed-source or limited in functionality.</p>
<p>While PocketCrafter (10.1186/s13321-024-00829-w) offers a structure-based generative framework, it differs from Gcoupler in several key respects. PocketCrafter requires proprietary preprocessing tools, such as the MOE QuickPrep module, to prepare protein pocket structures, limiting its accessibility and reproducibility. In addition, PocketCrafter’s pipeline stops at the generation of cavity-linked compounds and does not support any further learning from the generated data.</p>
<p>Similarly, DeepLigBuilder (10.1039/D1SC04444C) provides de novo ligand generation using deep learning, but the source code is not publicly available, preventing direct benchmarking or customization. Like PocketCrafter, it also lacks integrated learning modules, which limits its utility for screening large, user-defined libraries or compounds of interest.</p>
<p>Additionally, tools like AutoDesigner from Schrödinger, while powerful, are not publicly accessible and hence fall outside the scope of open benchmarking.</p>
<table-wrap id="sa3table1">
<label>Author response table 1.</label>
<caption>
<title>Comparison of de novo drug design tools.</title>
<p>SBDD refers to Structure-Based Drug Design, and LBDD refers to Ligand-Based Drug Design.</p>
</caption>
<graphic mime-subtype="jpg" xlink:href="elife-106397-sa3-table1.jpg" mimetype="image"/>
</table-wrap>
<p>In contrast, Gcoupler is a fully open-source, end-to-end platform that integrates both Ligand-Based and Structure-Based Drug Design. It spans from cavity detection and molecule generation to automated model training using GNNs, allowing users to evaluate and prioritize candidate ligands across large chemical spaces without the need for commercial software or advanced coding expertise.</p>
<disp-quote content-type="editor-comment">
<p>(2) In Figure 2, the authors mention that IC4 and IC5 potential binding sites are on the direct G protein coupling interface (&quot;This led to the identification of 17 potential surface cavities on Ste2p, with two intracellular regions, IC4 and IC5, accounting for over 95% of the Ste2p-Gpa1p interface (Figure 2a-b, Supplementary Figure 4j-n)...&quot;). Later, however, in Figure 4, when discussing which residues affect the binding of the metabolites the most, the authors didn't perform MD simulations of mutant STE2 and just Gpa1p (without metabolites present). It would be beneficial to compare the binding of G protein with and without metabolites present, as these interface mutations might be affecting the binding of G protein by itself.</p>
</disp-quote>
<p>Thank you for this insightful suggestion. While we did not perform in silico MD simulations of the mutant Ste2-Gpa1 complex in the absence of metabolites, we conducted experimental validation to functionally assess the impact of interface mutations. Specifically, we generated site-directed mutants (S75A, L289K, T155D) and expressed them in a ste2Δ background to isolate their effects.</p>
<p>As shown in the Supplementary Figure, these mutants failed to rescue cells from α-factor-induced programmed cell death (PCD) upon metabolite pre-treatment. This was confirmed through fluorometry-based viability assays, FUN1<sup>TM</sup> staining, and p-Fus3 signaling analysis, which collectively monitor MAPK pathway activation (Figure 4c–e).</p>
<p>Importantly, the induction of PCD in response to α-factor in these mutants demonstrates that G protein coupling is still functionally intact, indicating that the mutations do not interfere with Gpa1 binding itself. However, the absence of rescue by metabolites strongly suggests that the mutated residues play a direct role in metabolite binding at the Ste2p–Gpa1p interface, thus modulating downstream signaling.</p>
<p>While further MD simulations could provide structural insight into the isolated mutant receptor–G protein interaction, our experimental data supports the functional relevance of metabolite binding at the identified interface.</p>
<disp-quote content-type="editor-comment">
<p>(3) While the experiments, performed by the authors, do support the hypothesis that metabolites regulate GPCR signaling, there are no experiments evaluating direct biophysical measurements (e.g., dissociation constants are measured only in silicon).</p>
</disp-quote>
<p>We thank Reviewer #3 for raising these insightful comments. We would like to mention that we performed an array of methods to validate our hypothesis and observed similar rescue effects. These assays include:</p>
<p>a. Cell viability assay (FDA/PI Flourometry- based)</p>
<p>b. Cell growth assay</p>
<p>c. FUN1<sup>TM</sup>-based microscopy assessment</p>
<p>d. Shmoo formation assays</p>
<p>e. Mating assays</p>
<p>f. Site-directed mutagenesis-based loss of function</p>
<p>g. Transgenic reporter-based assay</p>
<p>h. MAPK signaling assessment using Western blot.</p>
<p>i. And via computational techniques.</p>
<p>Concerning the direct biophysical measurements of Ste2p and metabolites, we made significant efforts to purify Ste2p by incorporating a His tag at the N-terminal, with the goal of performing Microscale Thermophoresis (MST) and Isothermal Titration Calorimetry (ITC) measurements. Despite dedicated attempts over the past year, we were unsuccessful in purifying the protein, primarily due to our limited expertise in protein purification for this specific system. As a result, we opted for genetic-based interventions (e.g., point mutants), which provide a more physiological and comprehensive approach to demonstrating the interaction between Ste2p and the metabolites.</p>
<p>Furthermore, in addition to the clarification above, we have added the following statement in the discussion section to tone down our claims: “A critical limitation of our study is the absence of direct binding assays to validate the interaction between the metabolites and Ste2p. While our results from genetic interventions, molecular dynamics simulations, and docking studies strongly suggest that the metabolites interact with the Ste2p-Gpa1 interface, these findings remain indirect. Direct binding confirmation through techniques such as surface plasmon resonance, isothermal titration calorimetry, or co-crystallization would provide definitive evidence of this interaction. Addressing this limitation in future work would significantly strengthen our conclusions and provide deeper insights into the precise molecular mechanisms underlying the observed phenotypic effects.”</p>
<disp-quote content-type="editor-comment">
<p>(4) The authors do not discuss the effects of the metabolites at their physiological concentrations. Overall, this manuscript represents a field-advancing contribution at the intersection of AI-based ligand discovery and GPCR signaling regulation.</p>
</disp-quote>
<p>We thank reviewer #3 for this comment and for recognising the value of our work. Although direct quantification of intracellular free metabolite levels is challenging, several lines of evidence support the physiological relevance of our test concentrations.</p>
<p>- Genetic validation supports endogenous relevance: Our genetic screen of 53 metabolic knockout mutants showed that deletions in biosynthetic pathways for these metabolites consistently disrupted the α-factor-induced cell death, with the vast majority of strains (94.4%) resisting the α-factor-induced cell death, and notably, a subset even displayed accelerated growth in the presence of α‑factor. This suggests that endogenous levels of these metabolites normally provide some degree of protection, supporting their physiological role in GPCR regulation.</p>
<p>- Metabolomics confirms in vivo accumulation: Our untargeted metabolomics analysis revealed that α-factor-treated survivors consistently showed enrichment of CoQ6 and zymosterol compared to sensitive cells. This demonstrates that these metabolites naturally accumulate to protective levels during stress responses, validating their biological relevance.</p>
</body>
</sub-article>
</article>